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Abstract  
Obesity is a public health concern that presents considerable difficulty in its management. Efforts are 
extensive to discover and develop new strategies to reduce body weight and fat accumulation. A 
group of plant-derived chemicals, known as polyphenols and with recognised anti-oxidant and anti-
inflammatory properties, have been suggested as potential candidates to aid weight loss and 
management. On the other hand, great variability is observed in the individual responsiveness to 
weight-loss treatments; a multitude of factors, both physiological and environmental, may contribute to 
this variability, but their specific contributions are not properly understood. This project aimed to 
explore the relationships between obesity and selected lifestyle factors, metabolic and immunological 
markers, and to analyse the effect of a polyphenol-based weight-loss intervention, assessing 
individual responsiveness and determining potential predictors of weight loss.  
This project studied 79 men and women (≥18 years; 39.8% women) classified as overweight 
or obese, who received drinks containing polyphenol-rich extracts, in a placebo-controlled, double-
blind, crossover intervention. In a first stage, the associations between anthropometric indices and the 
above mentioned blood factors were analysed. Baseline and post-treatment values for all variables 
were then compared. Finally, participants were classified into tertiles according to their relative post-
treatment body weight change into high (≥1.5% initial weight loss) or low (any weight gain) 
respondents; those who neither lost nor gained weight were excluded from the analysis. The 
participants’ baseline characteristics were compared, and the correlations between body weight 
change and the different markers studied were analysed, in order to identify potential predictors for 
subsequent regression analysis.  
Obesity markers in our sample were linked to higher levels of metabolic syndrome and 
inflammation markers. The polyphenol-based treatment (B2) were associated with small but significant 
reductions in body mass index (BMI) in women, reductions in specific white blood cell subsets counts 
(white blood cell counts and neutrophil, total T helper cells (CD4+), naive T helper cells (CD4+RA+) 
counts), increased red blood cell haemoglobin concentration and levels of circulating non-esterified 
fatty acids. Body fat %, anthropometric indices, and all other blood variables analysed did not change 
significantly in response to the treatments. There was large variability in relative body weight change 
post-treatment (-4.63% to + 3.93%). High respondents presented lower baseline values for the obesity 
indices (BMI and WHeR), T naïve (CD8+RA+) counts and interleukin-6 (IL-6). Relative body weight 
change was negatively correlated with blood levels of triglycerides, very low-density lipoprotein-
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cholesterol (VLDL-cholesterol) and granulocyte-macrophage colony-stimulating factor (GM-CSF). A 
regression model including compliance with the treatment, triglycerides and BMI explained 18.1% of 
the variability in weight change (P=0.003). In women only, compliance and GM-CSF explained 30% of 
the variability (P=0.040), and in men, B cell (CD19+) count and BMI explained 13.6% of the variability 
(P=0.047). 
In conclusion, Future work is needed to study the contribution of lifestyle factors, in particular 
physical activity and dietary composition, to the responsiveness to the present treatment. Research in 
the field of personalised nutrition will allow a more streamlined approach to weight loss and contribute 
to manage the current obesity epidemic.  
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1. Introduction 
1.1. Definition of obesity, diagnosis, classification and epidemiology 
Obesity is the accumulation of excessive body fat to the extent that it has a negative influence on 
overall health (James et al., 2000; Ogden et al., 2007).  
The World Health Organisation (WHO) has stated that in 2008 half a billion adults worldwide were 
obese (WHO, 2013). Since 1980, the prevalence of obesity throughout the world has doubled (as 
reviewed by Bhurosy & Jeewon, 2014).  Obesity is a growing issue, not only in the developed world 
but also in developing countries (Bhurosy & Jeewon, 2014). The large increase in obesity prevalence 
is a major problem for healthcare systems throughout the world. The United Kingdom Government 
reported the cost accrued by the National Health Service (NHS) in England because of obesity was 
above £5 billion (UK Department of Health, 2015). This equates to 5% of the total NHS budget. It has 
been estimated that in other European countries the cost attributed to obesity and obesity-related 
illnesses is around 6% to 10% of total health department budgets (Finkelstein et al., 2009). Obesity-
related spending within the United States in 2010 was estimated at $315.8 billion, accounting for 
27.5% of health care expenditure (Cawley et al., 2014). This is a dramatic increase since 2008, where 
the United States health care cost for obesity-related health issues was $147 billion (Finkelstein et al., 
2009). A study conducted by Finkelstein and co-workers (2012) predicted that in the next two decades 
there will be a 33% increase in the prevalence of obesity, assuming the current trends continue. In 
light of this increase, the strain on the global health care systems will increase. This perspective 
demonstrates the importance of research within this field. 
 
There are several methods used to diagnose obesity. The most common and widely used is body 
mass index (BMI), which is calculated as:   
𝐵𝑀𝐼 =  
𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡 (𝑚)2
 
Adolphe Quetelet (1796–1874) first proposed this method for calculating BMI in 1832 (Eknoyan, 
2008). BMI classifies individuals into four main groups according to their score (Table 1.1); these cut 
offs apply to populations of non-Asian origin. In research and clinical fields, there has been an 
increase in the use of waist circumference (WC) as a method of identifying obese and overweight 
individuals, particularly those with abdominal obesity (Hu, 2007) (Table 1.1). Waist circumference (Wei 
et al., 1997; Welborn & Dhaliwal, 2007) along with waist-to-hip ratio (WHR) (Jansses et al., 2005; 
Bigaard et al., 2005) and waist-to-height ratio (WHeR) (Ho et al., 2003; Ashwell & Hsieh, 2005) 
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provide greater insight than BMI when assessing central adiposity. Alberti and colleagues (2009) 
discussed that abdominal adiposity consists of visceral fat which is metabolically active with strong 
associations with metabolic deregulation. Indeed, abdominal obesity has presented stronger 
associations than BMI with markers of disease such as serum levels of inflammatory proteins (Bastard 
et al., 2006; Hsiech et al., 2007).  
 
Table 1.1. Classification of obesity according to BMI, waist circumference, WHR and WHeR 
Classification BMI (kg/m2) WC (cm) WHR WHeR 
F M F M 
Under weight  ≤ 18.4 - - - - - 
Healthy weight 18.5 to 24.9 <80 < 94 <0.85 <0.90 <0.5 
Overweight  25 to 29.9 80 – 88 94 - 102 - - - 
Obese 30 to 39.9 >88 >102 ≥0.85 ≥0.90 <0.5 
Morbidly obese  ≥ 40 - - - - - 
Information sourced or BMI (National Health Service Choices, 2016); WC (National Insitute for Health Care 
Excellence, 2014); WHR (WHO, 1999); WHeR (Hsieh et al., 1995). BMI: body mass index; WC: waist 
circumference; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio; F: female; M: male.  
 
1.2. Causes of obesity  
It has been shown that the regulation of body weight has a significant genetic influence (Hjelmborg et 
al., 2008); however, genetics alone cannot account for the dramatic weight gain that has occurred 
over the past three decades which therefore, suggests a large environmental component. The culture 
and lifestyle of the western world promotes high consumption of energy rich foods and sedentary 
lifestyles (Hill & Commerford, 1996; Halton et al., 2006; Carrera-Bastos et al., 2011). French and co-
workers (2001) stated that this dietary and lifestyle pattern is also often related to increased 
prevalence of metabolic diseases (reviewed by Han & Lean, 2016). Over the past few decades it has 
been shown that a variety of internal regulators mediate the crosstalk between adipose tissue and 
metabolic organs, for example the liver, muscle, and the pancreas (Rosen & Spiegelman, 2006). With 
excess adiposity, dysfunctions in adipokine signalling pathways often result in impaired organ 
communications and metabolic abnormalities (Trujillo & Scherer 2006)(Table 1.2). 
 
7 
 
Table 1.2. Obesity related metabolic abnormalities  
 
The increase in the prevalence of obesity could be attributed to the spread of the western diet. 
Westernised diet is defined as a dietary pattern that is high in red and processed meat, refined grains, 
sugar and fat, and low in polyunsaturated fatty acids and fibre (Halton et al., 2006). This high–energy, 
low-fibre diet was originally observed in high-income, developed countries; however, its emergence in 
the developing world has greatly increased (Popkin, 2006). Alongside the spread of this westernised 
diet, an increase in degenerative diseases has been witnessed (reviewed by Carrera-Bastos et al., 
2011). However, whether it is strictly the caloric content of the food consumed or the quality of the diet 
as well that plays a role in inducing body adiposity and metabolic abnormalities is under debate 
(Heinonen et al., 2014).  Furthermore, is it the obesity that promotes the metabolic abnormalities, or 
the diet? Diets that have high fat contents has been shown to promote obesity (Mozaffarian et al., 
2011), however, it is generally unknown as to whether it is the high fat content or the western diet, that 
is rich is fat and sugar that exacerbates the promotion of obesity and other metabolic abnormalities 
(Heinonen et al., 2014). 
In addition to the spread of energy-dense food with a low fibre content, the reduction of energy 
expenditure due to low levels of physical activity and the promotion of a sedentary lifestyle are 
significant contributors to the prevalence of obesity (Bann et al., 2015) as a result of a positive energy 
balance. Energy intake exceeding energy expenditure results in an increase of body mass, of which 
60 to 80% is generally body fat (Hill & Commerford, 1996). The whole world has observed a dramatic 
increase in the availability of energy dense foods and sedentary lifestyles. This has led to the 
explosion in the prevalence of obesity and other related metabolic disorders (Chaput et al., 2011). 
 Early developmental factors have also been shown to influence obesity in adulthood. A 
plethora of articles have provided evidence to support that early developmental factors, such as birth 
weight (Parlee & MacDougald, 2014), or the effect of breastfeeding (Dietz, 2001) can have a 
significant effect on adult susceptibility to excessive weight gain. Parlee and MacDougald (2014) 
discussed in detail the relationship between birth weight and adult obesity. When using birth weight 
Metabolic abnormalities  Reference  
Type 2 diabetes mellitus  Donini et al., 2010; Kassi et al., 2011;  Cawley 
and Meyerhoefer, 2012 
Cardiovascular disease  Donini et al., 2010; Lubrano et al., 2012;  
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relative to parental size, a linear relationship was presented with BMI at ages seven, eleven, sixteen 
and twenty-three (Parsons et al., 2001). The same study also found that birth weight started to present 
a J shaped relationship with BMI from the age of thirty-three, showing both low and high birth weight 
were weakly correlated with subsequent obesity (Parsons et al., 2001). A relationship between birth 
weight and adult BMI, waist-to-hip ratio and body fat percentage has also been demonstrated in 
various other studies (Law et al., 1992; Dolan et al., 2007; Chen et al., 2012). The idea that both high 
and low birth weight can promote obesity in adult populations has created controversy. A meta-
analysis of fifteen studies only found a relationship between higher birth weight and the risk of being 
overweight and obese (Zhao et al., 2012; as reviewed by Parlee & MacDougald, 2014). On the other 
hand, in-utero nutritional deficiency has been shown to have both a promoting and preventative effect 
on adult obesity, depending on which gestational period it occurs (Ravelli et al., 1976). Ravelli and 
colleagues found that individuals who were exposed to famine in the last trimester of pregnancy and 
the first months of life presented significantly lower BMI values, while those exposed during the first 
half of the pregnancy reached higher BMI when adults (Ravelli et al., 1976). These differential 
development may explain the discrepancies in the findings on the relationship between birth weight 
and obesity prevalence that is observed within the literature.  
 Breastfeeding is another early developmental factor that has been shown to have an impact 
on adult obesity prevalence. Breastfeeding has a vast array of beneficial effects, such as reducing the 
prevalence of asthma and respiratory infections (Del Giudice et al., 2012), atopic eczema (Salpietro et 
al., 2011), or celiac disease (Akobeng et al, 2006). Dietz’s (2001) was one of the original studies to 
report a protective role of breastfeeding upon obesity prevalence in later life. A meta-analysis of 28 
studies conducted in 2005 suported that breastfeeding may act as a protective agent against the 
development of obesity(Owen et al., 2005), and a study commissioned by the WHO in 2007reported 
that breastfeeding reduced obesity prevalence in adults by as much as 22%  (Horta et al., 2007). 
Another study accounting for various maternal factors concluded that exclusive breastfeeding for 6 to 
7 months of age was strongly associated with an overall reduction in prevalence of overweight and 
obesity in comparison to infants fed by formula (Yamakawa et al., 2013; as reviewed by Marseglia et 
al., 2015).  The association between breastfeeding and obesity  could be due to human milk’s 
involvement in the programming of energy balance and regulation; from day to day the milk changes 
and influences the metabolic state of the infant, which in turn affects the BMI later in life (Dewey, 1998; 
Rodriguez-Palmero et al., 1999; as reviewed by Marseglia et al., 2015). In contrast to the above 
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studies, others did not find a protective effect of breastfeeding upon obesity in later life (Kwok et al., 
2010; Mohammadreza et al., 2012). Kwok and co-workers (2010) found that in a non-European setting 
breastfeeding did not reduce the risk of excess adiposity in children. Cofounding with environmental 
factors in the non-European settings were proposed as the reason (Kwok et al., 2010).  
1.3. Obesity related disorders: role of inflammation 
Obesity is connected to various medical conditions, such as metabolic syndrome (Table 1.2). An 
underlying inflammatory cause has been identified as the origin of metabolic disorders (Hotamisligil, 
2006). Obese individuals present higher circulating levels of inflammatory proteins, such as tumour 
necrosis factor alpha (TNFα), interleukin (IL) 6, or C-reactive protein; this has led to the suggestion of 
a relationship between obesity and inflammation (Festa et al., 2001; Bullo et al., 2003; Park et al., 
2005; Bastard et al., 2006; Perez de Heredia et al., 2012; Schmidt et al., 2015). Inflammatory 
cytokines (Furthermore, those with abdominal obesity present significantly higher values again in 
comparison to those without (except TNF-α).  The accumulation of excessive adiposity is linked to 
activation of immune cells and the establishment of an inflammatory response (Van Gaal et al., 2006; 
Esser et al., 2014). Elevated levels of inflammatory cytokines are the most probable link between 
obesity and metabolic disorders, in particular insulin resistance (Schmidt et al., 2015).Cytokines such 
as IL-1β hold an important role in the development of insulin resistance and type-2 diabetes (Larsen et 
al., 2007). IL-1 blockade using the IL-1-receptor antagonist anakinra can be sufficient to improve 
glycemia and insulin secretion (Larsen et al., 2007). In addition to this, Winer and colleagues (2011), 
showed that B cells promote insulin resistance through modulation of T cells and production of 
pathogenic IgG antibodies. This therefore suggests a critical role of obesity related inflammation in the 
development of metabolic syndrome. However, it is difficult to truly confirm which proceeds the other. 
It is a two way road, fatty acids can trigger inflammatory actions from macrophages through binding to 
toll-like receptors (Pal et al., 2012; Huang et al., 2012).  
 
The cells responsible for fat storage within adipose tissue are the adipocytes. Adipocytes 
contain large lipid droplets that encompass more than 95% of the entire body of the cell. The lipid 
droplet is used as a storage vessel for triglycerides. As the majority of the cell is dedicated to the 
storage of lipids, this led to the classic idea that adipose tissue’s sole responsibility was as a passive 
fat storage system. Over the past few decades, however, this viewpoint has undergone a dramatic 
shift. Adipose tissue is now considered to be a complex endocrine and immune organ (Grant & Dixit, 
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2015; Booth et al., 2016). The discovery of leptin in the early 1990’s by Zhang and colleagues (1994) 
led to an expansion in the understanding of the various roles that adipose tissue plays. Firstly, leptin 
was acknowledged as a regulator of body weight through the control of appetite and energy 
expenditure (Friedman & Halaas, 1998). It was then demonstrated to have an important relationship 
with the innate and adaptive immune system (Sanchez-Margalet et al., 2003). Leptin’s roles include 
promoting the production of IL-1, IL-6, IL-12, and TNF-α, and stimulating the innate immune response. 
Further to this, leptin is able to activate neutrophil chemotaxis, which in turn stimulates the production 
of reactive oxygen species (ROS), promoting the activation of phagocytosis by macrophages and their 
secretions (Zhao et al., 2003), demonstrating that leptin has the capability to act as a pro-inflammatory 
cytokine. 
 
Adipose tissue has the ability to secrete a variety of adipokines as well as pro- (e.g. TNF-α, IL-
1β) and anti-inflammatory (e.g. IL -10) cytokines (see Table 3). These proteins are capable of 
modifying insulin sensitivity both locally within adipose tissue and systemically (Grant & Dixit, 2015). 
Makki and co-workers (2013) discussed that adipose tissue of lean individuals favours the production 
of anti-inflammatory adipokines such as adiponectin, transforming growth factor beta (TGFβ), IL-10, 
IL-4, IL-13, and apelin, whereas, in contrast, the adipose tissue in obese individuals mainly releases 
pro-inflammatory adipokines including TNF-α, IL-6,  angiotensin II, and plasminogen activator inhibitor 
1 (Ouchi et al., 2011). Increased adiposity is therefore associated with increased levels of circulatory 
pro-inflammatory cytokines and acute-phase proteins (Pi-Sunyer, 2002; Caballero, 2003; Berg & 
Scherer, 2005). 
 
Consequently, obesity has been proposed as a state of low-grade chronic inflammation (Festa 
et al., 2001; Gregor & Hotamisligil 2011). Fundamental indicators are, however, not observed within 
this form of inflammation; redness, swelling, heat and pain are not present (Medzhitov, 2008). Instead, 
the inflammation in obesity is of a different nature; it is slow and unspecific, unlike normal inflammation 
that is rapid and focused to a site of injury or infection, which is normally neutralised and resolved 
(Hotamisligil, 2006). The use of circulating values of inflammatory cytokines can be useful to detect 
adipose deregulations and potential onset of metabolic disorders.  
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Table 1.3. Cytokines and their link to inflammation and obesity 
CRP: C-reactive protein; TNFα: Tumor necrosis factor alpha; IL-6: Interleukin-6; IL-1β: Interleukin-1 Beta; 
IL-4: Interleukin-4; IL-10: Interleukin-10 
  
1.4. Weight loss interventions 
1.4.1. Different approaches to weight loss 
Weight loss has been associated with reductions in the risk of morbidity and mortality (Poobalan et al., 
2007). There are various forms of therapeutic approaches to weight loss; these include 
pharmaceutical, surgical, behavioural changes, and dietary supplements (Avenell et al., 2004, Pories, 
2008; Caveny et al., 2011) 
 Pharmaceutical options have been shown to have lower uptake as a method of obesity 
treatment. Kushner (2014) discussed that pharmaceuticals are shrouded in concerns over safety. 
Drugs previously developed for weight loss have been removed from the marketplace due to 
undesired side effects. One such example would be amphetamines which were released in the 1930’s 
as appetite suppressors/anorexiants. The use of amphetamines carried the risk of addiction along with 
various side effects, such as euphoria, increased blood pressure, pulmonary hypertension, cardiac 
valvulopathy and even depending on dose, symptoms indicative of paranoid schizophrenia (Carney, 
1988; Silverstone, 1992; Abenhaim et al., 1996; Jick, 2000). Side effects such as these led to a 
reduction in peoples’ willingness to use pharmaceutical methods. Further development of these drugs 
allowed the desired anorectic effect without the stimulatory properties and potential addictiveness (as 
reviewed by Kushner, 2014). The most common of these appetite suppressors are the five compounds 
phentermine, benzphetamine, phendimetrazine, diethylpropion and mazindol. Mazindol was removed 
from the United Kingdom market in 1972 for links to risk of cardiac valvulopthay, whereas 
benzphetamine, phendimetrazine, diethylpropion and phentermine are still currently prescription based 
Cytokine  Effect in obesity References  
Pro- inflammatory    
CRP Elevated inflammation  Festa et al., 2001; Park et al., 
2005 
TNFα Increased inflammation and 
increased glycaemic 
deterioration 
Bulló et al., 2003; Park et al., 
2005; Ouchi et al., 2011; Schmidt 
et al., 2015 
IL-6 Obesity Park et al., 2005; Ouchi et al., 
2011 
IL-1β Increased glycaemic 
deterioration  
Dalmas et al., 2014  
Anti-inflammatory    
IL-4 Pro – M2 – properties  Schmidt et al., 2015 
IL-10 Reduces Treg activity  Schmidt et al., 2015 
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drugs approved for a 12-week basis (as reviewed by Caveny et al., 2011). Another form of 
pharmaceutical approach is to use gastrointestinal fat blockers; a drug used in this approach is 
Orlistat. This drug is a synthetic hydrogenated derivative of the naturally occurring lipase inhibitor 
lipostatin. This is an over-the-counter gastrointestinal fat blocker aimed as an inhibitor of pancreatic, 
gastric and carboxylester lipases and phospholipase A2, which are used in the hydrolysis of dietary fat 
(as reviewed by Kushner, 2014). Pancreatic lipase is a triglyceride digestion enzyme that is located in 
the small intestine. The lipase is secreted from the pancreas and is responsible for the hydrolysis of 
triglycerides into glycerol and fatty acids (Lowe, 1994). Therefore, combatting obesity with inhibitors of 
this enzyme, which in turn supresses the digestion of triglycerides has been suggested as a major 
approach in the prevention and treatment of obesity (Cha et al., 2012). Orlistat, however, carries a list 
of side effects, principally diarrhoea, faecal incontinence, oily spotting, flatulence, bloating and 
dyspepsia (Padwal et al., 2004; Ioannides-Demos et al., 2006).  
Bariatric surgery can be considered one of the most effective treatments for obesity (Pories, 
2008). It has high success rate with large improvements to patients’ weight and reduction in metabolic 
comorbidities, and is generally used in cases of morbid obesity (BMI≥40 kg/m2) (Picot et al., 2009; 
Colquitt et al., 2014). However, it has its downsides, too. It is a major surgical intervention that carries 
significant risk of morbidity and perioperative mortality (Colquitt et al., 2013); the risks of surgery 
include poor myocardial reserve, significant chronic obstructive airways disease or respiratory 
dysfunction, non-compliance of medical treatment, and infection (Colquitt et al., 2014). This increased 
risk leads to many individuals not meeting the eligibility criteria for the surgical intervention (Colquitt et 
al., 2009). Bariatric surgery also includes long-term after surgery care, including supplementation with 
vitamins and iron. Finally, it can also present high failure rates in the long term (te Riele et al., 2010). 
(te Riele et al., 2010; as reviewed by Puzziferri et al., 2014).  This may be due to the individual’s desire 
to eat unhealthy foods not being addressed or physiological issues being present (Sala et al., 2017).  
It is also possible to combat the negative impact of obesity through changes in behaviour such 
as eating patterns and physical activity (Avenell et al., 2004). This method of weight loss is a common 
and widespread treatment. Wardle and colleagues (2000) found that within the United Kingdom, 28% 
of adults were reported to have been actively attempting to lose weight using behavioural changes. In 
addition, Nicklas and colleagues (2012) conducted a study on a population of obese individuals from 
the United States that demonstrated that 63% of the participants had attempted to lose weight within 
the previous year using behavioural change treatment. This method has limitations, though. Nicklas 
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and co-workers (2012) reported that success rates in self-guided behavioural changes to induce 
weight loss were limited over a long period. Within the study, 40% of participants had succeeded in 
losing ≥5% of their initial weight and 20% had succeeded in losing ≥10% (Nicklas et al., 2012). In line 
with these findings, Jeffery and colleagues’ (2000) and the National Institutes of Health, National 
Heart, Lung, and Blood Institute’s report (1998) showed that the challenge of the treatment of obesity 
is the long-term maintenance of the weight loss. The findings from these studies showed that within 
first year post treatment the majority of individuals displayed significant weight gain, ranging from a 
third to half the weight they had previously lost (National Institutes of Health, National Heart, Lung, and 
Blood Institute’s report, 1998; Jeffery et al., 2000). Other studies found that only 20% of the 
participants who lost 10% of their initial body weight maintained this loss for a year post treatment 
(Wing & Hill, 2001). In contrast, Thomas and co-workers (2014) found that 87% of participants in the 
National Weight Control Registry were still maintaining at least a 10% weight loss after 10 years. 
Factors that contributed to weight regain, according to this study, were decreased leisure physical 
activity, dietary restraint, and frequency of self-weighing (Thomas et al., 2014).  
1.4.2. Plant polyphenols as nutritional aids in the treatment of obesity  
Various studies have presented the vast range of potential health benefits of natural products in the 
treatment of obesity (McDougall et al., 2008; Yun, 2010; della Garza et al., 2011). Example of this are 
bioactive compounds that act as pancreatic lipase inhibitors, including catechins, tannins, 
isoflavoniods, triterpene saponins or theasaponins (Han et al., 2001; Yoshikawa et al., 2002; Naksi et 
al., 2005; Karu et al., 2007; Guo et al., 2009; Lee et al., 2010). These chemicals fall under the term 
polyphenols. The vast array of polyphenols are classified based on structure, the phenolic hydroxyl 
groups being the common link between them. Variations in the primary aromatic rings, oxidation 
status, and functional groups delineate the individual polyphenols. Four main classifications of 
polyphenols exist in the majority of diets: flavonoids, lignans, phenolic acids, and stilbenes (Garcia-
Villalba et al., 2010). Polyphenols have been suggested to have some potential in reducing the onset 
of obesity via the inhibition of enzymes involved in the metabolism of fat (Yoshikawa et al., 2002). In 
addition, polyphenol extracts have the ability to reduce glucose, triglycerides, low-density lipoprotein 
(LDL) cholesterol and total cholesterol levels in the blood, increase energy expenditure and reduce 
body weight and adiposity (Terra et al., 2009; Garcia-Lafuete et al., 2009). Various foods contain 
polyphenol; fruits, vegetables, nuts, seeds, cocoa, coffee, wine, and chocolate are common sources 
within the diet (Kyle et al., 2006; reviewed by Motilva et al., 2013).  
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Green tea contains an abundance of bioactive substances, including polysaccharides, caffeine 
and polyphenols, primarily catechins (Friedrich et al., 2012). When green tea extracts were 
administered to young men, it was observed that they greatly increased energy expenditure and fat 
oxidation (Dullo et al., 1999; reviewed by Xu et al., 2014). Since the publication of this research, 
various clinical trials have shown the effectiveness of tea preparations on combating obesity through 
the increase of energy expenditure; fat oxidation, weight loss, and weight maintenance (see Table 
1.4.). A study by Nagao and co-workers (2005) demonstrated that there was a significant reduction in 
body weight, BMI, waist circumference and body fat mass in male participants who took a green tea 
extract compared to a control group (see Table 1.4). Nagao and colleagues (2005) presented that the 
decrease in measurement from baseline to post treatment in those who took the active compounds 
was significantly greater than the placebo group (−3.4 ± 0.5 cm and −1.6 ± 0.4 cm, respectively). The 
caffeine content was adjusted in both groups, so that the authors were able to attribute these effects to 
the polyphenols present in the green tea extract: the catechins (Nagao et al., 2005). Further to this, 
Suliburska and colleagues (2012) showed that when their participants had their diets supplemented 
with green tea extract a significant decrease in BMI and waist circumference compared to placebo 
was observed even when the dose of catechins was reduced to a third of that in the study conducted 
by Nagao and co-workers (2005) (see Table 1.4.).  Interestingly, Maki and co-workers (2009) 
observed that the benefits obtained from physical exercise were also increased in individuals 
consuming catechins (∼625 mg) compared to a control group (Maki et al., 2009).  They suggested that 
consumption of catechins could enhance the effects of exercise in weight loss (see Table 1.4.).  
Another potential health benefit of polyphenols is the claim that they are effective in reducing 
inflammation both in general, and that related to obesity (Chiva-Blanch et al., 2014; Martínez-
González et al., 2015). Various epidemiological studies have suggested that populations who have 
polyphenol-rich diets tend to have decreased prevalence of inflammatory disease (Yoon & Baek, 
2005). It should be noted that there may be cofounding present; the effects of the polyphenol-rich diets 
could be attributed to other factors such as olive (Jurado-Ruiz et al., 2017) and fish oils (de Boer et al., 
2016) in Mediterranean diets, or high fibre (Jiao et al., 2015). Mediterranean style diets are shown to 
have beneficial effects on inflammatory disease due to the significant amounts of bioactive 
components, including polyphenols (Siriwardhana et al., 2013). Wang and co-workers (2014) discuss 
in their review that several cell, animal and human studies have demonstrated that dietary bioactive 
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compounds act as anti-oxidants and anti-inflammatory agents, increasing thermogenesis and energy 
expenditure while decreasing inflammation and oxidative stress (Kalupahana & Moustaid-Moussa, 
2012). In addition to this, it has been reported that polyphenols have the ability to suppress the growth 
of adipose tissue through antiangiogenic activity and the modulation of adipose tissue metabolism, 
suggesting they could be useful therapeutic modulators of obesity (Lin & Lin-Shiau, 2006). 
 
There is controversy in the literature regarding the effects of treatments with polyphenols on 
the most common metabolic syndrome biomarkers. For example, studies using supplementation with 
green tea (Basu et al., 2011), cranberries (Broncel et al., 2010), aronia (Stull et al., 2010), blueberries 
(Egert et al., 2009), quercetin and resveratrol (Van der Made et al., 2015) showed no significant 
changes in the production of C-reactive protein (CRP). In contrast, studies using a citrus-based juice 
and hesperidin supplementation demonstrated a significant reduction in CRP and improvement in 
endothelial function in patients diagnosed with metabolic syndrome (Rizza et al., 2011). In this line, 
trials have shown that diets high in fruit and vegetables are associated with a decrease in IL-6 and IL-
1 in obese individuals (Yeon et al., 2012) and improved vascular heath in subjects with cardiovascular 
disease (Macready et al., 2014). An increase in dietary consumption of vegetables has been shown to 
decrease the concentrations of IL-6 but not of other inflammation markers (Navarro et al., 2014). 
Conversely, there have been trials that have not found any change in inflammation and oxidative state 
between subjects in dietary intervention or control groups (Almendingen et al., 2005; Freese et al., 
2004).  
 
Green tea’s abundance of polyphenols has been shown to reduce inflammation markers such 
as IL-6, IL-1, CRP, monocyte chemoattractant protein-1 (MCP-1), and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) in animal studies (Chen et al., 2011; Lu et al., 2012). Green tea 
supplementation has led to decreased serum levels of amyloid alpha (SSA) (Kovacs et al., 2004), 
TNF-α (Bogdanski et al., 2012), CRP (Basu et al., 2011), and leptin (Wang et al., 2008). In contrast, 
various studies have found that diets supplemented with green tea had no effect on levels of 
inflammatory markers such as CRP, IL-6, IL-1, vascular cell adhesion molecule-1 (VCAM-1), soluble 
intercellular adhesion molecule-1 (sICAM-1), adiponectin, and leptin (Basu et al., 2011).  
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Various studies have demonstrated the potential of polyphenols as treatment for reducing 
obesity and obesity-driven inflammation. However, this plethora of studies presents various conflicting 
findings, clearly indicating the need for further research into their effectiveness.  
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Table 1.4. Polyphenols and their effect upon obesity and metabolic syndrome 
 
 
Polyphenol  Effect Author 
Flavonoids  Significant reduction in body weight, 
BMI, waist circumference and body fat 
percentage in males with a doses of 
green tea (oolong tea containing 
690mg catechins, compared to control 
group who got oolong tea containing 
22mg catechins)  
 
Nagao et al., 2005 
 Significant decrease in BMI and waist 
circumference compared to placebo 
was observed           (p = 0.03 and p = 
0.04; respectively), even when the 
dose of catechins (379mg of green tea 
extract, versus a placebo) was 
reduced to a third of that in the study 
conducted by Nagao and co-workers 
(2005).   
 
Sulibruska et al., 2012 
 Percentage in total abdominal fat area 
[−7.7 (−11.7, −3.8) vs. −0.3 (−4.4, 
3.9); P = 0.013], subcutaneous 
abdominal fat area [−6.2 (−10.2, −2.2) 
vs. 0.8 (−3.3, 4.9); P = 0.019], and 
fasting serum triglycerides (TG) [−11.2 
(−18.8, −3.6) vs. 1.9 (−5.9, 9.7); P = 
0.023] were greater in the catechin 
group.  They suggested that 
consumption of catechins could 
enhance the effects of exercise in 
weight loss. 
Maki et al., 2009 
   
 Green tea containing caffeine 
(104mg/d) and catechins (573mg/d). 
Subjects lost 6.4 (±1.9) kg or 7.5 
(±2.2) % of their original body weight 
(P < 0.001) 
Kovacs et al., 2004 
Stilbenes Numerous pathways are associated 
with fat metabolism from stilbenes 
such as adiposegenesis, lipolysis, and 
thermogenesis. 
Chou et al., 2018 
Lignans Improved glycaemic control, at least in 
part, by enhancing insulin signalling 
and sensitivity in diet-induced obese 
mice 
Wang et al., 2015 
Phenolic acids Improved β-cell regeneration, insulin 
secretion, and lipid profiles 
Lartha and Daisy, 2011 
 Glucose uptake through translocation 
and activation of glucose transport 
(GLUT)4 in phosphatidylinositol‐3 
kinase (PI3K)/p‐Akt pathway 
 
Gandi et al., 2014 
Tannins  Lipase inhibitors and lipolytic  Yoshikawa et al., 2002 
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1.4.3. Predictors of responsiveness to weight loss interventions 
A major challenge related to the success of a weight loss intervention program is the identification of 
participants who are not responsive to that specific method (Teixeir et al., 2004; Elfhag & Rossner, 
2005; Teixera et al., 2010; Bacon & Aphramor, 2011). Successfulness of weight loss is not identical in 
every person and great variability is observed within the same treatment. Interesting ideas about 
tailored approaches towards weight loss programs have been proposed as a result of analysis of the 
interaction between genes, dietary habits and behavioural factors (Ordovas, 2008).  
A major contribution to the difference in success of the weight loss intervention programs has 
been attributed to the compliance of the participants (Wright et al., 2010). Non-compliance of 
participants has presented variability within weight loss interventions based on calorie restrictions 
(Foster et al., 1992; Reicke et al., 2010). Foster and co-workers (1992) and Reicke and co-workers 
(2010) both found similar weight loss when they compared diets with calorie intakes of 400kcal/day 
and 800kcal/day. This is most likely because of participants’ difference in compliance with the calorie-
restricted diets. In these studies, between 30-50% of the participants had dropped out of the 
treatments within 3 to 6 months. Compliance is seriously affected in weight loss intervention 
programmes in free-living situations, and over extended periods of time (Crichton et al., 2012; 
Desroches et al., 2013). 
Stroeve and co-workers (2016) observed that a relationship existed between weight loss 
success and the participants’ metabolic function at baseline, and that this relationship was stronger in 
those participants who were morbidly obese. This stronger relationship may be due to the increased 
energy needs observed in morbidly obese individuals (Stroeve et al., 2016). Other factors shown to 
influence weight loss interventions’ success include levels of physical activity (Jakicic, 2009; Delany et 
al., 2014), resting metabolic rate, and resting respiratory exchange ratio (Zurlo et al., 1990; Bray et al., 
2012; Ellis et al., 2012). Other studies showed increased weight loss in those subjects with higher 
baseline bodyweight values (Hansen et al., 2001; Greenberg et al., 2009; Finkler et al., 2012). This 
indicates those individuals with increased body mass may more easily reach an energy deficit.  
Current literature within this field is limited in many areas such as biochemical, endocrine and 
immunological markers. The present study attempted to identify potential predictors of weight loss 
through the analysis of participants’ anthropometric measurements, and biochemical, endocrine and 
immunological markers at baseline. 
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1. Hypotheses and Objectives  
The purpose of this study was to investigate the relationship between anthropometric, metabolic, 
endocrine and immunological factors in a group of overweight/obese subjects before and after 
participating in a weight loss intervention programme, based on the consumption of two beverages 
consisting of green tea, green coffee and apple extracts.  
Secondly, this study attempted to identify potential predictors of responsiveness to the dietary 
intervention.  
 
2.1. The main objectives  
1) To explore the relationships between indices of obesity (BMI, body fat %, WC, WHR, and 
WHeR) and early developmental factors, dietary habits, markers of metabolic function, 
markers of inflammation and counts of circulating immune cells at baseline in the participants.  
2) To investigate the effect of a dietary polyphenol-based weight loss intervention on 
anthropometric measurements, body composition and the biochemical, endocrine and 
immune parameters studied.  
3) To assess the individual responsiveness to the weight loss intervention program, and 
determine if and what factors may be predictors of responsiveness.  
 
2.2. Hypotheses  
1) Post-treatment anthropometry and body composition values will be reduced compared to 
baseline values.  
2) Biochemical, endocrine and immunological levels will be improved as a result of the dietary 
intervention.  
3) Compliance with treatment, caffeine consumption, and indices of obesity (BMI, body fat %, 
WC, WHR, WHeR,) will have the ability to predict responsiveness to this weight loss 
intervention.  
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2. Methods 
3.1. The PRONAOS Project 
The database used within this study was sourced by one of the subprojects of the PRONAOS project. 
PRONAOS was a specific project within the NAOS strategy (Estrategia para la Nutrición, Actividad 
Física y Prevención de la Obesidad, in Spanish: Nutrition, Physical Activity and Obesity Prevention 
Strategy) from the Spanish Government. ). PRONAOS was an initiative of the former (2008) Spanish 
Ministry of Science and Innovation, included in the CENIT (Consorcios Estratégicos Nacionales en 
Investigación Técnica) programme, with the objective to encourage the cooperation between public 
and private sectors to improve R+D+I in Spain. A consortium was formed between industry and 
research institutions and universities with the idea to contribute to the scientific development of new 
food products in order to help reduce the obesity epidemic.  
 The subproject that generated the data for this study was held between the food group DAMM 
and the Immunonutrition Research Group from the Institute of Food Science, Technology and Nutrition 
of the Spanish National Research Council (ICTAN-CSIC).   
 My role within this study consisted on data processing and analysis, and the interpretation of 
the results from this subproject.   
3.2 Weight loss intervention 
3.2.1. Participants and experimental design 
Participants were male and female adults (≥18 years of age; 38 women, 53 men) with a BMI of 
≥ 24.5 kg/m2, but otherwise healthy. They were recruited through posters, leaflets, Facebook and 
email. Written informed consent was obtained from all participants. The study protocol was reviewed 
and approved by the CSIC (Spanish National Research Council) Bioethics Committee and the Ethics 
Committee of the University Hospital “Puerta de Hierro” (Madrid, Spain) (see Annex 1 & 2).  
The experiment consisted on a randomized, double-blind, cross-over intervention. Participants 
were randomly assigned to one of four groups: two groups received an active beverage and two 
received a placebo. The active drinks had differing concentrations of bioactive ingredients that may be 
prospective tools in the reduction and management of body weight. These ingredients are mainly 
polyphenols present in green tea, green coffee, yerba mate and apple, plus L-carnitine. Drinks were 
tested under a double-blind procedure. Participants had to drink 1 litre of the corresponding beverage 
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every day for 8 weeks. After that time, the participants underwent a washout period of minimum 4 
weeks before repeating the protocol with a different treatment (placebo for those who had drunk a 
functional drink and vice versa) (Figure 3.1). Drinks were provided in powdered form, in specially 
designed plastic caps that allowed preservation of the formula and released the content into a 0.5 l 
plastic bottle containing water after being pressed. 
 The participants were monitored six times during the whole intervention: at the beginning of 
each phase, at week 4 in each phase, and at the end of each phase. Of the 91 initial participants, 79 
completed both phases of the intervention. 
 
     Figure 3.1. Experimental design of the weight loss intervention. G: group; B: active; P: placebo. 
3.2.2. Personal history and dietary habits 
Various information was gathered from the participants using a questionnaire. These data included: 
gender, age, country of birth, infant feeding style (breastfeeding or formula, which was decided as 
method received for the first 4 months), and birth weight. 
 Meal frequency was recorded from 3-day dietary records that included 2-week days and 1 
weekend/ festive day. 
 Caffeine consumption was estimated from a food frequency questionnaire, and the following 
were calculated: total caffeine (mg/d), caffeine from tea and coffee (mg/d), caffeine from caffeinated 
and energy drinks per day (mg/d). 
(n = 19) (n = 19) (n = 21) (n = 20) 
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Compliance with the treatment was recorded by requesting the participants to return any unused caps 
at the end of each phase, and calculated as the percentage of caps consumed in relation to caps 
provided. 
 
3.2.3. Anthropometrics  
Anthropometric measurements were conducted on each of the monitoring sessions. During the 
meeting, body weight and body fat % were determined with a bioimpedance scale (BC-545, Tanita, 
Tokyo, Japan), and waist circumference and hip circumference were measured with a flexible, 
inextensible tape; girth measurements were taken three times and the median values were chosen. 
From these measurements, the following indices were calculated: BMI (kg/m2), waist-to-hip ratio 
(WHR) and waist-to-height ratio (WHeR).  
 
3.2.4. Blood analysis  
Fasting blood samples were collected between 8 and 9 am, in vacuum tubes (Vacuette España, S.A.). 
EDTA tubes were used to collect blood samples (3 ml) for the haemogram and lymphocyte 
subpopulations; in order to obtain serum, 10 ml blood samples were collected using dry gel tubes; 2 ml 
blood samples were collected in EDTA tubes and the protease inhibitor aprotinin was added at a 
concentration of 6.5 µg/ml blood (1 µM) for plasma measurements.  
 
Aliquots of blood and serum were sent to an external laboratory (Sanilab Labco, Spain) by refrigerated 
courier for the analysis of: 
- Complete haemogram: red blood cells (x106cells/mm3), haemoglobin (Hb) (g/dl), 
haematocrit (%), mean corpuscular volume (fl), mean corpuscular Hb (pg), mean 
corpuscular Hb concentration (g/dl), platelets (x103/mm3), white blood cells (x103/mm3), 
neutrophils (x103/mm3), lymphocytes (x103/mm3), monocytes (x103/mm3), eosinophils 
(x103/mm3), and basophils (x103/mm3) 
- Biochemistry, hormones and acute phase proteins: concentrations of glucose (mmol/L), 
non-esterified fatty acids (NEFA) (mmol/L), triglycerides (mmol/L), total cholesterol 
(mmol/L), very low-density lipoprotein cholesterol (VLDL-c) (mmol/L), low-density 
lipoprotein cholesterol (LDL-c) (mmol/L), high-density lipoprotein cholesterol (HDL-c) 
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(mmol/L), apolipoprotein A (apoA) (mmol/L), apolipoprotein B (apoB) (mmol/L), iron 
(mg/dL), ferritin (mg/dL), transferrin (mg/dL), ceruloplasmin (mg/dL) and C-reactive protein 
(CRP) (mg/dL). 
 
Insulin resistance was estimated by the homeostatic model assessment (HOMA), calculated as: 
𝐻𝑂𝑀𝐴 =  
𝐺𝑙𝑢𝑐𝑜𝑠𝑒(mg/dl) 𝑥 𝐼𝑛𝑠𝑢𝑙𝑖𝑛(𝑚𝑈/𝑙)  
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Also, blood aliquots (500 ml) were immediately processed in the Immunonutrition laboratory to 
determine the percentages of several lymphocyte subpopulations, according to their membrane 
markers: total leukocytes (CD45+), T mature cells (CD3+), T helper (CD4+), T cytotoxic (CD8+), B 
lymphocytes (CD3–CD19+), natural killer cells (CD3–CD16+56), memory cells (CD3+CD45RO+, 
CD4+CD45RO+ and CD8+CD45RO+) and naive cells (CD3+CD45RA+, CD4+CD45RA+ and 
CD8+CD45RA+). Blood aliquots were incubated for 30 minutes at room temperature in the dark with 
fluorochrome-conjugated monoclonal antibodies (BD Biosciences, San José, CA, USA). A quadruple 
immunostaining procedure was performed as follows: CD3/CD8/CD45/CD4, 
CD3/CD16+56/CD45/CD19, CD45RA/CD45RO/CD4/CD3, and CD45RA/CD45RO/CD8/CD3. Once 
lysis of red blood cells was completed, flow cytometry (FACScan Plus Dual Laser, Becton Dickinson 
Sunnyvale, CA) was used to analyse the lymphocytes. The lympho-gate was defined on the forward 
and side scatter patterns of lymphocytes. The analysis protocol gated on lymphocytes stained with two 
of the fluorochromes and the selected population was then analysed with the two remaining colours, to 
obtain percentages of cell expressing the specific antigens.   
  
For further analysis of hormones and cytokines levels plasma samples were stored at −80 °C. 
Briefly, levels of insulin, ghrelin (pg/ml), leptin (ng/ml), adiponectin (ng/ml), interleukin-1 beta (IL-1β) 
(pg/ml), interleukin-2 (IL-2) (pg/ml), interleukin-4 (IL-4) (pg/ml), interleukin-6 (IL-6) (pg/ml), interleukin-8 
(IL-8) (pg/ml), interleukin-10 (IL-10) (pg/ml), granulocyte macrophage colony-stimulating factor (GM-
CSF) (pg/ml), interferon gamma (IFN-γ) (ng/ml), tumour necrosis factor alpha (TNF-α) (pg/ml), 
vascular cell adhesion molecule 1 (VCAM-1) (ng/ml), intercellular adhesion molecule 1 (ICAM-1) 
(ng/ml) were measured with the Bio-Plex® system and Luminex® xMAP technology (Bio-Rad 
Laboratories, Inc., USA) using a high sensitivity kit (Bio-Rad Laboratories, Inc., USA) and flow 
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cytometer (Bio-Plex® 200 system, Bio-Rad Laboratories, Inc., USA). The same kit was used to 
analyse all the samples and in the same day to avoid inter-assay variation. Beads that have been 
dyed with fluorochromes, associated optics, and high-speed digital signal processor are used in this 
system to identify and detect up to 100 different types of molecules in each single well of a 96-well 
microplate. The color-coded beads are pre-coated with analyte-specific capture antibodies, which bind 
to the hormone/cytokine of interest. Then, biotinylated detection antibodies specific to the analytes of 
interest are added and form an antibody-antigen sandwich. Finally phycoerythrin-conjugated 
streptavidin is added, binding to the biotinylated detection antibodies. Dyed beads are read on the Bio-
Plex® analyser. One laser classifies the bead and determines the analyte that is being detected while 
a second laser determines the magnitude of the phycoerythrin-derived signal, which is in direct 
proportion to the amount of molecule bound. 
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3.3. Work conducted as part of the MPhil investigation: statistical analysis 
All analysis was performed with the statistical program IMB SPSS 23. Significance was set P<0.05. All 
variables were checked for normal distribution using Shapiro-Wilk test prior to statistical testing.  
 
3.3.1. Description of the sample 
A description of the participants (n=91 at baseline; 79 completed the intervention) of the project was 
conducted according to the variables measured during the intervention. These variables were 
compared between genders due to the impact gender has upon many of them. Three participants who 
had indicated that they had taken laxatives were excluded from anthropometric measurement and 
body composition analysis.  
Participants were categorised according to BMI as obese (≥30kg/m2) or overweight 
(≥25kg/m2) (National Health Service Choices, 2016). Participants were classified as abdominally 
obese or not under three different criteria: waist (≥94 cm for males, ≥80 cm for females; National 
Institute for Health Care Excellence, 2014); WHR (≥1:0 males, ≥0.85 females; WHO, 1999); and 
WHeR (≥0.5 for males and females; Hsieh et al., 1995).  
Differences between genders were tested using the Chi Squared test for infant feeding style 
and country of birth. For the rest of variables analysed, genders were compared by the independent-t 
test or Mann-Whitney test, according to normality. 
Analysis of covariance (ANCOVA) (abdominal obesity markergender) was used to compare 
average values of the variables studied between abdominally obese and non-abdominally obese 
participants, according to WC, WHR and WHeR. 
 
 
3.3.2. Relationships between obesity and studied parameters 
The indices of obesity were tested against the participants’ infant feeding style, controlling for gender. 
A two-way ANOVA test was used to compare the indices of obesity between those who received 
breast milk and those who received formula. Participants who received both breast milk and formula 
simultaneously were excluded from this analysis. 
Partial Pearson correlations controlling for gender were used to analyse the relationships 
between markers of obesity, birth weight, caffeine consumption and all blood parameters studied.  
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Finally, participants classified as overweight (≥25kg/2) or obese (≥30kg/m2) were compared for 
their baseline anthropometry and blood parameters using an independent t-test or a Mann-Whitney 
test, according to normality.  
 
3.3.3. Analysis of the effects of the treatments 
Baseline and post-treatment values of the indices of obesity and blood parameters were compared 
within each treatment group, separately in male and female participants, using a paired t-test or a 
Wilcoxon test, depending upon normality. These variables were also analysed by two-way ANOVA, in 
order to compare between baseline and post treatment values, and between placebo and functional 
drinks at the same time, and to account for the interaction between these two factors. This analysis 
was conducted in males and females separately, as well as in the whole sample.    
In addition, relative changes were calculated for each participant, and compared between the 
four drinks (the two functional treatments B1 and B2 and their respective placebos P1 and P2). 
Kruskal-Wallis and ANOVA tests were used for comparison, depending on the normality of the data.  
 
3.3.4. Potential predictors of weight loss 
In order to identify possible predictors of responsiveness to the intervention only the data from the 
functional drinks (B1 and B2) were used.  
The relative change of the participants’ body weight was calculated. Participants were then 
ranked from lowest negative change to the highest positive change. Subjects were put into three 
evenly sized categories: high responsiveness, with a loss of more than 1.5% of body weight; low 
responsiveness, with any increase in body weight; and the middle category, which included 
participants with a relative body weight loss between 1.49% and 0% such as maintainers.  
Distribution of males and females within high and low responsiveness groups was compared 
by the Chi-squared; this was also done for the distribution of the functional drinks (B1 and B2).   
A correlation analysis was run between the relative body weight change and compliance with 
the treatment, estimated caffeine consumption and the baseline values for anthropometry and all 
blood variables. The correlation analysis was run separately on male and female participants as 
gender appeared to exert a significant effect on these relationships.  
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In addition, compliance and baseline values for anthropometry and all blood variables were 
compared between low and high respondents with both male and females combined, as 
responsiveness was not significantly affected by gender. 
 
Variables which presented significant associations with body weight change and were backed 
up by differences between high and low respondents were identified as a potential predictors of weight 
loss. A hierarchical multiple regression analysis was run with these potential predictors to produce a 
predictive model of responsiveness to the treatment for the whole sample, and for males and females 
separately. 
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4 Results 
4.1 Description of the sample 
4.1.1. Demographics, early developmental factors, caffeine consumption, and anthropometric 
characteristics 
Participants were on average 27 years old, and 90% of them Spanish. The majority had been 
breastfed during the first 4 months of life, and birth weight ranged between 3-4 kg approx. No 
differences were found between genders (Table 4.1). 
The variability in the caffeine consumption was high, ranging from no caffeine at all to the 
equivalent of 3-4 expresso cups (approx. 636 – 848 mg of caffeine) a day, with no significant 
differences observed between males and females (Table 4.2).  
The average BMI of the participants corresponded to that of overweight (28.3 kg/m2), with 
indication of abdominal fat deposition (WHeR>0.50) (Table 4.3). The proportion of participants defined 
as obese (BMI>30kg/m2) was 27.7% (25.7% of the female subjects and 28.8% of the males, with no 
significant difference between genders) (Figure 4.1). When assessing the prevalence of abdominal 
obesity in the sample, there was great disparity concerning the three commonly used indicators (Table 
4.4). When waist circumference and WHeR were used, they described the majority of females (>70%) 
as abdominally obese, in contrast to WHR, which displayed most females (>80%) as non-abdominally 
obese. Among male participants, waist circumference presented similar proportions of abdominally 
obese and non-abdominally obese, whereas WHR classified most men as non-abdominally obese 
(79%), and WHeR, in contrast, classified most male participants (77%) as abdominally obese. 
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Table 4.1. Demographics of the total sample and according to gender.  
  All 
(N = 91) 
Females 
(N = 38) 
Males 
(N = 53) 
P 
Age (y)  27 (24-35) 27 (24-34) 27 (24-35) 0.684 
Country of birth 
(% participants) 
Spain 90.1 86.8 92.5  
0.379 
Other  9.9 13.2 7.5 
Feeding style as 
an infant (%)  
Unknown 2.2 0 3.8 
0.426 
Breastfed 54.9 52.6 56.6 
Formula           27.5           31.6           24.5 
Both 15.4 15.8 15.1 
Birth weight (kg)  3.40 (3.00-3.60) 3.20 (2.90-3.50) 3.50 (3.13-3.80) 0.073 
Data presented as median (Q1, Q3), or percentage of participants. Mann-Whitney test used to compare between 
genders; Chi squared test used to compare frequencies for country of birth and feeding style as an infant between 
genders. Feeding style defined by method received in the first 4 months of life. Significance set as P<0.05. 
 
 
 
Table 4.2. Estimated caffeine consumption (mg/day) for total sample and according to gender. 
 All (N = 91) Females (N = 38) Males (N = 53) P 
Total caffeine 110.4 ± 104.4 110.6 ± 96.7 110.2 ± 110.6 0.671 
 0 - 424.8 1.9 – 332.8 0 – 424.8  
Caffeine from tea and coffee 75.8 ± 88.8 70.9 ± 83.9 79.4 ± 92.8 
0.768 
 0 - 296.1 1.9 – 296.1 0 – 286.9 
 
Caffeine from caffeinated and 
energy drinks 
27.8 ± 45.4 25.1 ± 38.5 29.7 ± 50.0 
0.658 
 0 – 276.8 0 – 149.6 0 – 276.8 
 
Data presented as the mean (± SD) and range. Independent-t test was used to compare between genders, with 
significance set at P<0.05.  
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Table 4.3. Anthropometric and body composition measurements in total sample and according to gender.  
 All (N = 91) Females (N = 38) Males (N = 53) P 
Weight (kg) 84.3 ± 12.4 76.2 ± 8.6 90.1 ± 11.5 <0.001 
Height (cm) 171.0 ± 0.10 162.0 ± 6.0 177.0 ± 7.0 <0.001 
Perception of BMI (kg/m2) 27.9 (26.3 – 34.5) 27.75 (26.1 – 36.3) 28.0 (26.3 – 34.5) 0.525 
BMI (kg/m2) 28.3 (26.4 – 34.5) 28.7 (26.9 – 36.5) 28.0 (26.1 – 34.5) 0.726 
Body fat (%) 29.2 ± 8.5 37.9 ± 4.0 23.5 ± 5.0 <0.001 
Waist circumference (cm) 90.0 (84.5 – 107.5) 85.0 (80.0 – 96.5) 92.0 (89.5 – 112.5) <0.001 
Hip (cm) 109.1 ± 7.6 111.9 ± 7.9 107.0 ± 6.7 0.002 
Waist-to-hip ratio 0.84 (0.78 – 0.97) 0.77 (0.72 – 0.91) 0.87 (0.84 – 0.97) <0.001 
Waist-to–height ratio  0.53 (0.50 – 0.63) 0.53 (0.49 – 0.63) 0.52 (0.50 – 0.63) 0.781 
Data presented as the mean ± SD or median (Q1, Q3). Significant differences between genders at P<0.05 highlighted in bold. Mann-Whiney test used to compare perception of 
BMI, BMI, waist circumference, waist-to-hip-ratio, and waist-to-height-ratio between genders; Student’s-t test used to compare weight, height and body fat between genders. 
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Figure 4.1. Classification of female and male participants according to body mass index as overweight 
(BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2). Chi square test was used to compare the proportions of 
the different categories between genders, significance set at P<0.05. 
 
 
  
     Table 4.4. Prevalence of abdominal obesity in the sample, according to three different markers. 
  Females (n=35) Males (n=53) 
WC over threshold Yes 74.3% (26) 43.4% (23) 
 No 25.7% (9) 56.6% (30) 
WHR over threshold Yes 14.3% (5) 20.8% (11) 
 No 85.7% (30) 79.2% (42) 
WHeR over threshold Yes 71.4% (25) 77.4% (37) 
 No 28.6% (10) 22.6% (12) 
Threshold for waist circumference (WC): 80 cm for females, 94 cm for males; for waist-to-hip ratio (WHR): 0.85 
for females, 1.0 for males; for waist-to-height ratio (WHeR): 0.5 for both females and males. 
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4.1.2. Blood cells  
Mean haemogram values for whole population fell within normal values for healthy adults. Female 
participants presented lower red blood cell counts, haemoglobin levels and haematocrit, higher 
platelet counts and transferrin, while male participants presented significantly higher levels of iron and 
ferritin (Table 4.5), while no differences were observed between genders for any of the leukocyte 
variables (Tables 4.6 and 4.7). 
 
Table 4.5. Red blood cell series in total sample and according to gender 
 
All 
(N = 91) 
Females 
(N = 38) 
Males 
(N = 53) 
P 
RBC (x106cells/mm3) 
4.8 
(4.5 – 5.5) 
4.5 
(4.2 – 5.1) 
5.0 
(4.8 – 5.5) 
<0.001 
Hb (g/dl) 14.1 ± 1.3 13.1 ± 0.9 14.9 ± 0.9 <0.001 
Haematocrit (%) 43.0 ± 3.8 40.0 ± 2.9 45.2 ± 2.7 <0.001 
MCV (fl) 89.7 ± 4.4 89.5 ± 4.8 89.9 ± 4.0 0.661 
MCH (pg) 
29.7 
(28.6 – 31.8) 
29.7 
(27.6 – 37.7) 
29.6 
(28.8 – 31.8) 
0.347 
MCHC (g/dl) 32.9 ± 0.9 32.7 ± 0.9 33.0 ± 0 .9 0.058 
Anisocytosis Index 
(%) 
12.6 
(12.0 – 13.2) 
12.5 
(11.8 – 13.4) 
12.6 
(12.1 – 13.2) 
0.710 
Platelets (x103/mm3) 252 ± 51 271 ± 53 249 ± 46 0.003 
Iron (mg/dl) 
86.0 
(59.0 – 160.0) 
76.5 
(50.0 – 156.0) 
94.0 
(72.0 – 168.0) 
0.022 
Ferritin (ng/dl) 
54.0 
(27.0 – 274.0) 
27.5 
(13.0 – 75.0) 
127.0 
(58.0 – 292.0) 
<0.001 
Transferrin (mg/dl) 250.1 ± 50.3 278.5 ± 43.2 229.8 ± 45.2 <0.001 
Data presented as mean ± SD or median (Q1, Q3). Student’s-t test used to compare haemoglobin 
(Hb), haematocrit, mean corpuscular volume (MCV), mean corpuscular Hb concentration (MCHC), 
and platelets between genders. Mann-Whitney test used to compare red blood cells (RBC) count 
and mean corpuscular Hb (MCH) between genders. Differences significant at P < 0.05. 
 
Table 4.6.  White blood cell counts in total sample and according to gender. 
Cells  (x103/mm3) All (N = 91) Females (N = 38) Males (N =58) P 
White blood cells  6.2 (5.2 – 9.4) 6.5 (5.2 – 9.6) 5.9 (5.0 – 9.2) 0.282 
Neutrophils 3.2 (2.6 – 5.4) 3.3 (2.7 – 6.0) 3.1 (2.6 – 5.1) 0.173 
Lymphocytes 2.1 (1.8 – 3.2) 2.1 (1.9 – 3.0) 2.1 (1.7 – 3.6) 0.974 
Monocytes 0.5 (0.4 – 0.8) 0.5 (0.4 – 0.7) 0.5 (0.4 -0.8) 0.642 
Eosinophils 0.2 (0.1 – 0.5) 0.1 (0.1 – 0.5) 0.2 (0.1 – 0.4) 0.386 
Basophils 0.0 (0.0 – 0.1) 0.00 (0.0 – 0.1) 0.00 (0.0 -0.10) 0.688 
Data presented as median (Q1, Q3). Mann-Whitney test used to compare white cell counts between 
genders. Significance set as P<0.05. 
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Table 4.7.  Lymphocyte subset counts in total sample and according to gender. 
Cells/mm3 All (N = 91) Females (N = 38) Males (N =58) P 
CD3+  1608.0 ± 479.8 1631.3 ± 421.1 1591.3 ± 521.1 0.697 
CD3+CD4+ 
900.4 
(720.0 – 1476.2) 
922.5 
(784.0 – 1476.2) 
823.1 
(658.8 – 1547.6) 
0.145 
CD3+CD8+ 
508.6 
(382.6 – 994.5) 
504.0  
394.7 – 932.4) 
508.6 
(356.1 – 1006.7) 
0.681 
CD3+CD19+ 237.2 ± 93.1 217.2 ± 73.3 251.5 ± 103.3 0.083 
NKCD3- (NK) 
237.3 
(154.0 – 698.1) 
229.2 
(154.0 – 556.6) 
239.0 
(160.8 – 771.8) 
0.486 
CD4+RA+ 
353.42 
(232.6 – 676.3) 
373.2 
(262.9 – 707.4) 
315.2 
(224.3 – 614.5) 
0.102 
CD4+RO+ 
476.1 
(404.7 – 855.1) 
526.1 
(404.7 – 855.1) 
455.3 
(391.5 – 932.7) 
0.421 
CD8+RA+ 
297.2 
(213.6 – 631.7) 
301.9 
(219.8 – 631.7) 
288.1 
(194.1 – 784.0) 
0.551 
CD8+RO+ 
211.7 
(138.9 – 554.1) 
188.6 
(142.0 – 566.1) 
214.8 
(138.9 – 554.1) 
0.543 
NKCD3+ 
70.6 
(31.3 – 282.3) 
71.2 
(31.30 – 176.20) 
69.2 
(31.60 – 305.00) 
0.655 
CD4/CD8 
1.80 
(1.32 – 3.39) 
1.87 
(1.37 – 3.27) 
1.84 
(1.27 -3.62) 
0.504 
CD3/CD19 
6.95 
(5.39 – 15.09) 
7.20 
(5.68 – 18.46) 
6.60 
(5.00 – 12.63) 
0.057 
Data presented as the median (Q1, Q3) or mean ±SD. Lymphocyte populations are designated by their cell membrane markers, and defined by the anchor marker, 
which appears in first place of the subset name. Mann-Whitney test used to compare between genders for CD4+, CD8+, NKCD3-, CD4+RA+, CD4+RO+, CD8+RA+, 
CD8+RO+, NKCD3+, CD4/CD8, and CD3/CD19; and Student’s t-test used for CD3+, and CD19+. Significance set at P<0.05. 
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4.1.3. Biochemistry, hormones and cytokines 
The average values of glucose, insulin and lipids fell within the normal range (Table 4.8). Female 
participants had slightly higher concentrations of glucose and insulin, which resulted in significantly 
higher values for the HOMA index. They also presented higher levels of total cholesterol, HDL-c and 
ApoA.  
 
The concentrations of hormones, cytokines and adhesion molecules in the studied sample presented 
great variability. In addition, the levels of certain cytokines fell below the detection levels of the kit used 
for analysis. Female subjects presented significantly higher levels of leptin, ceruloplasmin, CRP, GM-
CSF, and IFNγ. Male participants presented significantly higher levels of IL-1β (Table 4.9).   
 
 
 Table 4.8. Blood biochemistry and iron markers in the total sample and according to gender.  
 
All 
( N = 91)* 
Female 
(N = 38)* 
Male 
(N = 53)* 
P 
Glucose (mmol/L) 4.8 ± 0.7 5.0± 0.4 4.7 ± 0.8 0.076 
Insulin  (mU/l) 
2.2 
(1.5 – 12.8) 
2.2 
(1.57 – 4.4) 
2.1  
1.31 – 18.1) 
0.717 
HOMA 
1.8 
(0.0 – 10.9) 
2.8 
(1.3 – 6.3) 
0.5 
(0.0 – 18.8) 
0.006 
NEFA (mmol/L) 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.482 
Triglycerides (mmol/L) 
4.8 
(3.2 – 12.3) 
4.4 
(3.1 – 9.6) 
4.9 
(3.2 – 13.6) 
0.346 
Total cholesterol (mmol/L) 
9.3 
(8.1 – 18.4) 
9.8 
(8.7 – 13.4) 
8.7 
(7.7 – 11.9) 
0.001 
VLDL-c (mmol/L) 
0.9 
(0.7 – 2.4) 
0.9 
(0.6 – 1.9) 
1.0 
(0.7 – 2.7) 
0.348 
LDL-c (mmol/L) 
5.2 
(4.6 – 8.1) 
5.6 
(5.0 – 8.8) 
5.2 
(4.6 – 7.9) 
0.108 
HDL-c (mmol/L) 2.6 ± 0.8 3.2 ± 0.8 2.2 ± 0.6 <0.001 
APOA (mmol/L) 
7.8 
(7.2 – 11.1) 
8.1 
(7.4 – 11.2) 
7.4 
(6.9 – 9.4) 
0.008 
APOB (mmol/L) 
4.4 
(3.8 – 7.0) 
4.4 
(3.7 – 8.1) 
4.6 
(3.8 – 6.9) 
0.693 
Data presented as median (Q1, Q3) or mean ±SD. Student’s-t test or Mann-Whitney test used, depending on 
normality. Significant differences between genders highlighted in bold, at P<0.05. HOMA: homeostasis model 
assessment; NEFA: non-esterified fatty acids; VLDL-c: very low-density lipoprotein cholesterol; LDL-c: low-density 
lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; ApoA: apolipoprotein A; ApoOB: 
apolipoprotein B. *N values for insulin and HOMA: 84 (all), 36 (females), and 48 (males).  
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Table 4.9.  Circulating levels of adipokines, acute phase proteins, cytokines, and adhesion molecules, in total sample and according to gender.  
 N All N Female N Male P 
Ghrelin (pg/ml) 90 
274.7 
(203.7 – 576.5) 
38 
251.1 
(194.4 – 360.9) 
52 
283.0 
(231.6 – 367.2) 
0.356 
Leptin (ng/ml) 91 
4.84 
(2.44 – 19.43) 
38 
10.88 
(7.86 – 16.36) 
53 
2.86 
(1.43 – 4.24) 
<0.001 
Adiponectin (ng/ml) 91 
4726 
(3285 – 13579) 
38 
5562 
(3770 – 8755) 
53 
4601 
(3285 – 6018) 
0.055 
Ceruloplasmin (mg/dl) 91 
27.1 
(23.7 – 43.4) 
38 
29.2 
(27.0 – 36.6) 
53 
25.0 
(22.2 – 28.3) 
<0.001 
CRP (mg/dl) 91 
0.90 
(0.21 – 11.82) 
38 
1.31 
(0.47 – 3.67) 
53 
0.52 
(0.16 – 1.60) 
0.005 
IL-1β (pg/ml) 26 
0.89 
(0.38 – 670.21) 
15 
0.45 
(0.17 – 1.10) 
11 
3.20 
(0.85 – 9.13) 
0.003 
IL-2 (pg/ml) 19 
39.3 
(10.6 – 8905.6) 
1 66.6 18 
30.9 
(10.6 – 72.8) 
0.632 
IL-4 (pg/ml) 17 
2.33 
(0.68 – 4.84) 
0 - 17 
2.33 
(0.68 – 4.84) 
N/A 
IL-6 (pg/ml) 91 
13.1 
(8.8 – 58.6) 
38 
14.0 
(8.1 – 18.0) 
53 
12.9 
(9.0 – 19.5) 
0.968 
IL-8 (pg/ml) 91 
22.6 
(16.3 – 174.9) 
38 
21.1 
(16.3 – 33.8) 
53 
24.2 
(16.0 – 49.0) 
0.791 
IL-10 (pg/ml) 33 
11.2 
(2.09 – 416.9) 
13 
4.4 
(1.96 – 12.0) 
20 
14.7 
(3.36 – 93.1) 
0.094 
GM-CSF (pg/ml) 71 
291.7 
(140.7 – 1779.2) 
25 
714.8 
(543.7 – 857.7) 
46 
226.4 
(103.7 – 390.1) 
<0.001 
IFNγ (ng/ml) 38 
0.41 
(1.75 – 144.1) 
6 
2.23 
(0.41 – 2.47 
32 
0.31 
(0.10 – 0.77) 
0.041 
TNF-α (pg/ml) 79 
4.44 
(1.75 – 144.05) 
38 
3.47 
(1.75 – 10.17) 
41 
6.65 
(2.69 – 27.39) 
0.148 
VCAM-1 (ng/ml) 91 
108.9 
(95.2 – 165.4) 
38 
108.6 
(102.0 – 125.0) 
53 
109.5 
(94.5 – 131.0) 
0.859 
ICAM-1 (ng/ml) 91 94.6 ± 25.78 38 93.7 ± 18.39 53 95.2 ± 30.7 0.783 
Data presented as the median (Q1, Q3) or mean +SD. Student’s-t test used to compare ICAM-1 between genders, and Mann-Whitney test used for all the other variables. 
Significance set at P< 0.05. CRP: C-reactive protein; GM-CSF: granulocyte macrophage colony-stimulating factor; IL: interleukin; IFNγ: interferon gamma; TNF-α: tumor 
necrosis factor alpha; VCAM-1: vascular cell adhesion protein 1; ICAM1: intercellular adhesion molecule 1. 
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4.2. Relationships between indices of obesity and studied variables 
4.2.1. Indices of obesity and early developmental factors 
The average values in the indices of obesity were lower those participants who had been breastfed, 
the difference being significant for waist circumference for WHR, there was a significant interaction 
between feeding style and gender, with breastfed females but not males presenting lower values than 
the formula-fed counterparts (Table 4.10). 
 
There were moderate significant relationships between birth weight and adult BMI. This was quadratic 
for females (R2 = 0.248, F(2, 28) = 4.627, P = 0.018) (Figure 4.2), suggesting a U-shaped association 
between birth weight and BMI, with the optimum range between approximately 3 – 3.5 kg. In males, 
the relationship was linear (R2 = 0.139, F(1, 49) = 7.900, P = 0.007) (Figure 4.3). Strong significant 
quadratic relationships were observed as well between birth weight and abdominal obesity indices; 
moderate in females (waist circumference: R2 = 0.358, F(2, 28) = 7.802, P = 0.002; WHeR: R2 = 0.311, 
F(2, 28) = 7.006, P = 0.003) (Figures 4.4 and 4.5), and moderate in males (R2 = 0.148, F(2,48) = 4.181, P 
= 0.021) (Figure 4.6). 
 
Table 4.10. Body composition of sample according to gender and feeding habits as infants.  
 Females (N =32) Males (N =43) P feeding P interaction 
 Breastfed Formula Breastfed Formula   
N 20 12 30 13   
BMI (kg/m2) 28.4 ± 3.0 30.2 ± 3.2 28.4 ± 3.1 29.2 ± 3.1 0.343 0.626 
Body fat (%) 37.2 ± 3.3 39.5 ± 4.3 23.1 ± 5.3 24.1 ± 4.0 0.522 0.757 
WC (cm) 83.3 ± 5.6 89.8 ± 7.6 94.3 ± 9.4 96.1 ± 7.6 < 0.001 0.160 
WHR 0.74 ± 0.06 0.82 ± 0.08 0.89 ± 0.06 0.88 ± 0.07 0.234 0.022 
WHeR 0.51 ± 0.04 0.57 ± 0.06 0.53 ± 0.05 0.53 ± 0.05 0.157 0.088 
Data presented as mean ± SD. Two-way ANOVA test was used to analyse the effect of gender and feeding style. 
Significance set at P< 0.05. BMI: body mass index; WC: waist circumference; WHR: waist-to-hip ration; WHeR: 
waist-to-height ratio. 
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Figure 4.2. Association between birth weight (kg) and BMI (kg/m2) in females (n=34, 
R2 = 0.248, P = 0.018). 
 
 
 
Figure 4.3. Association between birth weight (kg) and BMI (kg/m2) in males (n=51, 
R2 = 0.139, P = 0.007). 
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Figure 4.4. Association between birth weight (kg) and waist circumference (cm) in females 
(n=34, R2 = 0.358, P = 0.002). 
 
 
 
Figure 4.5. Association between birth weight (kg) and waist-to-height ratio (WHeR) in females 
(n=34, R2 = 0.311, P = 0.003). 
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Figure 4.6. Association between birth weight (kg) and waist circumference (cm) in males 
(n=51, R2 = 0.148, P = 0.021). 
 
 
4.2.2. Indices of obesity, estimated caffeine consumption and dietary habits 
None of the indices of obesity studied presented any significant correlations with total consumption of 
caffeine per day, caffeine from tea and coffee, or caffeine from caffeinated and energy drinks (Annex 
9).  
The majority of the participants presented a high frequency of meals per day; only 1 in 5 
(24%) skipped breakfast always or sometimes, and 82% ate four or more times a day. Table 4.11 
presents the average values for different indices of obesity in relation to the number and type of meals 
consumed by the participants. No significant difference was observed between individuals who 
consumed breakfast, mid-morning snack, lunch, afternoon snack and evening meals and those who 
did not. Similarly, there were no significant differences between participants who consumed a higher 
number of meals per day (4 or more) and those who had fewer meals (3 or fewer).
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Table 4.11. Values of different indices of obesity according to meal distribution patterns.  
 
Data presented as the mean ± SD. Significance set at P<0.05, analysed by two-way ANOVA. Pg: Significance for gender effect; Pm: Significance for meal effect; Pi: Significance 
of the interaction. BMI: body mass index; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio; Y: yes; N: no; S: sometimes; N/S: no/sometimes. 
 
 Female (N = 38) Male (N= 53) Pg Pm Pi 
 
N 
BMI 
(kg/m2) 
Body 
Fat (%) 
Waist 
(cm) 
WHR WHeR N 
BMI 
(kg/m2) 
Body Fat 
(%) 
Waist  
(cm) 
WHR WHeR 
   
Breakfast        Y 28 28.8 ± 3.0 37.9 ± 4.4 86.4 ± 7.8 0.77 ± 0.07 0.53 ± 0.06 29 28.3 ± 2.8 23.2 ± 4.8 94.5 ± 9.3 0.89 ± 0.07 0.53 ± 0.05 0.278 0.386 0.478 
N/S 5 30.0 ± 3.7 38.6 ± 2.3 88.2 ± 6.2 0.78 ± 0.08 0.54 ± 0.01 13 28.4 ± 2.7 23.2 ± 4.9 93.5 ± 5.3 0.87 ± 0.06 0.52 ± 0.05    
Mid-Morning  Y 12 28.9 ± 3.3 38.2 ± 4.9 88.3 ± 7.4 0.77 ± 0.07 0.53 ± 0.07 12 28.1 ± 3.1 23.8 ± 5 92.6 ± 7.8 0.88 ± 0.09 0.53 ± 0.07 0.356 0.789 0.861 
N 5 28.8 ± 4.3 38.0 ± 4.4 83.6  ± 8.0 0.77 ± 0.08 0.52 ± 0.06 9 28.4 ± 2.7 22.2 ± 3.4 97.5 ± 9.6 0.87 ± 0.06 0.53 ± 0.04    
S 16 29.1 ± 2.7 37.9 ± 3.7 87.0  ± 6.2 0.78 ± 0.08 0.53 ± 0.04 21 28.4 ± 2.8 23.3 ± 5.3 92.1 ± 3.2 0.89 ± 0.05 0.53 ± 0.04    
Lunch             Y 32 29.0 ± 3.1 37.9 ± 4.2 86.7 ± 7.7 0.77 ± 0.07 0.53 ± 0.05 39 28.5 ± 2.8 23.4 ± 4.8 94.7 ± 9.0 0.89 ± 0.06 0.53 ± 0.05 0.421 0.547 0.487 
N/S 1 28.8 40.2 87.0 0.82 0.54 3 26.2 ± 1.6 20.9 ± 4.6 89.8 ± 2.3 0.82 ± 0.04 0.49 ± 0.02    
Afternoon       Y 6 29.1 ± 2.6 38.0 ± 3.8 89.1 ± 6.6 0.76 ± 0.04 0.52 ± 0.04 13 26.9 ± 1.6 21.3 ± 4 93.8 ± 10.1 0.88 ± 0.05 0.52 ± 0.03 0.328 0.347 0.262 
N 12 28.9 ± 3.4 37.9 ± 4.0 83.8  ± 7.8 0.76 ± 0.09 0.52 ± 0.06 10 29.7 ± 2.6 25.2 ± 4.4 94.9 ± 7.9 0.91 ± 0.08 0.55 ± 0.06    
S 15 29.1 ± 3.2 38.1 ± 4.7 78.5  ± 4.9 0.80 ± 0.06 0.55 ± 0.06 19 28.6 ± 3.1 23.4 ± 5.2 96.3 ± 11.5 0.87 ± 0.06 0.53 ± 0.05    
Evening          Y 31 29.0 ± 3.1 38.0 ± 4.1 87.5 ± 7.3 0.77 ± 0.07 0.53 ± 0.05 34 28.3 ± 2.7 23.0 ± 4.5 94.7 ± 9.1 0.89 ± 0.06 0.53 ± 0.05 0.341 0.784 0.698 
N/S 5 29.4 ± 2.3 39.4 ± 3.2 81.3 ± 8.0 0.79 ± 0.06 0.54 ± 0.01 8 28.2 ± 3.3 24.0 ± 6.0 91.8 ± 5.1 0.86 ± 0.08 0.53 ± 0.06    
≥4 meals/day 26 29.2 ± 2.8 38.5 ± 3.9 86.1 ± 6.7 0.78 ± 0.07 0.54 ± 0.05 33 28.3 ± 2.8 23.3 ± 5.0 94.8 ± 8.1 0.89 ± 0.06 0.53 ± 0.05 0.415 0.783 0.652 
≤3 meals/day 5 28.3 ± 4.9 35.3 ± 5.1 83.2 ± 8.5 0.72 ± 0.06 0.49 ± 0.04 8 28.5 ± 3.2 22.9 ± 4.5 94.0 ± 9.3 0.87 ± 0.07 0.53 ± 0.05    
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4.2.3. Indices of obesity and blood cells 
Moderate but significant positive correlations were observed between all indices of obesity except 
WHR and red blood cell counts and platelets (Table 4.12). In this line, when overweight and obese 
participants were compared, the red blood cell count was significantly higher in the latter (4.75 ± 0.45 
vs 4.96 ± 0.35 x106 cell/mm3, respectively, P=0.035). In contrast, significant negative correlations were 
observed between BMI, waist circumference and WHeR and the size and haemoglobin concentration 
of red blood cells. Ferritin was positively correlated with BMI in the total sample (Table 4.12), until split 
according to gender, when females presented a negative trend (Figure 4.7).  
All indices of obesity except body fat (%) presented weak but significant positive correlations 
with total white blood cell counts, however, when split according to gender only females presented a 
significant correlation (Figure 4.8). Positive correlations were also found between all indices of obesity 
and neutrophil counts (Table 4.13). Lymphocyte counts were inversely correlated with body fat (%) 
and positively with WHR. Monocytes showed significant positive correlations with BMI and WHeR 
(Table 4.13). BMI was also positively associated with memory T helper cells (CD4+RO+) while body fat 
(%) presented a significant negative correlation with T cytotoxic (CD8+) memory/naïve ratio 
(CD8+RO+/CD8+RA+). Abdominal obesity (as WHR) was, however, positively correlated with T (CD3+) 
T cytotoxic (CD8+) cells, and memory TCD8+cells (Table 4.14). 
   
  Table 4.12. Correlation coefficients between indices of obesity and red series and iron status. 
 BMI Body fat (%) WC WHR WHeR 
RBC 0.307** 0.260* 0.266* 0.172 0.341*** 
Hb 0.152 0.129 0.91 -0.033 0.106 
Haematocrit 0.147 0.111 0.101 0.032 0.144 
MCHC -0.221* -0.207 -0.224* -0.17 -0.263* 
MCV -0.221* -0.194 -0.236* -0.254 -0.315** 
MCH 0.001 0.03 -0.029 -0.162 -0.106 
Platelets 0.270* 0.251* 0.253* 0.246 0.384*** 
Iron -0.05 -0.153 -0.058 -0.113 -0.108 
Ferritin 0.329** 0.326** 0.373** 0.246* 0.350** 
Transferrin 0.159 -0.043 0.189 0.141 0.168 
Partial Pearson correlation adjusted for gender. Significance at *P<0.05, **P<0.01, and ***P<0.001. BMI: 
body mass index; WC: waist circumference; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio; RBC: red 
blood cells; Hb: haemoglobin; MCHC: mean corpuscular Hb concentration; MCV: mean corpuscular volume; 
MCH: mean corpuscular Hb. N = 84. 
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Figure 4.7. Association between ferritin (ng/ml) and BMI in females (n=34) and males 
(n = 52). Females: r = −0.188, P = 0.278; males: r = 0.472, P < 0.001. 
 
 
Figure 4.8. Association between white blood cells (WBC) (x103/mm3) and waist-to-height 
ratio (WHeR) in females (n=34) and males (n = 52). Females: r = 0.414, P = 0.013; males: 
r = 0.178, P = 0.203. 
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 Table 4.13.  Correlation coefficients between indices of obesity and white blood cells. 
  BMI Body fat (%) WC WHR WHeR 
WBC 0.220* 0.203 0.247* 0.277** 0.297** 
Neutrophils 0.248* 0.267* 0.255* 0.235* 0.309** 
Lymphocytes 0.073 -0.235* 0.115 0.216* 0.131 
Monocytes 0.235* 0.101 0.193 0.168 0.260* 
Eosinophils -0.007 0.086 0.099 0.118 0.058 
Basophils 0.028 0.105 -0.009 -0.012 -0.002 
Partial Pearson correlation adjusted for gender. Significance at *P<0.05, **P<0.01. BMI: body mass index; 
WC: waist circumference; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio; WBC: white blood cells. 
N = 85. 
 
 
 
Table 4.14. Correlation coefficients between indices of obesity and lymphocyte subsets 
 BMI Body Fat (%) WC WHR WHeR 
CD3+ 0.05 0.011 0.113 0.276* 0.149 
CD4+ 0.135 0.119 0.127 0.184 0.139 
CD8+ -0.047 -0.089 0.047 0.259* 0.104 
CD19+ -0.086 -0.032 0.006 0.068 -0.033 
NK 0.201 0.09 0.05 -0.121 0.042 
CD4+RA+ -0.034 -0.097 -0.033 0.139 0.007 
CD4+RO+ 0.215* 0.182 0.179 0.127 0.169 
CD8+RA+ -0.069 -0.14 0.003 0.23 0.057 
CD8+RO+ 0.031 0.077 0.137 0.216* 0.166 
NKCD3+ 0.046 -0.014 0.058 0.094 0.047 
CD4/CD8 0.089 0.207 0.007 -0.104 -0.021 
CD3/CD19 0.168 0.061 0.131 0.181 0.202 
CD4RO/CD4RA 0.103 0.08 0.065 -0.055 0.036 
CD8RO/CD8RA -0.157 -0.243* -0.120 0.138 -0.048 
Partial Pearson correlations adjusted for gender. Significance set at *P<0.05. Lymphocyte populations are 
designated by their cell membrane markers, and defined by the anchor marker, which appears in first place of the 
subset name. BMI: body mass index; WC: waist circumference; WHR: waist-to-hip ratio; WHeR: waist-to-height 
ratio. N = 85. 
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4.2.4. Indices of obesity and serum biochemistry, adipokines, and inflammation markers 
Moderate significant positive correlations were observed between indices of general and abdominal 
obesity and glucose, HOMA index, triglycerides, total cholesterol, and VLDL-c (Table 4.15 and Figures 
4.9-11). When females and males were tested separately for glucose and waist circumference, only 
females presented a moderate significant correlation (Figure 4.9). When overweight and obese 
participants were compared, glucose, triglycerides and VLDL-c levels were significantly higher in the 
latter (median [Q1, Q3]):  glucose: 4.8 [4.5 – 5.1] vs 5.2 [4.8 – 5.3] mmol/L, P = 0.002; triglycerides: 
4.3 [3.1 – 6.4] vs 5.4 [4.0 – 8.8] mmol/L, P = 0.037; VLDL-c: 0.9 [0.6 – 1.3] vs 1.1 [0.8 – 1.8] mg/dl, P = 
0.041 respectively.   
 
In relation to inflammatory markers, BMI had significant positive associations with leptin, 
ceruloplasmin, CRP and ICAM1 (Table 4.16 and Figures 4.12-15). When ceruloplasmin and ICAM1 
were tested split by gender, only males had significant correlations with BMI (Figures 4.13 & 4.15), 
and the adhesion molecule presented as well a significant positive correlation with WHR in males 
(Figure 4.16). When overweight and obese participants were compared, CRP levels were significantly 
higher in the latter (0.50 [0.17 – 1.53] vs 1.76 [0.55 – 5.88] mg/dl, respectively, P = 0.003). 
Table 4.15.  Correlation coefficients between indices of obesity and blood biochemistry 
 BMI Body Fat (%) WC WHR WHeR 
Glucose 0.235* -0.076 0.345** 0.238* 0.243* 
Insulin 0.132 0.052 0.133 0.109 0.092 
HOMA 0.282** 0.162 0.138 0.233 0.259* 
NEFA 0.092 0.105 0.05 -0.107 0.032 
Triglycerides 0.303** 0.185 0.352** 0.492*** 0.396*** 
Cholesterol 0.175 -0.031 0.19 0.238** 0.223* 
VLDL-c 0.302** 0.184 0.356** 0.494*** 0.397*** 
LDL-c 0.119 -0.033 0.128 0.133 0.151 
HDL-c -0.054 -0.197 -0.087 -0.087 -0.08 
ApoA -0.006 -0.051 -0.047 -0.016 -0.005 
ApoB 0.198 0.159 0.086 0.210* 0.219* 
Partial Pearson correlations adjusted for gender. Significance at *P< 0.05, **P<0.01, and ***P<0.001. BMI: body 
mass index; WC: waist circumference; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio; HOMA: homeostatic 
model assessment; NEFA: non-esterified fatty acids, VLDL-c: very low-density lipoprotein cholesterol; LDL-c: low-
density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; ApoA: apolipoprotein A; ApoB: 
apolipoprotein B. N = 85. 
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Figure 4.9. Association between glucose (mmol/L) and waist circumference (WC) in females 
(n=34) and males (n = 52). Females: r = 0.450, P = 0.007; males: r = 0.103, P = 0.463. 
 
 
 
Figure 4.10. Association between triglycerides (mmol/L) and waist-to-hip ratio (WHR) in 
females (n=34) and males (n = 52). Females: r = 0.419, P = 0.012; males: r = 0.573, P < 
0.001. 
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Figure 4.11. Association between VLDL-c (mmol/L) and waist-to-hip ratio (WHR) in females 
(n=34) and males (n = 52). Females: r = 0.428, P = 0.010; males: r = 0.570, P < 0.001. 
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Table 4.16. Correlation coefficients between indices of obesity and markers of inflammation 
 BMI Body Fat (%) WC WHR WHeR 
Ghrelin -0.166 -0.317 -0.314 -0.009 -0.091 
Leptin 0.396*** 0.183 0.184 -0.085 0.101 
Adiponectin -0.156 -0.392 -0.324 -0.03 -0.139 
Ceruloplasmin 0.312** 0.332 0.369 0.394 0.396 
CRP 0.354*** 0.493 0.098 0.046 0.102 
IL-1β 0.166 0.194 -0.295 -0.034 -0.091 
IL-2 -0.234 -0.202 -0.28 -0.101 -0.187 
IL-6 -0.111 -0.183 -0.133 -0.131 -0.186 
IL-8 -0.169 -0.092 -0.236 -0.405 -0.287 
IL-10 -0.278 -0.194 -0.257 -0.142 -0.199 
GM-CSF 0.193 0.124 0.086 0.335 0.252 
IFNγ 0.152 0.075 0.055 0.361 0.242 
TNFα 0.253 0.147 0.132 0.418 0.318 
VCAM-1 0.357 -0.039 -0.019 0.314 0.342 
ICAM-1 0.232* 0.308 0.375 0.384 0.175 
Partial Pearson correlations adjusted for gender. Significance at *P<0.05, **P<0.01, and ***P<0.001. BMI: body mass index; WC: waist circumference; WHR: waist-
to-hip ratio; WHeR: waist-to-height ratio; CRP: C-reactive protein; GM-CSF: granulocyte macrophage colony-stimulating factor; IL: interleukin; IFNγ: interferon 
gamma; TNF-α: tumor necrosis factor alpha; VCAM-1: vascular cell adhesion protein 1; ICAM-1: intracellular adhesion molecule.  
IL4 not included in the analysis due to insufficient data. N=91
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Figure 4.12. Association between leptin (pg/dl) and BMI in females (n=34) and males (n = 52). 
Females: r = 0.425, P = 0.011; males: r = 0.559, P < 0.001. 
 
 
Figure 4.13. Association between ceruloplasmin (mg/dl) and BMI in females (n=34) and 
males (n = 52). Females: r = 0.293, P = 0.088; males: r = 0.425, P < 0.001. 
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Figure 4.14. Association between C-reactive protein (CRP) (mg/dl) and BMI in females (n=34) 
and males (n = 52). Females: r = 0.355, P = 0.037; males: r = 0.506, P < 0.001. 
 
 
 
 
Figure 4.15. Association between ICAM-1 (ng/dl) and BMI in females (n=34) and males (n = 
52). Females: r = −0.158, P = 0.363; males: r = 0.390, P = 0.004. 
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Figure 4.16. Association between ICAM-1 (ng/dl) and waist-to-hip ratio (WHR) in females 
(n=34) and males (n = 52). Females: r = −0.208, P = 0.231; males: r = 0.340, P = 0.013. 
 
 
 
4.2.3 Abdominal obesity and markers of metabolic disease 
 
Different biochemical and hormonal markers were compared between abdominally obese and non-
abdominally obese participants. In general, values in the abdominally obese groups were higher than 
in the non-abdominally obese groups. Triglycerides, VLDL-c, and leptin presented significantly 
elevated values in the abdominally obese; glucose, total cholesterol, LDL-c, and ApoB presented 
similar trends. HDL-c, iron, ferritin, and ghrelin presented inconsistent directions of difference between 
the abdominally obese and the non-abdominally obese, depending on which criterion was used (Table 
4.17).  
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Table 4.17. Average values of biochemical markers in participants classified as abdominally obese (AO) or non-abdominally obese (Non-AO) according to 
indicators. 
HOMA: homeostatic model assessment; NEFA: non-esterified fatty acids, VLDL-c: very low-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; HDL-c: 
high-density lipoprotein cholesterol; ApoA: apolipoprotein A; ApoB: apolipoprotein B. 1Valid n: For waist circumference: 19 (Non-AO) and 38 (AO); for WHR: 52 (Non-AO) and 5 
(AO); for WHeR: 12 (Non-AO) and 45 (AO). 2Valid n: For Waist circumference: 38 (Non-AO) and 49 (AO); for WHR: 80 (Non-AO) and 7 (AO); for WHeR: 22 (Non-AO) and 65 
(AO). 3Valid n: for waist circumference: 39 (Non-AO) and 47 (AO); for WHR 80 (Non-AO) and 6 (AO); for WHeR: 22 (Non-AO); and 64 (AO). *Values are presented as 
geometric means ±SD for all criteria. #Values are presented as geometric means ±SD for comparisons based on WHR; 

Values are presented as geometric means ±SD for 
comparisons based on WHeR.
  WAIST CIRCUMFERENCE WAIST-TO-HIP RATIO WAIST-TO-HEIGHT RATIO 
  
Non-AO 
(N=39) 
AO 
(N=49) 
P 
Non-AO 
(N=81) 
AO 
(N=7) 
P 
Non-AO 
(N=22) 
AO 
(N=66) 
P 
Glucose (mmol/L)* 4.5±0.1 4.9±0.1 0.087 4.7±0.1 5.2±0.1 0.259 4.6±0.1 4.8±0.1 0.197 
Insulin (pmol/l)*
1
 12.7±2.8 12.7±2.0 0.956 12.5±2.3 14.2±1.6 0.767 11.0±2.2 13.2±2.3 0.493 
HOMA index*
1
 0.4±2.9 0.5±2.2 0.696 0.4±2.5 0.5±1.5 0.733 0.4±2.2 0.5±2.5 0.375 
NEFA (mmol/L)

 0.02±0.01 0.02±0.01 0.872 0.02±0.01 0.02±0.01 0.682 0.02±0.07 0.02±0.07 0.682 
Triglycerides (mmol/L)* 4.2±0.1 5.3±0.1 0.009 4.65±0.1 7.2±0.1 0.016 3.8±0.1 5.2±0.1 0.009 
Total cholesterol (mmol/L) 8.8±1.7 9.6±1.8 0.203 9.1±1.8 10.2±1.3 0.291 8.8±1.8 9.4±1.8 0.127 
VLDL-c (mmol/L)* 0.8±0.1 1.1±0.1 0.010 0.9±0.1 1.4±0.1 0.014 0.8±0.1 1.0±0.1 0.011 
LDL-c (mmol/L)
#
 5.3±1.3 5.6±1.35 0.473 5.3±0.1 5.7±0.1 0.644 5.3±1.4 5.7±1.3 0.274 
HDL-c (mmol/L)* 2.4±0.1 2.6±0.1 0.407 2.5±0.1 2.7±0.1 0.835 2.6±0.1 2.5±0.1 0.677 
ApoA (mmol/L)* 7.9±0.1 7.9±0.1 0.451 7.9±0.1 8.5±0.1 0.511 8.1±0.1 7.9±0.1 0.548 
ApoB (mmol/L)* 4.4±0.1 4.7±0.2 0.245 4.4±0.1 4.9±0.1 0.244 4.2±0.1 4.6±0.1 0.128 
Iron (mg/dl)* 86.6±1.5 79.8±1.7 0.951 85.0±1.5 60.6±1.7 0.123 81.7±1.6 83.2±1.5 0.987 
Ferritin (ng/ml)* 63.86±2.6 53.03±3.6 0.128 60.1±3.1 35.4±3.4 0.984 42.8±2.7 63.6±3.3 0.190 
Transferrin (mg/dl)
#
 237.6±44.4 259.4±51.0 0.460 242.6±1.3 262.4±1.19 0.926 248.2±50.4 250.3±51.5 0.600 
Adiponectin (ng/ml)* 4365.2±0.0 4786.3±0.0 0.842 4786.3±0.0 3388.4±0.0 0.081 4073.8±0.0 4786.3±0.0 0.227 
Ghrelin (pg/ml)
2
* 288.40±1.5 263.03±1.5 0.418 269.15±1.5 331.13±1.6 0.228 269.15±1.4 275.42±1.6 0.728 
Leptin (ng/ml)
3
* 2.57±0.0 6.65±0.0 <0.001 4.07±0.0 8.51±0.0 0.934 3.31±0.0 4.68±0.0 0.005 
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4.3. Effect of the treatments 
4.3.1. On the indices of obesity 
Female participants in group 1 presented significant reductions in waist circumference with both 
treatment B1 and the placebo. Females in group 2 lost weight with both the treatment B2 and the 
placebo, but a reduction in BMI was significant only with the treatment, and reductions in WHR and 
WHeR were significant only with placebo (Table 4.18).  
Male participants in group 1 presented significant reductions in weight and BMI with the 
treatment B1, and in waist circumference, WHR, and WHeR with both treatment and placebo. In group 
2, male participants presented significant reductions in abdominal obesity markers only under the 
treatment B2 (Table 4.19).  
When the interactions between time-point and type of drink and were analysed, no significant 
differences were observed between baseline and post-treatment, or between placebo and functional 
drinks, for any of the variables studied, in females and males separately as well as in the whole 
sample (Supplementary annex 9 & 10).  
 
4.3.2. On the red blood cell series  
No evident effects were observed in the participants after the consumption of treatments B1 and B2 
(Tables 4.20 and 4.21), except for relative changes in haemoglobin concentration in red cells (MCH) in 
males, where all drinks but treatment B1 were associated with an increase (Figure 4.17). 
The analysis of the interactions between time-point and type of drink confirmed the lack of 
significant differences between baseline and post-treatment, and between placebo and functional 
drinks, for most of the variables studied. In both females and males, transferrin levels were 
significantly different between baseline and post-treatment; in males only, iron levels were different 
between placebo and functional drinks. These differences were not observed in the whole sample 
except transferrin (Supplementary annex 9 & 10). 
 
4.3.3. On the white blood cells  
In female participants, treatment B2 had a significant effect on white blood cells, in particular, it 
reduced neutrophil counts (Tables 4.22) No changes were observed in lymphocyte subsets (Table 
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4.24). In male participants, treatment B2presented significant reductions in total white blood cell 
counts and neutrophil counts (Table 4.23; Figures 4.18 & 4.19), total T helper cells (CD4+) and naive T 
helper cells (CD4+RA+) (Table 4.25; Figures 4.20 & 4.21). 
In males, the analysis of the interactions between time-point and type of drink confirmed 
significant differences in white blood cells (P = 0.047, and detected differences in lymphocytes, 
eosinophils and basophils (P < 0.001), between placebo and functional drinks, but not between 
baseline and post-treatment values. In females, CD4+RA+ and CD4+RO+ were significantly different 
between placebo and functional drinks, but not between baseline and post-treatment. When the whole 
sample was tested, the significant difference remained only for basophils (Supplementary annex 9 & 
10).  
 
4.3.4. On the serum and plasma variables  
In females, both treatment B2 and placebo caused significant reductions in glucose and HDL-c, but 
only B2 reduced as well total cholesterol, LDL-c, and ApoA levels (Table 4.26). In males, both B2 and 
placebo caused significant increases in NEFA; B2 also caused a significant increase in glucose, while 
placebo saw a significant increase in VLDL-c and a decrease in ApoB (Table 4.27). The analysis of 
the interactions between time-point and type of drink confirmed significant differences in glucose and 
total cholesterol between placebo and functional drinks in females, and in NEFA in males. In the whole 
sample, NEFA were significantly higher at the end of the treatment, but no differences were detected 
between placebo and functional drinks (Supplementary annex 9 & 10). 
In relation to markers of inflammation, in females ghrelin increased after all treatments, and 
leptin increased after all drinks but B1; similarly, only B1 reduced IL-6, while VCAM-1 and IL-8 
increased under the placebo (Table 4.28). In males, leptin levels increased significantly with placebos 
but not with treatments; VCAM-1 decreased with all treatments but B2; finally, IL-8 presented a 
significant the reduction with treatment B1 (Table 4.29).  
When males and females were tested separately males presented significant difference 
between baseline and post treatment levels in NEFA and Transferrin (P < 0.05), Iron between placebo 
and functional drink (P < 0.05) and for VCAM1 and ICAM1 for the interaction between drink type and 
baseline/ post treatment (P < 0.05 for both) (Annex 10). For females, Ghrelin, Leptin, Glucose, Total 
cholesterol, and Transferrin presented significant different vales between baseline and post treatment 
(P ≤ 0.001, P < 0.005, P < 0.005, P < 0.05, P < 0.05, respectively) (Annex 10). IL-1β and TNA- α in 
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females and VCAM1 and ICAM1 presented significance for the interaction of placebo/functional and 
baseline/post treatment, but not separately (P < 0.05 for all).  
In the whole sample, leptin, VCAM1 and ICAM1 levels were significantly different between 
baseline and post–treatment, irrespective of the type of drink consumed (Supplementary annex 9 & 
10).  
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Table 4.18. Effect of the treatments on indices of obesity in female participants. 
 
 
Table 4.19. Effect of the treatments on indices of obesity in male participants. 
 
Data presented as the mean ± SD or median (Q1, Q3). Bold characters indicate significant differences between baseline and endpoint values at *P < 0.05, **P < 0.01. Weight, 
body fat, and WHR analysed by the paired-t test. BMI, waist and WHeR analysed by Wilcoxon. BMI: body mass index; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio. 
 Group 1 Group 2 
 
B1 
(N=17) 
P1 
(N=19) 
B2 
(N=18) 
P2 
(N=16) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Weight (kg) 77.5 ± 8.1 77.1 ± 8.2 77.9 ± 8.1 77.3 ± 7.9 73.0 ± 8.3 72.3 ± 8.4* 71.3 ± 7.3 70.8 ± 7.3* 
BMI 
28.8 
(27.7 – 29.9) 
28.6 
(27.0 – 30.9) 
28.9 
(27.0 – 31.4) 
28.90 
(27.1 – 31.3) 
27.6 
(26.3 – 29.1) 
27.3 
(25.7 – 29.0)* 
27.15 
(25.8 – 28.6) 
27.0 
(25.5 – 28.7) 
Body Fat (%) 38.0 ± 3.3 37.8 ± 4.0 37.9 ± 4.0 36.9 ± 4.3 36.5 ± 4.5 35.5 ± 4.8 36.2 ± 4.1 35.5 ± 3.9 
Waist (cm) 
85.0 
(80.0 – 91.2) 
84.2 
(77.4 – 89.5)* 
85.5 
(79.5 – 89.2) 
83.0 
(79.6 – 90.5)* 
84.5 
(80.2 – 88.5) 
83.2 
(80.4 – 88.0) 
83.8 
(79.7 – 88.1) 
84.3 
(79.0 – 86.0) 
WHR 0.76 ± 0.07 0.75 ± 0.07 0.76 ± 0.07 0.75 ± 0.07* 0.78 ± 0.08 0.77 ± 0.07 0.78 ± 0.07 0.77 ± 0.07* 
WHeR 
0.53 
(0.49 – 0.56) 
0.51 
(0.48 – 0.54)* 
0.51 
(0.49 – 0.56) 
0.49 
(0.49 – 0.56) 
0.53 
(0.49 – 0.55) 
0.53 
(0.49 – 0.54) 
0.53 
(0.49 – 0.55) 
0.52 
(0.48 – 0.54)* 
 Group 1 Group 2 
 
B1 
(N=23) 
P1 
(N=26) 
B2 
(N=26) 
P2 
(N=25) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Weight (kg) 89.5 ± 10.7 88.7 ± 11.1* 89.5 ± 10.6 89.0 ± 11.4 91.3 ± 13.1 90.3 ± 13.4 90.7 ± 13.3 90.7 ± 13.5 
BMI 
27.7 
(25.9 – 31.2) 
27.3 
(25.8 – 31.2)* 
27.3 
(25.8 – 31.3) 
27.2 
(25.7 – 30.5) 
28.3 
(26.2 – 31.1) 
27.7 
(26.0 – 31.1) 
27.6 
(25.8 – 31.8) 
27.5 
(26.2 – 31.4) 
Body Fat (%) 23.3 ± 5.0 22.7 ± 6.1 23.9 ± 4.7 23.4 ± 5.3 23.7 ± 5.2 23.3 ± 5.8 23.5 ± 5.1 23.0 ± 5.9 
Waist (cm) 
92.4 
(87.5 – 99.8) 
90.4 
(86.8 – 98.1)* 
91.3 
(88.5 – 100.0) 
90.5 
(87.2 – 99.2)* 
93.3 
(89.8 – 101.5) 
91.5 
(86.7 – 99.8)** 
91.0 
(86.8 – 100.6) 
90.7 
(85.8 – 100.0) 
WHR 0.88 ± 0.06 0.87 ± 0.06* 0.88 ± 0.06 0.87 ± 0.06* 0.89 ± 0.07 0.88 ± 0.07* 0.88 ± 0.07 0.88 ± 0.07 
WHeR 
0.52 
(0.49 – 0.57) 
0.51 
(0.48 – 0.57)* 
0.52 
(0.49 – 0.57) 
0.52 
(0.48 – 0.56)* 
0.52 
(0.50 – 0.58) 
0.52 
(0.48 – 0.56)** 
0.52 
(0.49 – 0.56) 
0.52 
(0.48 -0.56) 
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Table 4.20. Effect of the treatments on red blood series in female participants. 
 Group 1 Group 2 
 
B1 
(N=19) 
P1 
(N=19) 
B2 
(N=19) 
P2 
(N=17) 
Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
RBC 
(x106cells/mm3) 
4.44±0.30 4.48±0.43 4.44±0.41 4.41±0.43 4.43±0.40 4.35±0.41 4.48±0.33 4.44±0.29 
Hb (g/dl) 
13.3 
(13.0 – 13.5) 
13.3 
(12.6 – 14.0) 
13.0 
(12.4 – 13.7) 
12.9 
(12.4 – 13.7) 
12.8 
(11.9 – 13.4) 
12.9 
(11.2 – 13.3) 
13.2 
(12.5 – 13.9) 
12.9 
(12.7 – 13.9) 
Haematocrit (%) 40.2±2.2 40.4±3.3 39.6±3.1 40.0±3.1 39.5±3.1 38.8±3.5 40.1±3.3 40.1±3.4 
MCV (fl) 
92.0 
(87.0 – 94.0) 
91.5 
(88.0 – 93.0) 
90.0 
(85.0 – 93.0) 
92.0 
(87.0 – 94.0)* 
90.0 
(88.0 – 92.0) 
91.0 
(86.0 – 92.0) 
89.0 
(88.0 – 92.0) 
91.0 
(86.0 – 93.0) 
MCH (pg) 
30.3 
(28.7 – 30.7) 
30.1 
(28.5 – 31.0) 
29.4 
(28.3 – 30.2) 
30.1 
(27.8 – 31.6) 
28.9 
(27.6 – 29.9) 
29.3 
(26.6 – 31.1) 
29.5 
(28.1 – 30.0) 
29.7 
(28.3 -30.4) 
MCHC (g/dl) 32.8±1.1 33.0±1.0** 32.9±1.1 32.8±1.0 32.4±0.7 32.6±1.2 32.7±0.9 32.8±1.1 
Anisocytosis 
Index (%) 
12.6 
(12.0 – 13.7) 
12.7 
(12.2 – 13.4) 
12.8 
(12.0 – 13.7) 
12.9 
(12.6 – 13.6) 
12.5 
(11.8 – 13.5) 
12.5 
(12.0 – 13.1) 
12.2 
(11.8 – 12.9) 
13.0 
(11.9 – 13.6) 
Platelets 
(x103/mm3) 
272.7±51.7 276.6±42.5 273.7±53.4 278.5±59.4 264.5±53.5 266.4±68.77 266.1±34.4 253.1±48.0* 
MPV (fl) 
9.1 
(8.6 – 9.7) 
8.9 
(8.7 – 9.5) 
8.7 
(8.3 – 9.9) 
9.0 
(8.4 – 9.6) 
9.10 
(8.3 – 9.5) 
8.9 
(8.4 – 9.3) 
9.2 
(8.6 – 9.6) 
9.1 
(8.4 – 9.3) 
Iron (mg/dl) 
71.0 
(53.0 – 98.0) 
65.5 
(39.0 – 103.0) 
63.5 
(43.0 – 80.0) 
47.0 
(40.0 – 74.0) 
80.26±38.37 71.11±42.49 79.06±36.21 82.35±41.73 
Ferritin (ng/dl) 
36.0 
(16.0 – 51.0) 
37.5 
(22.5 – 60.5) 
27.5 
(13.0 – 46.0) 
28.0 
(20.0 – 37.0) 
23.0 
(13.0 – 40.0) 
17.0 
(10.0 – 34.0) 
25.0 
(14.0 – 49.0) 
27.0 
(14.0 – 40.0) 
Transferrin 
(mg/dl) 
255.2±63.2 255.3±48.2 258.0±50.7 247.1±56.2 266.5±42.6 233.9±53.0** 
257.0 
(240.0 – 288.0) 
224.0** 
(208.0 – 268.0) 
Data presented as the mean ± SD or median (Q1, Q3). Baseline and final values compared by the paired-t test or Wilcoxon test, depending on normality. Significance at 
*P < 0.05, **P < 0.01. RBC: red blood cells; Hb: haemoglobin; MCHC: mean corpuscular Hb concentration; MCV: mean corpuscular volume; MCH: mean corpuscular Hb, MPV: 
mean platelet volume. 
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Table 4.21. Effect of the treatments on red blood series in male participants. 
Data presented as the mean ± SD or median (Q1, Q3). Baseline and final values compared by the paired-t test or the Wilcoxon test, depending on normality. Significance at 
*P < 0.05, **P < 0.01. RBC: red blood cells; Hb: haemoglobin; MCHC: mean corpuscular Hb concentration; MCV: mean corpuscular volume; MCH: mean corpuscular Hb, MPV: 
mean platelet volume.  
 
 Group 1 Group 2 
 
B1 
(N=23) 
P1 
(N=26) 
B2 
(N=26) 
P2 
(N=25) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
RBC 
(x106cells/mm3) 
5.06±0.48 5.03±0.39 5.09±0.98 5.00±0.51 5.03±0.30 5.02±0.31 5.08±0.30 5.04±0.26 
Hb (g/dl) 
15.0 
(14.2 – 15.5) 
15.2 
(13.8 – 15.7) 
14.8 
(14.4 – 15.6) 
15.1 
(14.2 – 15.7) 
14.8 
(14.3 – 15.2) 
15.0 
(14.7 – 15.7)* 
15.0 
(14.3 – 15.7) 
15.1 
(14.5 – 15.8) 
Haematocrit (%) 44.8±3.0 44.9±3.1 45.4±3.3 44.8±3.4 44.7±2.9 45.1±5.5 45.5±3.0 45.4±3.0 
MCV (fl) 
90.0 
(86.0 – 93.0) 
90.0 
(88.0 – 95.0) 
91.0 
(88.0 – 93.0) 
90.0 
(89.0 – 93.0) 
90.0 
(86.0 – 92.0) 
89.5 
(87.0 – 92.0) 
91.0 
(89.0 – 92.0) 
90.0 
(88.0 – 93.0)* 
MCH (pg) 
30.1 
(28.9 – 31.0) 
29.9 
(29.2 – 30.8) 
29.9 
(28.9 – 31.1) 
30.7 
(29.3 – 31.9)* 
29.4 
(28.6 – 30.2) 
29.8 
(29.4 – 31.1)** 
30.0 
(28.8 – 30.5) 
30.0 
(28.9 – 30.7) 
MCHC (g/dl) 33.3±1.0 33.0±1.0 33.0±0.8 33.6±1.0 33.1±1.1 33.5±0.9 33.0±1.1 33.0±0.7 
Anisocytosis 
Index (%) 
12.6±1.2 12.9±1.1 
12.7 
(12.1 – 13.3) 
13.3 
(12.0 – 13.7) 
12.7 
(11.9 – 13.2) 
13.0 
(12.1 – 13.8) 
12.3 
(12.1 – 13.0) 
12.6 
(12.1 – 13.2) 
Platelets 
(x103/mm3) 
237.0 
(210.0 – 271.0) 
232.0 
(205.0 – 276.0) 
245.0±44.3 244.6±57.2 232.27±54.7 232.75±58.0 234.5±55.9 231.2±68.3 
MPV (fl) 
9.0 
(8.6 – 9.9) 
9.1 
(8.6 – 9.9) 
9.1 
(8.4 – 9.6) 
9.2 
(8.8 – 9.6) 
9.2 
(8.4 – 9.7) 
9.2 
(8.6 – 10.1) 
9.2 
(8.6 – 9.9) 
9.0 
(8.7 – 9.9) 
Iron (mg/dl) 
85.0 
(67.0 – 102.0) 
83.0 
(69.0 – 123.0) 
105.0 
(92.0 – 119.0) 
96.0 
(75.0 – 100.0) 
94.27±33.64 85.8±21.7 93.2±32.5 100.3±35.7 
Ferritin (ng/dl) 
133.0 
(86.0 – 200.0) 
140.0 
(90.0 – 203.0) 
142.5 
(102.0 – 175.0) 
135.0 
(72.0 – 188.0) 
119.5 
(52.0 – 194.0) 
106.5 
(59.5 – 170.5) 
96.0 
(57.0 – 170.0) 
117.0 
(72.0 – 166.0) 
Transferrin 
(mg/dl) 
239.4±38.6 251.7±29.0 241.0±25.9 254.0±26.3* 245.5±43.7 261.5±35.9 
248.0 
(235.0 – 268.0) 
254.0 
(236.0 – 278.0) 
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Figure 4.17. Mean corpuscular Hb (pg) change observed in participants according to treatment. 
Females: n = 19 for B1, P1, and B2; n = 17 for B2; males: n = 23 for B1, n = 26 for P1, n = 25 for P2, 
n = 26 for B2. Both phases of treatment have been combined. ** Significant difference between 
treatments at P < 0.05, as analysed by the Kruskal-Wallis test. Error bars: +/- 1 SD. 
** 
59 
 
 
 
Figure 4.18. White blood cell count (x103cells/mm3) change observed in participants according to 
treatment. Females: n = 17 for B1, P1, and B2; n = 15 for P2; males: n = 22 for B1, n = 25 for P1 and 
P2, n = 26 for B2. Both phases of treatment have been combined. * Significant difference between 
drinks at P < 0.05, as analysed by the ANOVA test. Error bars: +/- 1 SD. 
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Figure 4.19. Neutrophil count (x103cells/mm3) change observed in participants according to treatment 
consumed. Females: n = 17 for B1, P1, and B2; n = 15 for P2; males: n = 22 for B1, n = 25 for P1 and P2, 
n = 26 for B2. Both phases have been combined. * Significant between treatments at P < 0.05, as analysed by 
the ANOVA test. Error bars: +/- 1 SD. 
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Table 4.22. Effect of the treatments on white blood cells in female participants. 
  Group 1 Group 2 
Cell count 
(x103/mm3) 
B1 
(N=17) 
P1 
(N=17) 
B2 
(N=17) 
P2 
(N=15) 
  Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
White Blood Cells 5.85  
(4.85 – 7.35) 
6.10  
(5.10 – 7.10) 
6.50  
(5.35 – 7.05) 
6.70  
(5.95 – 7.40) 
7.20  
(6.30 – 8.30) 
6.35  
(5.70 – 7.65) 
6.70  
(5.80 – 7.70) 
6.10  
(5.70 – 7.20) 
Neutrophils 2.85  
(2.60 – 3.95) 
3.20 
 (2.60 – 5.00) 
3.45  
(2.90 – 3.75) 
3.50  
(3.05 – 3.95) 
4.40  
(3.40 – 5.00) 
3.20  
(2.90 – 4.55)* 
3.70  
(2.80 – 4.70) 
3.10  
(2.90 – 3.70) 
Lymphocytes 2.25  
(1.80 – 2.60) 
2.20  
(1.60 – 2.60) 
2.30  
(1.90 – 2.60) 
2.35  
(1.85 – 3.00) 
2.20  
(2.00 – 2.60) 
2.40  
(2.10 – 2.60) 
2.30  
(2.00 – 2.50) 
2.20  
(1.80 – 2.70) 
Monocytes 0.45  
(0.30 – 0.55) 
0.50  
(0.40 – 0.50) 
0.50  
(0.40 – 0.50) 
0.50  
(0.35 – 0.55) 
0.50  
(0.40 – 0.60) 
0.50  
(0.40 – 0.55) 
0.40  
(0.40 – 0.60) 
0.40  
(0.40 – 0.50) 
Eosinophils 0.10  
(0.10 – 0.25) 
0.20 
 (0.10 – 0.30) 
0.15  
(0.10 – 0.20) 
0.20  
(0.10 – 0.25) 
0.50  
(0.10 – 0.30) 
0.20  
(0.10 – 0.25) 
0.20  
(0.10 – 0.30) 
0.10  
(0.10 – 0.30) 
Basophils 0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.10) 
Data presented as median (Q1, Q3). Baseline and endpoint values compared by the Wilcoxon test. Significance at *P < 0.05.  
 
Table 4.23. Effect of the treatments on white blood cells in male participants. 
Data presented as median (Q1, Q3). Baseline and endpoint values compared by the Wilcoxon test. Significance at *P < 0.05.  
 Group 1 Group 2 
Cell count 
(x103/mm3) 
B1 
(N=22) 
P1 
(N=25) 
P2 
(N=25) 
B2 
(N=26) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
White Blood Cells 6.25  
(5.90 – 7.60) 
6.30  
(4.90 – 7.70) 
6.20  
(5.30 – 7.20) 
6.20  
(5.50 – 7.10) 
5.40  
(4.90 – 6.50) 
6.00  
(4.90 – 6.70) 
5.95  
(5.40 – 7.10) 
5.65  
(4.90 – 6.20)* 
Neutrophils 3.35  
(2.80 – 4.00) 
3.40  
(2.50 – 3.80) 
3.10  
(2.60 – 3.90) 
3.25  
(2.50 – 3.60) 
3.10  
(2.40 – 3.50) 
3.30  
(2.50 – 3.90) 
3.15  
(2.90 – 4.00) 
2.85  
(2.50 – 3.25)* 
Lymphocytes 2.25  
(1.90 – 2.70) 
2.25  
(1.80 – 2.80) 
2.20  
(1.70 – 2.60) 
2.30  
(2.00 – 3.00)* 
1.90  
(1.70 – 2.20) 
2.00  
(1.80 – 2.40) 
2.20  
(2.00 – 2.60) 
2.10  
(1.80 – 2.35) 
Monocytes 0.50  
(0.40 – 0.60) 
0.50  
(0.40 – 0.60) 
0.50  
(0.40 – 0.60) 
0.50  
(0.40 – 0.60) 
0.40  
(0.40 – 0.60) 
0.50  
(0.40 – 0.60) 
0.50  
(0.40 – 0.60) 
0.40  
(0.40 – 0.50) 
Eosinophils 0.20  
(0.10 – 0.30) 
0.20  
(0.10 – 0.30) 
0.20  
(0.10 – 0.20) 
0.20  
(0.10 – 0.20) 
0.10  
(0.10 – 0.20) 
0.20  
(0.10 – 0.20) 
0.20  
(0.10 – 0.20) 
0.15  
(0.10 – 0.20) 
Basophils 0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.10) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.00) 
0.00  
(0.00 – 0.00) 
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Figure 4.20. CD4+ count (cells/mm3) change observed in participants according to treatment 
consumed. Females: n = 17 for B1, P1, and B2; n = 15 for P2; males: n = 22 for B1, n = 25 for P1 and 
P2, n = 26 for B2. Both phases have been combined. * Significant at P < 0.05, as analysed by the 
Kruskal-Wallis test. Error bars: +/- 1 SD. 
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Figure 4.21. CD4+RA+ count (cells/mm3) change observed in participants according to treatment 
consumed. Females: n = 17 for B1, P1, and B2; n = 15 for P2; males: n = 22 for B1, n = 25 for P1 and P2, 
n = 26 for B2. Both phases have been combined. * Significant at P < 0.05, as analysed by the Kruskal-
Wallis test. Error bars: +/- 1 SD. 
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Table 4.24. Effect of the treatments on lymphocyte subset count in female participants. 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by the paired-t test or the Wilcoxon test, depending on 
normality. Significance at *P < 0.05. Lymphocyte populations are designated by their cell membrane markers, and defined by the anchor marker, which appears in first place of 
the subset name. 
 
 
 
 Group 1 Group 2 
Cell/mm3 
B1 
(N=17) 
P1 
(N=17) 
B2 
(N=17) 
P2 
(N=15) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
CD3+ 1708.8±389.5 1644.7±498.8 1727.5±411.5 1726.8±491.7 1691.5±447.7 1742.9±451.4 
1834.2 
(1260.6–1982.6) 
1830.5 
(1311.7–2071.6) 
CD8 595.2±198.9 580.3±245.7 
610.8 
(405.4–752.4) 
615.1 
(526.4–752.4) 
577.0±198.9 595.7±180.3 
524.2 
(421.1–706.9) 
585.4 
(452.9–722.8) 
CD4+ 987.2±238.9 943.4±292.2 
986.9 
(800.1–1181.7) 
1068.5 
(916.5–1337.6) 
1010.9±307.1 1034.4±313.8 
1018.9 
(814.6–1271.30) 
873.1 
(827.6–1271.3) 
CD8+RA+ 
317.0 
(204.3–488.6) 
312.6 
(172.7–377.3) 
274.7±127.11 312.0±166.4 
292.1 
(172.8–441.5) 
350.3 
(186.0–420.6) 
257.9 
(187.9–293.6) 
242.1 
(199.1–349.2) 
CD8+RO+ 257.8±125.9 281.7±128.4 
303.0 
(210.0–428.0) 
365.5 
(251.8–464.7) 
237.0 
(215.2–297.2) 
268.1 
(232.2–333.4) 
314.4 
(136.1–442.4) 
334.2 
(144.3–455.8) 
CD4+RA+ 535.9±151.8 496.5±166.2 
402.3 
(303.8–607.3) 
484.4 
(388.0–635.9) 
569.9 
(344.0–658.9) 
604.4 
(427.35–709.4) 
465.6 
(205.7–585.1) 
492.2 
(268.6–618.9)* 
CD4+RO+ 
397.0 
(281.4–587.5) 
374.3 
(247.4–624.7) 
516.3±229.2 437.3±238.6 
419.8 
(277.2–512.5) 
472.0 
(353.0–664.1) 
571.6 
(336.0–707.1) 
536.3 
(383.6–713.6) 
CD3-16+56 
250.0 
(152.5–315.4) 
215.9 
(117.4–405.3) 
253.2 
(138.8–341.8) 
198.2 
(128.1–259.9) 
180.4 
(163.7–272.7) 
191.5 
(131.6–329.2) 
203.5 
(128.9–350.3) 
232.2 
(111.6–285.7) 
CD19+ 
183.5 
(154.9–254.9) 
179.9 
(119.7–263.2) 
213.8±77.6 225.3±87.1 224.3±87.2 221.2±103.6 236.1±84.0 254.6±100.1 
CD4/CD8 
1.67 
(1.42–1.98) 
1.75 
(1.24–2.25) 
1.50 
(1.33–2.26) 
1.68 
(1.34–2.26) 
1.82 
(1.47–2.03) 
1.84 
(1.41–2.01) 
1.85 
(1.37–2.05) 
1.78 
(1.47–2.09) 
CD3/CD19 
8.40 
(7.20–11.08) 
9.19 
(6.75–11.29) 
7.93 
(6.64–10.64) 
8.44 
(5.98–9.47) 
7.01 
(5.93–9.03) 
7.01 
(5.69–9.20) 
6.48 
(5.5–9.10) 
7.01 
(5.70–11.44) 
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Table 4.25. Effect of the treatments on lymphocyte subset count in male participants 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by the paired-t test or the Wilcoxon test, depending on 
normality. Significance at *P < 0.05. Lymphocyte populations are designated by their cell membrane markers, and defined by the anchor marker, which appears in first place of 
the subset name
 Group 1 Group 2 
cell/mm3 
B1 
(N=22) 
P1 
(N=25) 
B2 
(N=26) 
P2 
(N=25) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
CD3+ 1712.1±550.8 1684.3±506.0 1640.3±553.9 1786.5±528.9 1690.4±489.5 1519.5±390.7 
1402.0 
(1261.0–1634.2) 
1420.2 
(1268.1–1707.8) 
CD8+ 623.1±302.6 586.4±219.7 
512.1 
(435.8–678.5) 
571.0 
(458.2–826.2) 
577.2±264.7 525.9±212.7 
501.4 
(356.1–614.9) 
435.1 
(364.0–688.6) 
CD4+ 944.1±289.4 958.2±341.1 
938.1 
(736.8–1079.5) 
1039.5 
(736.8–1079.5) 
965.8±316.2 858.3±267.3 
780.0 
(654.6–901.7) 
850.2 
(731.2–976.1) 
CD8+RA+ 
327.6 
(173.8–399.1) 
266.1 
(175.4–416.9) 
286.5±133.2 310.9±121.6 
274.8 
(180.0–391.0) 
233.3 
(179.4–331.9) 
220.1 
(168.1–313.0) 
262.5 
(175.9–289.8) 
CD8+RO+ 297.5±121.9 294.8±143.4 
250.1 
(213.6–335.8) 
293.8 
(209.2–387.4) 
266.9 
(158.2–382.2) 
244.3 
(165.9–337.7) 
233.1 
(170.8–317.0) 
251.4 
(186.8–341.6) 
CD4+RA+ 456.9±212.8 468.9±260.0 
459.7 
(314.4–512.5) 
507.0 
(376.7–655.9) 
436.0 
(364.3 – 559.7) 
384.65 
(270.1–520.0)* 
347.9 
(313.3–413.8) 
412.6 
(339.5–492.1) 
CD4+RO+ 
429.7 
(264.2–614.8) 
470.2 
(265.3–660.9) 
419.2±172.0 478.5±212.4* 
411.4 
(313.9–542.1) 
404.5 
(326.5–455.7) 
401.3 
(236.5–477.1) 
385.0 
(294.1–544.0) 
CD3-16+56 
289.2 
(177.9–578.0) 
299.2 
(158.7–362.3) 
219.7 
(162.3–360.7) 
267.6 
(193.7–467.9)* 
238.4 
(156.2–339.0) 
225.7 
(162.1–362.8) 
240.0 
(137.3–285.0) 
222.7 
(185.6–282.9) 
CD19+ 
256.9 
(161.9–334.6) 
224.1 
(168.5–347.4) 
233.9±104.4 256.3±126.8 288.9±90.6 261.9±77.9 247.5±87.4 260.3±71.8 
CD4/CD8 
1.56 
(1.31–1.92) 
1.64 
(1.34–1.88) 
1.66 
(1.29–1.95) 
1.51 
(1.37–1.82) 
1.95 
(1.27–2.28) 
1.65 
(1.41–2.18) 
1.85 
(1.28–2.20) 
1.82 
(1.31–2.22) 
CD3/CD19 
6.74 
(5.41–7.61) 
6.62 
(5.06–9.38) 
7.21 
(5.77–8.91) 
7.46 
(5.16–9.50) 
6.06 
(4.48–7.43) 
6.01 
(4.39–7.56) 
5.65 
(5.11–7.20) 
5.65 
(5.11–7.28) 
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Table 4.26. Effect of the treatments blood biochemistry in female participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by paired-t test or Wilcoxon test, according to normality. 
Significance at *P < 0.05. NEFA: non-esterified fatty acids; VLDL-c: very low-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density 
lipoprotein cholesterol; APOA: apolipoprotein A; APOB: apolipoprotein B. 
 
 
 
 
 
 Group 1 Group 2 
 
B1 
(N=19) 
P1 
(N=19) 
B2 
(N=19) 
P2 
(N=17) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Glucose (mmol/L) 
4.8 
(4.4 – 5.2) 
4.3 
(4.0 – 4.6) 
4.8 
(4.6 – 5.3) 
4.6 
(4.0 – 4.7) 
4.8 
(4.7 – 5.1) 
4.4 
(3.8 – 4.8)* 
4.8 
(4.4 – 5.1) 
4.4 
(3.9 – 4.8)* 
NEFA (mmol/L) 0.03±0.01 0.03±0.01 
0.03 
(0.02 – 0.03) 
0.03 
(0.02 – 0.03) 
0.02 
(0.02 – 0.03) 
0.03 
(0.02 – 0.03) 
0.03 
(0.02 – 0.03) 
0.03 
(0.02 – 0.03) 
Insulin  (mU/l) 77.1±43.7 160.6±125.6 57.4±39.7 103.8±123.8 98.4±79.0 61.4±58.9 64.4±33.0 80.7±77.6 
Triglycerides 
(mmol/L) 
3.4 
(2.4 – 5.4) 
4.7 
(3.0 – 6.2) 
4.0 
(2.8 – 8.1) 
3.4 
(2.8 – 5.9) 
4.3 
(3.4 – 5.5) 
3.6 
(1.2 – 4.9) 
4.5 
(3.3 – 5.9) 
4.5 
(2.8 – 5.7) 
Cholesterol 
(mmol/L) 
8.9±1.9 8.9±1.31 9.2±2.0 8.6±1.7 10.1±1.8 8.6±2.0* 10.2±2.2 9.5±2.3 
VLDL-c (mmol/L) 
0.7 
(0.5 – 1.1) 
0.9 
(0.6 – 1.3) 
0.8 
(0.6 – 1.6) 
0.7 
(0.6 – 1.2) 
0.8 
(0.7 –1.1) 
0.8 
(0.6 – 1.0) 
0.9 
(0.7 – 1.2) 
0.9 
(0.6 – 1.1) 
LDL-c (mmol/L) 5.1±1.3 5.0±1.0 5.4±1.4 4.9±1.1 6.0±1.5 5.0±1.5* 6.0±1.9 5.7±1.8 
 
HDL-c (mmol/L) 2.8±0.9 2.9±0.9 
2.7 
(2.1 – 3.4) 
2.3 
(2.2 – 3.2) 
2.9 
(2.7 – 3.5) 
2.5 
(2.2 – 3.2)* 
3.3 
(2.9 – 3.6) 
2.9 
(2.4 – 3.1)* 
APOA (mmol/dL) 
8.4 
(7.3 – 9.3) 
8.7 
(7.6 – 9.7) 
8.4±1.3 8.2±1.6 
8.0 
(7.4 – 9.3) 
7.9 
(7.29 – 9.2)* 
8.8 
(7.7 – 9.5) 
8.5 
(8.2 – 9.2) 
APOB (mmol/L) 
4.4 
(3.9 – 4.8) 
4.3 
(3.8 – 4.7) 
4.5±0.9 4.3±0.9 
4.1 
(3.5 – 5.3) 
4.0 
(3.5 – 5.1) 
4.2 
(3.6 – 5.2) 
4.7 
(3.8 – 5.4) 
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Table 4.27. Effect of the treatments blood biochemistry in male participants. 
 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by paired-t test or Wilcoxon test, according to normality.  
Significance at *P < 0.05. NEFA: non-esterified fatty acids; VLDL-c: Very low-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; HDL-c: High-density 
lipoprotein cholesterol; APOA: Apolipoprotein A; APOB: Apolipoprotein B. 
 
 
 
 
 Group 1 Group 2 
 
B1 
(N=23) 
P1 
(N=26) 
B2 
(N=26) 
P2 
(N=25) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Glucose (mmol/L) 
5.0 
(4.5 – 5.2) 
4.9 
(4.6 – 5.3) 
5.0 
(4.7 – 5.2) 
5.0 
(4.9 – 5.4) 
5.1 
(4.5 – 5.3) 
5.3 
(5.0 – 5.6)* 
5.1 
(4.8 – 5.2) 
5.1 
(4.7 – 5.4) 
NEFA (mmol/L) 0.03±0.01 0.03±0.01 
0.03 
(0.02 – 0.04) 
0.03 
(0.03 – 0.03) 
0.03 
(0.02 – 0.03) 
0.03 
(0.02 – 0.04)* 
0.03 
(0.02 – 0.03) 
0.03 
(0.02 – 0.04)* 
Insulin (mU/l) 607.2±1906.3 248.1±717.8 189.1±380.2 88.9±143.9 106.6±140.9 97.4±169.5 149.5±285.7 126.5±317.7 
Triglycerides 
(mmol/L) 
5.2 
(3.3 – 8.1) 
5.9 
(3.7) 
5.7 
(4.2 – 8.3) 
5.9 
(3.9 – 6.8) 
6.2 
(3.7 – 10.1) 
4.3 
(3.3 – 8.3) 
4.2 
(3.2 – 6.5) 
5.1 
(3.5 – 7.8) 
Cholesterol 
(mmol/L) 
9.1±1.4 171.0±29.5 167.7±25.8 174.0±24.7 172.3±37.0 179.9±26.6 168.6±41.2 180.0±33.9 
VLDL-c (mmol/L) 
1.1 
(0.7 – 1.6) 
1.2 
(0.7 – 1.8) 
1.1 
(0.8 – 1.7) 
1.2 
(0.8 – 1.3) 
1.3 
(0.7 – 2.0) 
0.9 
(12.0 – 29.5) 
15.0 
(0.7 – 1.3) 
1.0 
(0.7 – 1.6)* 
LDL-c (mmol/L) 5.3±1.2 5.5±1.3 5.6±1.2 5.7±1.4 5.8±1.4 6.2±1.3 5.9±1.7 6.2±1.7 
HDL-c (mmol/L) 2.5±0.6 2.6±0.7 
2.3 
(2.2 – 2.7) 
2.7 
(2.2 – 2.9) 
2.4 
(2.0 – 2.7) 
2.4 
(2.3 – 2.6) 
2.3 
(2.1 – 2.6) 
2.5 
(2.2 – 2.7) 
APOA (mmol/L) 
7.4 
(4.8 – 11.1) 
7.8 
(6.8 – 8.5) 
7.8±1.0 7.9±1.1 
7.4 
(6.9 – 7.9) 
7.4 
(6.9 – 8.0) 
7.2 
(6.8 – 8.2) 
7.7 
(7.2 – 8.2) 
APOB (mmol/L) 
4.3 
(3.8 – 5.3) 
4.3 
(3.7 – 4.8) 
4.5±0.9 4.2±1.0 
4.6 
(3.9 – 5.7) 
4.6 
(3.9 – 5.1) 
4.4 
(3.8 – 5.5) 
4.3 
(3.7 – 5.1)* 
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Table 4.28. Effect of the treatments on adipokines, acute phase proteins and cytokines in female participants. 
 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by the paired-t test or the Wilcoxon test, according to normality. 
Significance at *P < 0.05. CRP: C-reactive protein; GM CSF: granulocyte macrophage colony-stimulating factor; IL: interleukin; IFNγ: interferon gamma; TNF-α: tumor necrosis 
factor alpha; VCAM-1: vascular cell adhesion protein 1; ICAM-1: Intracellular adhesion molecule 1. For IL2 and IL4, n stated next to value, in brackets.   
 Group 1 Group 2 
 
B1 
(N=17) 
P1 
(N=17) 
B2 
(N=17) 
P2 
(N=15) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Ghrelin 
(pg/ml) 
174.9±105.5 368.4±136.2** 
126.5 
(71.4–267.5) 
359.5 
(280.3–459.9)** 
167.7 
(97.9–341.5) 
465.3 
(328.3–643.9)** 
247.0±165.5 549.3±197.9** 
Leptin (ng/ml) 10.89±7.34 13.27±8.02 9.03±4.67 14.64±6.99** 10.05±7.92 12.63±6.86** 6.92±2.93 11.11±6.62** 
Adiponectin 
(ng/ml) 
6721±5216 6478±4771 6999±4825 6109±5283 
5367 
(3770–8407) 
6545 
(5458–7845) 
7763±4200 6660±3059 
Ceruloplasmin 
(mg/dl) 
32.9±7.4 33.5±9.6 31.9±8.9 32.1±9.4 29.3±7.1 29.4±7.6 30.6±7.9 31.8±8.9 
CRP (mg/dl) 
1.46 
(0.34–4.11) 
1.30 
(0.50–7.22) 
3.03±3.49 3.17±4.00 
0.54 
(0.41–1.20) 
0.39 
(0.18–1.52) 
1.68±1.95 1.86±2.53 
IL-1β (pg/ml) 
0.17 
(0.03–0.45) 
0.61 
(0.28–3.18) 
0.93 
(0.38–1.57) 
1.42 
(0.33–2.08) 
0.30 
(0.17–0.59) 
0.69 
(0.37–0.85) 
7.52±11.63 1.57±2.32 
IL-2 (pg/ml) 16.0 (1) 
10.32 
(4.33–11.29)(5) 
(0) 8.30±3.56 (4) 5.20 (1) 
5.92 
(4.33–8.06) (5) 
66.61 (1) 
8.45 
(3.28–160.9)(4) 
IL-4 (pg/ml) 0.16 (1) 1.77 (1) 
0.17 
(0.06–0.44)(4) 
1.04 
(0.27–2.75)(4) 
0.32 (1) 0.75±0.43 (2) 0.24±0.07 (3) 0.85±0.15 (2) 
IL-6 (pg/ml) 
5.18 
(1.52–9.22) 
4.73 
(3.52–25.04)* 
9.10±9.54 10.94±9.46 
6.84 
(2.48–15.97) 
6.82 
(4.43–14.71) 
7.53 
(1.79–21.03) 
5.86 
(3.52–11.72) 
IL-8 (pg/ml) 
15.5 
(2.3–21.1) 
11.7 
(10.2–17.6) 
9.4 
(1.8–21.4) 
12.5 
(6.7–26.2)* 
14.0 
(1.5–23.1) 
10.6 
(7.0–16.4) 
16.7 
(2.4–22.1) 
12.1 
(8.6–17.0) 
IL-10 (pg/ml) 
2.90 
(1.01–10.86) 
5.05 
(2.42–9.55) 
1.20 
(0.24–11.99) 
1.94 
(1.19–3.50) 
0.40 
(0.07–0.88) 
2.46 
(1.30–38.46) 
0.14 
(0.02–5.85) 
1.58 
(1.12–1.88) 
TNF-α (pg/ml) 
2.04 
(0.75–4.03) 
1.48 
(0.93–34.50) 
1.22 
(0.72–2.43) 
1.04 
(0.62–32.24) 
1.18 
(0.57–2.83) 
0.93 
(0.66–1.81) 
3.12 
(0.72–11.34) 
2.26 
(0.16–9.95) 
VCAM-1 
(ng/ml) 
113.4±18.0 130.2±16.1* 113.3±19.4 107.2±27.0 119.1±30.8 112.9±25.4 115.1±34.5 107.1±30.1 
ICAM-1 
(ng/ml) 
93.0 
(73.7–110.9) 
93.2 
(72.2–100.8) 
86.2 
(70.3–103.4) 
93.5 
(69.4–107.7) 
77.9 
(73.1–93.9) 
89.5 
(67.8–106.6) 
82.7 
(65.0–92.5) 
85.5 
(64.9–92.9) 
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Table 4.29. Effect of the treatments on adipokines, acute phase proteins and cytokines in male participants. 
 
 Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and endpoint values compared by the paired-t test or the Wilcoxon test, according to 
normality. Significance at *P < 0.05. CRP: C-reactive protein; GM CSF: granulocyte macrophage colony-stimulating factor; IL: interleukin; IFNγ: interferon gamma; TNF-α: tumor 
necrosis factor alpha; VCAM-1: vascular cell adhesion protein 1; ICAM-1: Intracellular adhesion molecule 1. 
 Group 1 Group 2 
 
B1 
(N=22) 
P1 
(N=25) 
B2 
(N=26) 
P2 
(N=25) 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
Ghrelin (pg/ml) 263.4±93.8 1362±5175 
241.3 
(183.4–368.4) 
258.6 
(197.4–333.0) 
281.2 
(188.1–365.5) 
236.9 
(172.0–303.3) 
442.8±913.6 290.3±139.1 
Leptin (ng/ml) 3.59±3.38 3.75±3.59 2.69±1.91 3.47±2.32* 3.60±2.37 4.31±3.45 3.25±2.02 3.99±2.42* 
Adiponectin 
(ng/ml) 
4230±3204 3859±2777 3967±1952 3597±1687 
4057 
(2778–5522) 
4195 
(2950–5157) 
4728±2296 4101±2057 
Ceruloplasmin 
(mg/dl) 
25.2±4.5 25.9±7.4 24.6±3.8 24.2±4.2 28.0±13.2 24.3±4.7 24.8±4.5 24.2±3.8 
CRP (mg/dl) 
0.44 
(0.19–2.10) 
0.67 
(0.23–2.83) 
1.22±1.64 1.76±1.98* 
0.54 
(0.18–1.44) 
0.37 
(0.15–1.62) 
1.03±1.54 1.37±2.18 
IL-1β (pg/ml) 
6.13 
(1.04–674.1) 
0.97 
(0.83–1.29) 
39.43 
(1.18–77.7) 
0.96 
(0.88–1.13) 
0.67 
(0.36–335.5) 
1.09 
(0.93–1.74) 
70.1±147.0 37.7±167.3 
IL-2 (pg/ml) 
22.4 
(3.5–39.3) 
11.8 
(2.4–44.0) 
34.4±28.7 12.9±14.2 
35.3 
(10.6–63.9) 
4.9 
(2.0–39.9) 
73.6 
(12.1–440.3) 
13.7 
(3.5–51.9) 
IL-4 (pg/ml) 28.6±83.6 35.3±75.0 
2.36 
(1.21–2.94) 
5.77 
(0.05–24.3) 
7.43±9.21 2.98±5.02 5.61±6.65 6.13±7.94 
IL-6 (pg/ml) 
9.66 
(5.06–19.9) 
6.48 
(4.51–8.90) 
9.06±9.53 5.68±3.72* 
10.97 
(3.05–19.4) 
5.14 
(3.05–11.6) 
10.72 
(5.76–18.6) 
5.35 
(3.73–9.98) 
IL-8 (pg/ml) 
23.4 
(12.1–29.9) 
15.6 
(8.5–19.2)* 
16.5 
(10.1–31.0) 
12.9 
(8.0–20.1) 
16.1 
(9.2–56.4) 
11.0 
(8.4–19.0) 
18.9 
(14.0–35.2) 
12.1 
(9.8–27.3) 
IL-10 (pg/ml) 
4.51 
(1.15–55.48) 
2.59 
(0.65–35.9) 
3.87 
(0.80–24.2) 
2.91 
(0.50–15.6) 
2.90 
(0.47–12.2) 
1.54 
(1.02–2.78) 
3.21 
(0.52–30.5) 
4.59 
(1.81–23.5) 
TNF-α (pg/ml) 
4.16 
(0.44–9.88) 
3.85 
(1.27–9.72) 
1.69 
(0.71–14.26) 
3.30 
(2.38–5.26) 
10.00 
(0.87–27.39) 
2.23 
(1.28–8.30) 
4.58 
(1.63–7.22) 
4.00 
(2.22–7.20)* 
VCAM-1 
(ng/ml) 
120.7±31.2 112.0±32.9** 116.9±31.0 106.8±25.2* 121.2±26.2 115.2±23.6 129.7±37.3 106.2±32.0** 
ICAM-1 (ng/ml) 
99.8 
(82.8–125.0) 
92.1 
(73.4–177.4) 
103.7 
(87.1–118.7) 
96.7 
(89.1–149.9) 
96.7 
(80.7–116.5) 
84.4 
(78.3–164.4) 
101.5 
(79.2–118.5) 
86.2 
(70.7–136.8) 
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4.4. Predictors of responsiveness to weight loss treatments 
Figure 4.22 illustrates the relative body weight changed observed in all participants between baseline 
and the end of the intervention with the active drinks (B1 and B2).  
 
Figure 4.22. Individual relative body weight change (% initial weight) after treatments with either drink B1 or drink 
B2.  
 
The analysis of correlations between relative body change and the variables studied identified 
compliance with treatment, baseline levels of triglycerides and VLDL-c counts of B lymphocytes 
(CD19+) and GM-CSF as potential positive predictors of weight loss, while baseline BMI was a 
candidate negative predictor of weight loss (Table 4.30). 
Table 4.30. Associations between relative body weight change and studied variables. 
 Body weight (%) 
 All Females Males 
 r P r r 
Compliance  -0.199 0.087 -0.422* NS 
BMI 0.215 0.062 NS NS 
Triglycerides -0.234 0.042 NS NS 
VLDL-c -0.231 0.044 NS NS 
B lymphocytes (CD19+) -0.202 0.079 NS -0.296* 
GM-CSF -0.083 0.637 -0.422* NS 
Pearson’s correlation; significance set at *P<0.05. BMI: body mass index; VLDL-c: very low density lipoprotein 
cholesterol; GM-CSF: Granulocyte-macrophage colony-stimulating factor. 
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When high and low responsiveness groups were compared, no significant differences were observed 
for the frequency distributions of gender (X2 = 0.178, P = 0.458) or active drink consumed (B1 or B2) 
(X2 = 0.025, P = 0.555) (Figures 4.23 and 4.24, respectively); therefore, both genders and drinks were 
pooled together for the rest of comparisons between high and low responsiveness. 
 
Figure 4.23. Distribution of high and low respondents in females and males (X2 = 0.178, P = 0.458). 
 
Figure 4.24. Distribution of high and low respondents in treatments B1 and B2 (X2 = 0.025, P = 0.555). 
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There was no difference in compliance to the treatment between the high and the low responsive 
participants (96.9% v. 96.2%, respectively). When meal distribution patterns were compared, a lower 
frequency of midmorning snack consumption was associated with greater responsiveness to the 
treatment; there was also a trend for the low respondents to skip lunch more often than the high 
respondents (Table 4.31). No relationship was found between caffeine consumption and 
responsiveness (Table 4.32).  
High respondents presented significantly lower baseline BMI and WHeR values (Table 4.33); 
trends towards higher MCHC and lower platelets counts (Table 4.34); lower TC naive cell (CD8+RA+) 
counts, and as a result, a trend towards higher CD8+RO+/CD8+RA+ values (Tables 4.35 and 4.36); 
trends to lower LDL-c levels (Table 4.37), lower IL-8 and IL-10 values, and significantly lower IL-6 
values (Table 4.38).  
Table 4.31. Eating patterns in high and low respondents  
  Responsiveness  
  High (%) Low (%) P 
Breakfast  No 6.7 4.4 0.673 
 Yes 44.4 44.4  
Midmorning No 31.1 11.1 0.005 
 Yes 15.6 37.8  
 Sometimes 4.4 0  
Lunch No 0 6.7 0.067 
 Yes 51.1 42.2  
Afternoon No 33.3 24.4 0.403 
 Yes 17.8 22.2  
 Sometimes 0 2.2  
Evening meal No 2.2 2.2 0.613 
 Yes 46.7 46.7  
 Sometimes 2.2 0  
Meals per day ≤3 13.2 7.9 0.547 
 ≥4 44.7 34.2  
Frequency of meals collected from the 3-day dietary records. High and low responsive groups 
compared by the Chi – squared; significance set at P < 0.05. 
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Table 4.32. Estimated caffeine consumption (mg/day) of high and low respondents.  
Data presented as median (Q1, Q3). High and low responsive groups compared by the Mann-Whitney test; 
significance set at P <0.05. 
 Responsiveness  
 High Low P 
Total caffeine 107.2 
(41.2 – 176.3) 
91.0 
(14.4 – 172.6) 
0.447 
Caffeine from tea and coffee 95.0 
(17.3 – 106.1) 
21.4 
(4.0 – 152.6) 
0.211 
Caffeine from caffeinated and 
energy drinks 
11.2 
(6.7 – 41.2) 
9.0 
(1.6 – 24.5) 
0.380 
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Table 4.33. Baseline anthropometric and body fat (%) values in high and low respondents. 
Data presented mean ± SD, or median (Q1, Q3); the Mann-Whitney or the independent-t tests were used, 
according to normality; significance set at P <0.05. WC: waist circumference; WHR: waist-to-hip ratio; WHeR: 
waist-to-height ratio. 
 
Table 4.34. Baseline values of red blood cell series in high and low respondents. 
 High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
RBC (x106cells/mm3) 4.86  ± 0.51 4.76  ± 0.42 0.488 
Hb (g/dl) 14.5  ± 1.3 14.0  ± 1.2 0.153 
Haematocrit (%) 43.8  ± 3.6 42.8  ± 3.6 0.322 
MCV (fl) 90.5  ± 4.3 90.1  ± 4.5 0.716 
MCH (pg) 30.0  ± 1.4 29.5  ± 1.5 0.253 
MCHC (g/dl) 33.1  ± 0.8 32.7  ± 0.8 0.088 
Anisocytosis Index (%) 11.9 (11.7 – 12.4) 12.4 (11.8 – 12.8) 0.207 
Platelets (x103/mm3) 229.3  ± 44.3 255.1  ± 57.8 0.099 
MPV (fl) 9.5  ± 0.9 9.3  ± 0.9 0.436 
Iron (mg/dl)  94.5 ± 37.0 88.8 ± 44.3 0.644 
Ferritin (ng/dl) 87.0 (40.0 – 172.0) 66.0 (26.0 – 151.0) 0.276 
Transferrin (mg/dl)  237.7 ± 46.2 59.4 ± 244.8 0.657 
Data presented mean ± SD, or median (Q1, Q3); the Mann-Whitney or the independent-t tests were used, 
according to normality; significance set at P <0.05. RBC: red blood cells; Hb: haemoglobin; MCV: mean 
corpuscular volume; MCH: mean corpuscular Hb; MCHC: mean corpuscular Hb concentration; MPV: mean 
platelet volume.  
 
 
 
 High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
Height (cm) 175 ± 0.1 170 ± 0.1 0.147 
Body weight (kg) 84.9 ± 10.6 86.5 ± 15.2 0.673 
BMI 27.7 ± 2.3 29.6 ± 3.0 0.021 
Body fat (%) 24.2 (20.7 – 29.6) 26.7 (22.7 – 34.7) 0.302 
WC (cm) 88.9 ±7.2 92.9 ± 11.2 0.154 
WHR 0.83 ± 0.8 0.85 ± 0.09 0.452 
WHeR 0.50 (0.47 – 0.53) 0.54 (0.51 – 0.56) 0.006 
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Table 4.35. Baseline values of white blood cell counts in high and low respondents. 
Data presented mean ± SD or median (Q1, Q3); independent t-test or Mann-Whitney test were used, according to 
normality; significance set at P <0.05.  
 
Table 4.36. Baseline values of lymphocyte subsets in high and low respondents 
Cell count (cell/mm3) High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
CD3+ 1586.0 ± 618.7 1555.3 ± 375.5 0.843 
CD8+ 502.4 (338.4 – 576.5) 541.1 (402.0 – 624.3) 0.398 
CD4+ 921.9 ± 345.2 881.9 ± 211.3 0.645 
CD8+RA+ 140.1 (106.5 – 251.5) 260.1 (153.6 – 305.9) 0.027 
CD8+RO+ 295.9 (220.2 – 386.2) 301.40 (219.9 – 364.6) 0.925 
CD4+RA+ 453.9 (377.3 – 662.1) 494.8 (380.7 – 585.7) 0.851 
CD4+RO+  368.0 ± 235.4 351.1 ± 127.7 0.769 
CD3-16+56 242.5 (155.7 – 334.2) 241.3 (168.0 – 300.6) 0.907 
CD19+  258.8 ± 105.4 230.6 ± 97.7 0.323 
CD4/CD8 1.92 ± 0.76 1.79 ± 0.62 0.544 
CD3/CD19 6.67 (4.48 – 8.25) 7.01 (5.68 – 8.44) 0.201 
CD8RO/CD8RA 1.99 (0.90 – 2.79) 1.12 (0.91 – 1.54) 0.071 
CD4RO/CD4RA 0.53 (0.36 – 1.06) 0.67 (0.43 – 0.98) 0.453 
Data presented mean ± SD or median (Q1, Q3); independent t-test or Mann-Whitney test were used, according to 
normality; significance set at P < 0.05. Lymphocyte populations are designated by their cell membrane markers, 
and defined by the anchor marker, which appears in first place of the subset name.  
 
 
 
 
 
 
 
 High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
White Blood Cells (x103/mm3) 6.20 (5.20 – 7.10) 5.80  (5.10 – 6.90) 0.964 
Neutrophil (x103/mm3) 3.21 ± 0.82 3.40 ± 1.24 0.544 
Lymphocyte (x103/mm3) 2.10 (1.60 – 2.30) 2.10 (1.90 – 2.50) 0.864 
Neutrophil/Lymphocyte ratio 1.50 (1.19 – 2.10) 1.63 (1.28 – 2.11) 0.708 
Monocyte (x103/mm3) 0.50 (0.30 – 0.60) 0.45 (0.40 – 0.60) 0.736 
Eosinophil (x103/mm3) 0.20 (0.10 – 0.20) 0.20 (0.10 – 0.30) 0.774 
Basophil (x103/mm3) 0.00 (0.00 – 0.10) 0.00 (0.00 – 0.00) 0.140 
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Table 4.37. Baseline values of blood biochemistry and iron levels in high and low respondents. 
 High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
Glucose (mmol/L) 4.7 ± 0.8 4.8 ± 0.7 0.679 
Insulin  (mU/l) 98.3 (66.7 – 106.9) (14) 71.4 (52.6 – 126.5) (12) 0.471 
HOMA 18.5 (12.3 – 23.0) (14) 15.4 (11.1 – 31.8) (12) 0.607 
NEFA (mmol/L) 0.01 ± 0.01 0.02 ± 0.001 0.111 
Triglycerides (mmol/L)  4.5 (1.3 – 7.6) 3.6 (3.2 – 5.9) 0.296 
Cholesterol (mmol/L)  8.8 ± 1.6 9.3 ± 2.2 0.325 
VLDL-c (mmol/L) 0.9 (0.7 – 1.5) 0.7 (0.6 – 1.2) 0.270 
LDL-c (mmol/L) 5.05 ± 1.9 5.8 ± 1.5 0.088 
HDL-c (mmol/L) 2.6 ± 0.7 2.7 ± 0.8 0.678 
APOA (mmol/L) 8.0 (7.3 – 8.9) 8.1 (7.1 – 8.9) 0.820 
APOB (mmol/L)  4.4 ± 1.1 4.6 ± 1.2 0.529 
Data presented mean ± SD or median (Q1, Q3); independent t-test or Mann–Whitney test were used, according 
to normality; significance set at P < 0.05. NEFA: non-esterified fatty acids; VLDL-c: very low-density lipoprotein 
cholesterol; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; APOA: 
apolipoprotein A; APOB: apolipoprotein B. N for insulin and HOMA in brackets. 
 
Table 4.38. Baseline values of adipokines, acute phase proteins, and cytokines in high and low 
respondents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented mean ± SD or median (Q1, Q3); independent-t test or Mann-Whitney test used, according to 
normality; significance set at P < 0.05. CRP: C-reactive protein; IL: interleukin; TNF-α: tumor necrosis factor 
alpha; VCAM-1: vascular cell adhesion protein 1. ICAM: intracellular adhesion molecule 1. 
 
 
 High responsiveness 
(N=22) 
Low responsiveness 
(N=22) 
P 
Ghrelin (pg/ml) 292.3 (196.4 – 365.4) (21) 268.4 (238.4 – 309.9) 0.923 
Leptin (ng/ml) 2.9 (1.5 – 7.0) 6.0 (2.9 – 10.5) 0.159 
Adiponectin (ng/ml) 4437.9 ± 2502.3 5481.0 ± 3231.3 0.238 
Cerulopl (mg/dl) 25.1 (22.7 – 32.0) 27.5 (22.2 – 28.9) 0.925 
CRP (mg/dl) 0.5 (0.1 – 1.1) 1.2 (0.2 – 2.7) 0.302 
IL-1β (pg/ml) 3.5 (0.2 – 20.9) (7) 0.8 (0.5 – 6.1) (6) 0.731 
IL-2 (pg/ml) 66.6 (0.9 – 147.4) (3) 140.2 (46.7 – 901.8) (6) 0.381 
IL-4 (pg/ml) 0.7 (0.5 – 280.2) (3) 2.9 (1.0 – 16.9) (7) 0.667 
IL-6 (pg/ml) 10.5 (6.0 – 16.7) 18.2 (10.2 – 36.0) 0.021 
IL-8 (pg/ml) 18.9 (12.1 – 23.1) 25.5 (16.1 – 63.9) 0.054 
IL-10 (pg/ml) 1.4 (0.5 – 49.0) (11) 16.7 (4.4 – 161.2) (11) 0.088 
TNF-α (pg/ml) 3.4 (1.7 – 40.3) (16) 10.2 (1.3 – 35.6) (19) 0.545 
VCAM-1 (ng/ml) 110.3 (95.2 – 132.8) 102.1 (86.2 – 131.5) 0.105 
ICAM-1 (ng/ml) 91.7 (80.4 – 107.3) 91.1 (74.9 – 110.6) 0.622 
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All analysis considered, the following variables were selected as likely candidates for predicting 
responsiveness to weight loss in multiple regression analysis: gender, type of functional drink 
consumed, compliance, triglycerides, VLDL-c and CD19+ from the correlation analysis, and BMI, 
WHeR, CD8+RA+, and IL-6 from comparing high vs low responsiveness groups.  A forced entry 
multiple regression analysis was conducted, where VLDL was excluded due to high collinearity with 
triglycerides, and WHeR was excluded due to high collinearity with BMI. The resulting model (Model 1) 
was a significant predictor of body weight change, explaining 20.8% variability, although not all 
predictors introduced were significant contributors (Table 4.39). A second analysis was then 
performed including only significant contributors, resulting in another model that was a significant 
predictor of body weight change, explaining 18.1% variability (Model 2). 
Multiple regression analysis was then conducted on males and females separately. For female 
participants, the following variables were included as potential predictors: compliance and GM-CSF 
from the correlation analysis, and BMI, WHeR, CD8+RA+, and IL-6 from the comparisons high vs low 
responsiveness groups. A hierarchical analysis was performed including compliance as the most likely 
predictor, followed by GM-CSF, and then the rest of variables in a single block. Model 1 (compliance 
alone) was a significant predictor of body weight change, explaining 19.5% of the variability (Table 
4.41). Model 2 (compliance and GM-CSF) was also a significant predictor, explaining 30% variability, 
but was not significantly better than Model 1 and the individual contributors lost strength. The model 
including all 6 variables was not a significant predictor of body weight change (P = 0.325) and 
revealed again high collinearity between BMI and WHeR. WHeR was therefore excluded from the 
analysis. Given that not all cases had values for GM-CSF levels, another regression analysis was 
conducted excluding this variable. The regression analysis revealed BMI and IL-6 as weak 
contributors, so that Models 3 and 4 were developed with compliance and naive TC cells (CD8+RA+), 
explaining 17.8% and 25.2% of the variability (Table 4.40). 
For male participants, the following variables were included in a hierarchical multiple 
regression analysis: CD19+ from the correlations (first block), and BMI, WHeR, CD8+RA+, and IL6 from 
the comparisons high vs low responsiveness groups (second block). CD19+ alone was a weak but 
significant predictor of body weight change, explaining 8.8% variability (Model 5), while the addition of 
the other variables resulted in a non-significant model (P = 0.135). A second analysis was conducted, 
excluding WHeR due to collinearity, and CD8+RA+ and IL-6 due to poor contributions.  When BMI was 
added to the analysis, the model was not significantly better than Model 5 (P = 0.133 for the 
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comparison between models) and the individual contributions lost strength, but overall the model was 
still significantly good and explained 13.6% variability (Model 6) (Table 4.40). 
Table 4.39. Multiple regression analysis of relative body weight change. 
   Predictors Final model 
Model N Predictors  Coefficients 95% CI P R2 P 
1 75 
Gender 
Drink 
Compliance 
Triglycerides 
BMI 
CD8+RA+ 
IL6 
CD19+ 
0.188 
-0.043 
-0.098 
-0.011 
0.165 
0.000 
0.000 
-0.002 
-0.614, 0.990 
-0.815, 0.729 
-0.197, 0.000 
-0.018, -0.003 
0.034, 0.296 
-0.002, 0.003 
0.000, 0.001 
-0.006, 0.003 
0.641 
0.912 
0.050 
0.008 
0.014 
0.669 
0.229 
0.471 
0.208 0.042 
2 75 
Compliance 
Triglycerides 
BMI 
-0.097 
-0.010 
0.157 
-0.191, -0.002 
-0.017, -0.004 
0.034,   0.280 
0.046 
0.004 
0.013 
0.181 0.003 
Unstandardized-β coefficients, 95% confident intervals and individual P values are shown for each predictor 
included in the analysis.  
Table 4.40. Multiple regression analysis of relative body weight change in females and males. 
    Predictors Final model 
Gender  Model N Predictors  B 95% CI P R2 P 
Females 1 30 Compliance -0.204 -0.402, -0.005 0.045 0.195 0.045 
 2 21 
Compliance 
GM-CSF 
-0.162 
-0.001 
-0.360, 0.035 
-0.003, 0.000 
0.102 
0.117 
0.300 0.040 
 3 30 Compliance -0.239 -0.437, -0.040 0.020 0.178 0.020 
 4 30 
Compliance 
CD8+RA+ 
-0.247 
-0.003 
-0.441, -0.054 
-0.007, 0.001 
0.014 
0.113 
0.252 0.020 
Males 5 45 CD19+ -0.005 -0.009, 0.000 0.049 0.088 0.049 
 6 45 
CD19+ 
BMI 
-0.004 
0.115 
-0.009, 0.000 
-0.037, 0.266 
0.061 
0.133 
0.136 0.047 
Unstandardized-β coefficients (B), 95% confident intervals and individual P values are shown for each predictor 
included in the analysis. Significance set at P < 0.05. GM-CSF: Granulocyte-macrophage colony-stimulating 
factor. 
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5. Discussion  
5.1 Relationship between obesity and early developmental factors  
The aims of this study were to explore the relationships between indices of obesity and several 
biological factors (early development, dietary habits, markers of metabolic function and inflammation, 
and circulating immune cells); to investigate the effect of a polyphenol-based weight loss intervention 
on the indices of obesity and the parameters studied; to assess individual responsiveness to the 
intervention; and to determine if and what factors may be predictors of responsiveness. 
My results support a potential protecting effect of breastfeeding against abdominal obesity in 
both male and female participants. The findings of my study showed a general trend for lower indices 
of obesity in those who were breastfed the first four months of their lives. The potential protecting 
effect of breastfeeding appeared to be more prominent in the female participants, with a significant 
reduction in female’s waist circumference on those who were breastfed.   
Various studies have suggested that breastfeeding during infancy confers protection against 
diseases; for example, breastfeeding is associated with reduced risk of a number of neonatal 
infections such as gastro-intestinal, diarrhoeal, and certain types of extra-intestinal infections (Jackson 
& Nazar, 2006). There is also evidence for a negative relationship between breastfeeding and obesity, 
showing increased obesity rates in non-breastfed populations and individuals (Poulton & Williams, 
2001; Parson et al., 2003; Frye & Heinrich, 2003; Owen et al., 2005). The idea of the importance of 
infant nutrition on an individual’s long-term adiposity was first suggested in the 1960s through the 
revolutionary work of McCance (1962). He showed that rats who were breastfed for longer as infants 
were larger as adults. This effect was not observed with nutritional intake after weaning, suggesting 
nutrition acts in the critical early post-natal window, which programs later body size (McCance, 1962; 
as reviewed by Singhal et al., 2007). Although it is noted that a variety of complex factors affect 
obesity, a 15% to 30% reduction in adolescent and adult obesity has been observed if any 
breastfeeding happened in infancy compared with no breastfeeding at all (Owen et al. 2005; Ip et al. 
2007). 
Dewey and co-workers (2003) proposed three possible explanations for the protective quality 
breastfeeding has against obesity: learned self-control, properties of the breast milk and/or metabolic 
programming, and residual confounding by parental attributes and/or the family environment. The 
authors discussed first that breastfeeding was able to instil the ability of self-control in the infant. 
Breastfeeding, compared to formula feeding, teaches the infant to control the amount of milk they wish 
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to consume, whereas bottle-fed infants may be encouraged to finish the bottle (Dewey & Lonnerdal, 
1986; as reviewed by Dewey et al., 2003). Secondly, breast milk is believed to contain different 
hormones, including leptin (Casabiell et al., 1997). Leptin exerts a key role as a regulator of appetite 
and adiposity (Dewey et al., 2003). Adiposity is positively correlated with leptin, and under normal 
conditions (in the absence of leptin resistance), increased leptin levels will inhibit appetite. Although 
the adipose tissue is the primary producer of the hormone, leptin is also secreted by other tissues, 
such as the mammary epithelium (Smith-Kirwin et al., 1998) and is therefore naturally present within 
breast milk (Casabiell et al., 1997; as reviewed by Palou & Pico, 2009). Dewey and colleagues 
discussed that breastfeeding may affect leptin metabolism both in childhood and throughout later life. 
The concentration of leptin within human milk can vary significantly, and it is positively correlated with 
maternal plasma levels and adiposity (Houseknecht et al.,1997; Miralles et al., 2006; as reviewed by 
Palou & Pico, 2009). Thus, the infant’s exposure to leptin during lactation is directly linked to the 
adiposity of the mother, suggesting that the positive effects of breastfeeding may be negated by 
maternal obesity.  
 
In addition, breast milk has the ability of modulating metabolic programming. This has been 
suggested from the finding that infants who were formula fed had elevated insulin levels and 
prolonged insulin response compared to those who were breastfed (Lucus et al., 1981; Owen et al., 
2006). Increased insulin levels are able to stimulate adiposity (Odeleye et al., 1997). The mechanism 
by which feeding style can alter insulin levels is through the infant’s intake of protein; it was reported 
that infants fed by formula consumed 66% to 70% more protein than their breastfed counterparts and 
diets with increased protein content encourage insulin secretion(Heinig et al., 1993). In addition to this, 
a study conducted by Dorotsy and co-workers (2000) found a positive association between high 
protein intake in early life and obesity in childhood. 
In my study we also observed a U-shape relationship between birth weight and indices of 
obesity, particularly in females. In addition, significant positive associations presented between birth 
weight and BMI, waist circumference and waist-to-height-ratio in males. 
Positive correlations have been identified between birth weight and ensuing childhood and 
adult obesity (Rasmussen & Johansson, 1998; Celi et al, 2003; Rugholm et al, 2005; Monasta et al, 
2010; as reviewed by Yu et al, 2011). A study conducted by Kahn and co-workers (2000) suggested 
the increased prevalence in elevated adult body weight observed in individuals who had a higher birth 
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weight may be due to an increased lean mass, instead of an increased amount of fat tissue. Their 
study found that adult BMI reflected increments in lean tissue more than increments in adipose tissue 
(Kahn et al, 2000). Therefore, Kahn and co-workers would indicate that increased birth weight is not 
an indicator of obesity but of greater body weight, which could explain elevated levels of BMI seen in 
the participants, as no relationship was identified in body fat (%).  
In contrast, Schellong and colleagues (2012) demonstrated that a higher birth weight (4 kg 
and above) lead to a two-fold increased risk of obesity. They did so through a meta-analysis of data 
from western and westernized, developing countries from northern and southern America, Europe, 
Asia, and Australia, and the increased risk obtained was independent of confounding variables like 
geographic/ethnic origin, socio-economic status, or parental weight status. The study conducted by 
Schellong and colleagues did not discuss however the relationships or associations between reduced 
birth weights and increased prevalence of obesity.   
A study by Sorensen and co-workers (1997), did present, similar to my study, a U-shaped 
association, showing higher prevalence of obesity for the lowest and highest birth weights. Labayen 
and co-workers (2008) showed that a lower body weight was linked to inadequate intrauterine 
conditions (e.g., excessive or insufficient energy supply, deficiencies or excess of specific nutrients, 
maternal stress, etc.) that lead to abnormal foetal development. Connections have been made 
between decreased infant birth weight and lower lean body mass and greater central obesity, using 
measurements such as waist-to-hip ratio or skinfold thickness in adults (Labayen et al., 2008). This 
was further suggested in this present study which presented significant associations between 
decreased birth weight and elevated indices of abdominal obesity in both male and female 
participants.   
Another explanation proposed between low birth weight and adult obesity is the development 
of the thrifty phenotype. The hypothesis proposes that pregnant women exposed to poor nutritional 
conditions can alter an unborn child development in such a way that it will be prepared for survival in 
an environment lacking in resources (Hales & Barker, 1992). Hale and Barker (1993) hypothesised 
that the in utero low sustenance resulted in the development of a thrifty phenotype in anticipation of a 
life with limited food (as reviewed by Beauchamp et al., 2015). Beauchamp and co-workers (2015) 
found that the mice whose mothers experienced undernourishment during their pregnancies had 
elevated levels of adiposity in adulthood, and when entered into a weight loss program presented a 
significantly reduced ability to lose weight. They also observed that those subjected to undernutrition 
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had decreased mitochondrial content in mixed fibre muscles and reduced respiration in mitochondria, 
which contributed to elevated adiposity.   
5.2 Relationship between obesity and dietary factors  
 
This study did not find a relationship between the indices of obesity and caffeine consumption in the 
participants. Over 55% of adults are reported to consume coffee or tea (Bleich et al., 2009), and 
various epidemiological studies have reported relationships between tea and coffee consumption and 
reduced risk of type 2 diabetes and coronary heart diseases (Higdon et al., 2006; Schneider & Serge, 
2009; Balk et al., 2009). Greenberg and co-workers (2005) hypothesised that this protective nature of 
coffee and tea from type 2 diabetes might be linked to a reduction in obesity. Inconsistency appears, 
however, throughout the available literature. Various other studies found that coffee and tea 
consumption presented no relationship with obesity, as shown in my study (Egger et al., 1999; Van 
Dam & Feskens, 2002; Rosengren et al., 2004; Tuomilehto et al., 2004; Bouchard et al., 2010). The 
use of additives such as milk, sugar and sweeteners may reduce the anti-obesity qualities of tea and 
coffee (Balk et al., 2009; Bouchard et al., 2010), as research has presented positive associations 
between body weight gain and milk/dairy (Moore et al., 2008), sugar (Bray & Popkin, 2014) and even 
sweeteners (Feijo et al., 2013). We did not analyse these additives in this study, so a clear conclusion 
requires further analysis.  
Another avenue investigated within this study was the relationship between meal distribution 
patterns and indices of obesity. There is a consensus that breakfast consumption can protect against 
overweight and obesity versus skipping breakfast (Berg et al., 2009; Huang et al., 2010; Casazza et 
al., 2013; Brown et al., 2013; Reeves et al., 2013; Deshmukh-Taskar et al., 2013; O’Neil et al., 2014). 
One of the largest and most comprehensive meta-analysis was conducted by Brown and co-workers 
(2013), where they analysed 88 study groups and yielded a pooled odds ratio of 1.55 (95% Cl: 1.46, 
1.65) for the likelihood of being overweight/obese among breakfast skippers versus consumers 
(Brown et al., 2013; as reviewed by Barr et al., 2016). Other authors, on the contrary (Song et al., 
2005; Grujic et al., 2009; Lee et al., 2016), found no significant relationship between breakfast 
consumption and BMI or prevalence of overweight/obesity. In the current study, we found no 
significant differences in the indices of obesity between participants who consumed breakfast and 
those who did not, although a trend was observed for lower obesity values in females who consumed 
breakfast. Song and co-workers (2005) found that female participants presented differences in the 
indices of obesity according to the type of breakfast they consumed. Those who ate a ready-to-eat 
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cereal for breakfast presented a lower odds ratio for being overweight or obese, compared to those 
who consumed other foods for breakfast. These findings could indicate that not just the act of eating 
breakfast, but the type of foods consumed could act as a protective factor against obesity, indicating 
that further study is needed to understand the effect of breakfast on obesity in this present study.  
5.3. Relationship between obesity and blood cells  
All indices of obesity (except WHR) were positively correlated with red blood cell counts in this studies 
participants. The current studies results are in agreement with other work (Vuong et al., 2014), and 
previous studies have linked increased erythropoiesis with the metabolic syndrome (Rangno et al., 
2001; Mardi et al., 2005). A possible explanation for the relationship between red blood cell counts 
and obesity is an increase in insulin (Vuong et al., 2014), as insulin and insulin-like-growth factors 
enhance erythropoiesis (Ratajczak et al., 1998; Miyagawa et al., 2000). Other explanation may be 
sleep apnoea and/or obesity-related hypoxia (Graham et al., 1980), leading to increased numbers of 
red blood cells to combat the oxygen deficit. In addition, adipokines such as leptin and adiponectin 
could be linked to erythrocyte metabolism (Tsuda & Nishio, 2004; Tsuda, 2006). Tsuda and Nishio 
(2004) presented data that clearly demonstrated that leptin had the ability to modulate the fluidity of 
the erythrocyte membrane. They suggested that this might be of considerable biological and clinical 
significance in determining rheological properties of the cell membranes. Leptin has elevated levels in 
those with increased adiposity (Ouchi et al., 2011) and therefore this could link obesity to increased 
red blood cell counts.  
On the other hand, a negative correlation was observed between BMI and abdominal obesity 
and the size and haemoglobin concentrations of red blood cells. One possible explanation for these 
associations may be iron deficiency (Vuong et al., 2014), and actually a negative trend was observed 
between indices of obesity and iron levels in the present study. Tussing-Humphreys and co-workers 
(2012) found that obese individuals have elevated levels of hepcidin. Hepcidin is the main regulator of 
iron homeostasis, which in turn means it plays a critical part in the aetiology of several iron-related 
disorders. Hepcidin traps circulating iron in macrophages and liver cells, and decreases gut 
absorption; therefore, Tussing-Humphreys proposed that hepcidin might play an important role in iron 
depletion often observed in obesity. In this line, in the current study ferritin was found to be positively 
correlated with all indices of obesity. Ferritin is an intracellular protein that plays a critical role in the 
regulation of iron homeostasis, and has been shown to be a biomarker of elevated body iron stores 
(Cook et al., 1974). Ausk and Ioannou (2008) discussed that they found ferritin levels increased with 
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indices of obesity, and stated that obesity-related inflammation is expected to cause increased ferritin 
serum levels, as ferritin is a common acute phase reactant. Ausk and Ioannou theorised that serum 
ferritin might be used to reduce the oxidative stress by binding to free redox-active iron. Furthermore, 
obesity-related inflammation would induce hypoferremia, a biological response to infection (Means, 
2004). Ausk and Ioannou therefore concluded that obesity association with changes in ferritin serum 
levels are linked to inflammation and not obesity-related anaemia. Therefore, the contradictory 
elevation in ferritin and negative trend between iron and obesity could be related to different 
processes. Various studies have also indicated a link between elevated body iron stores and 
metabolic syndrome, and elevated serum ferritin levels have been significantly associated with 
visceral and subcutaneous fat stores (Iwasaki et al., 2005) and presented as a potential predictor of 
type 2 diabetes (Bao et al., 2012; Zhoa et al., 2012; Kunutsor et al., 2013). Elevated ferritin levels 
have also been linked to central adiposity (Gillum, 2001), in agreement with this current study’s 
findings.  
We also observed increased platelet counts with all indices of obesity (except WHR). Elevated 
platelet counts have been associated with insulin resistance and cardiovascular disease (Thaulow et 
al., 1991; Taniguchi et al., 2003). The participants within this current study did not present insulin 
resistance or cardiovascular disease; however, as previously discussed elevated adiposity presented 
in this study is linked to the development of metabolic syndrome-related disorders. Coban and co-
workers (2005) found that obese participants presented greater mean platelet volume in comparison 
to non-obese controls. Platelet counts and platelet activation are associated to a person’s state of 
chronic inflammation, and as obesity is a form of chronic inflammation, this would explain the 
association between platelets counts and indices of obesity (Yudkin et al., 2000).  
Elevated counts of white blood cells were observed when all tested indices of obesity were 
raised (except body fat %). In agreement with the current study’s findings, Fisch and co-workers 
(1975), in a study upon almost 15,000 healthy women, presented that obesity was associated with 
higher white blood cell counts. The makeup of inflammation and metabolic syndrome and its 
associated ailments have all been connected to elevated white blood cell counts (Nagasawa et al., 
2004; Dehghani et al., 2016). Various studies have demonstrated a chronic inflammation status in 
individuals with elevated indices of obesity (Stofkova, 2009; Karalis et al., 2009; Iyer et al., 2010). This 
increase is believed to be due to the development of metabolic syndrome (Fadini et al., 2012). The 
increase in the number of white blood cells in participants with elevated indices of obesity within the 
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current study is similar to the increased measures of inflammation observed in other studies (Vallianou 
et al., 2010, Johnson et al., 2012).  
Neutrophil counts presented significant positive correlations with all indices of obesity. This 
increase may be explained by a variety of chemo-attractants for neutrophils such as CXCL8 and 
CCL5, which are increased in obese individuals (Trellakis et al., 2012). Further to this, leptin is known 
to promote neutrophil chemotaxis and is presumed to be a survival cytokine for neutrophils 
(Fernandez-Riejos et al., 2010). Neutrophil numbers are also associated with the formation of 
atheromatous plaque (Avanzas et al., 2004). Buyukkaya and co-workers (2012) found elevated 
numbers of neutrophils in individuals with metabolic syndrome, with the number of neutrophils 
increasing as metabolic syndrome became more severe. The elevated numbers of neutrophils seen in 
the current study may therefore indicate an early onset of metabolic syndrome.  
In the current study, significant positive correlations were identified as well between monocyte 
counts and BMI and WHeR. This association has been observed in other studies (Kullo et al., 2002; 
Ilavska et al., 2012), and might be explained by increased secretion of monocyte chemoattractant 
protein (MCP)-1 by the elevated number of pre-adipocytes and adipocytes in obesity (Gerhardt et al., 
2001). Other studies, however, did not fully agree with the current study’s findings; for example, 
Rogacev et al., (2010) looked into CD16+ Monocytes and found no significant relationship/difference. 
Nevertheless, Rogacev and co-workers agreed that there was an association, and that obesity should 
not be discounted as a potential mediator of macrophage infiltration.   
In contrast to neutrophils and monocytes, lymphocytes counts in the current study presented a 
negative correlation with body fat %. Perez de Heredia and co-workers (2015) found higher 
neutrophil/lymphocyte ratio association with increasing BMI, as seen within this present study. At the 
same time, there was a significant positive association between lymphocyte counts and WHR. This 
finding is more in line with other studies who found elevated lymphocyte counts and obesity (Marti et 
al., 2001).  
WHR also presented positive associations with T mature cells (CD3+), T cytotoxic (CD8+), 
memory T cytotoxic CD8+RO+, and memory T helper CD4+RO+ cells presented positive correlations 
with BMI. Obese participants had significantly higher T/B lymphocyte (CD3+/CD19+) ratio than 
overweight ones. This is in agreement with other studies which found higher CD3+ and CD4+ cell 
counts with increasing BMI (Perez de Heredia et al., 2015).  
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5.4 Relationship between obesity and serum and plasma variables  
 
Obesity and abdominal obesity were positively associated with glucose, HOMA index, triglycerides, 
and VLDL, while total cholesterol was associated with abdominal obesity, in agreement with the most 
of literature (Kuksis et al., 1991; Jones, 2013). Insulin resistance, disruption to lipoprotein metabolism, 
and increased serum triglyceride levels are common features in subjects with elevated indices of 
obesity and abdominal obesity (Despres et al., 1990; Chan et al., 2002; Katsuki et al., 2003). It has 
been reported that elevated levels of triglycerides and glucose when fasting are useful indicators of 
insulin resistance (Simental-Mendía et al., 2008).  
BMI also was significantly correlated with levels of leptin, cerpuloplasmin, CRP and ICAM-1. 
Pathophysiological mechanisms that link increased adiposity and elevated levels of CPR have been 
documented (Bastard et al., 2006; Ferrante, 2007; Rocha & Lippy, 2009; Brooks et al., 2010); 
increased adiposity leads to elevated CRP levels because adipose tissue is an active endocrine organ 
with the ability to release a range of cytokines and hormones (Van Gaal et al., 2006). The 
accumulation of free fatty acids caused by activated pro-inflammatory serine kinase cascades, for 
example IkB kinase and c-Jun-N-terminal kinase, leads to secretion of cytokines such as IL-6, which 
stimulates the synthesis of CRP (Rocha & Lippy, 2009). The increases in the levels of ceruloplasmin 
seen with elevated levels of obesity are in line with the findings of another study which found that 
adipose tissue of obese subjects can result in the overexpression of ceruloplasmin (Arner et al., 2014). 
Nishimura and co-workers (2008) how the endothelial cells within adipose tissue express higher levels 
of adhesion molecules, which would explain positive correlation.  
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5.5 Effect of the treatments 
 
The current study used a selection of four treatments within this obesity intervention programme. Two 
of these tested treatments were active drinks (B1 and B2) and two placebos (P1 and P2). Only 
treatment B2 presented a significant reduction in female BMI, which was not observed in the placebo. 
In contrast, Nagao and co-workers (2005) presented significant reductions in body weight, BMI, waist 
circumference and body fat mass in their participants who were administer green tea extract. In 
comparison, it would appear that the treatment given in the current study was not successful in 
improving overweight.  
Treatment B1 presented a significant increase in mean corpuscular Hb concentration in 
female participants. Vuong and co-workers (2014), as stated previously, demonstrated a link between 
obesity and reduced red blood cell size and mean corpuscular Hb concentrations. The improvement of 
the haemoglobin status in this studies female participants could also be due to reductions in adiposity 
levels, as seen in markers of abdominal obesity like waist and WHeR, although similar reductions 
were obtained with the placebo as well. In line with this theory, treatment B2 presented significant 
increases in haemoglobin and mean corpuscular Hb in males (but again similar increases were 
observed with the placebo).  
Treatment B2 showed also significant reductions in total white blood cells and neutrophil 
counts. Even if we cannot ascertain that these reductions were linked to an improvement in indices of 
obesity, they could be a positive outcome, as higher white blood cell counts have been associated 
with higher risk of developing metabolic syndrome (Odagiri et al., 2011), and neutrophil counts have 
been connected with obesity (Trellakis et al., 2012). In addition to this, B2 presented a significant 
reduction of CD4+RA+ levels in males. Again, there is little research to date on the role of specific 
lymphocyte subsets on obesity, but a recent study suggested that CD4+ can confer “obese memory”, 
and stimulate weight regain in rodents (Zou et al., 2017). 
In relation to blood biochemistry, treatment B2 presented significant decreases in total 
cholesterol, LDL, and apoA1 in the female subjects, whereas it presented significant increases in 
glucose and NEFA in the male subjects. On the one hand, this may indicate that treatment B2 had a 
beneficial effect upon female participants’ lipid profile, and suggest higher lipolytic activity in male 
participants (as indicated by the rise in NEFA). On the other hand, these changes may indicate that 
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participants changed their lifestyle habits (e.g. diet, physical activity levels) during this trial, indicating 
that future research will need to investigate lifestyle throughout the intervention. 
Significant increases were observed for ghrelin and VCAM-1, and reductions for IL-6 in female 
participants under treatment B1. The reduction in IL-6 could represent an improvement in the 
participants’ immune status. Similarly to what was observed in immune cell counts, changes in IL-6 
may not be a direct consequence of reductions in adiposity, but an indication of other beneficial effects 
of the polyphenol-rich treatments upon markers of inflammation. In addition to this, treatment B1 
presented significant decreases in IL-8 and VCAM-1 in males, further supporting that participants’ 
immune status improved.  
 
5.6 Predictors of responsiveness to weight loss treatments 
 
Successfulness of weight loss interventions is highly variable. Therefore, the identification of 
predictors of success is an important area of research. However, prediction of responsiveness to 
weight loss treatments have been demonstrated in literature to not be easily obtainable. We attempted 
to identify potential predictors of weight loss in the current studies participants in the hope of 
expanding the understanding of the great variability observed in the outcomes of most weight loss 
interventions. We used Body weight (%) as the classifying criterion for success of intervention, 
because body weight is a key indicator of most weight loss treatments success. There was great 
variability in the response to the weight loss intervention in the current study (from -4.63% to +3.93% 
initial body weight).  
In the search for a model to predict the response to a weight loss treatment, Wadden and 
colleagues (1992) presented that baseline body weight (r = 0.27, P < 0.05), weight loss in the first 
month (r = 0.44, P < 0.001) and compliance (r = 0.37, P < 0.01) were the most effectively correlated 
with weight loss after a low calorie diet or a mix of behavioural treatments over a 4-month period. 
Hansen and co-workers (2001) explained 8% of the variation observed in their study by the 
combination of baseline body weight, treatment group and age, while Leibbrand & Fichter (2002) 
found that baseline BMI was the only potential predictor to have a significant result at the 18-month 
follow up assessment  (R2 = 0.07, P < 0.01). It needs to be noted that although all these studies 
presented baseline BMI/body weight as significant predictors of weight loss, the variability explained 
by these factors was very low, being only 7% for BMI in Leibbrand & Fichter’s, and less than 8% for 
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body weight in Hansen and co-workers’. This indicates the necessary contribution of other factors to 
explain why different individuals respond differently to weight loss treatments.  
In the current study, the analysis of correlations between relative body weight change and 
baseline values of the studied variables showed that BMI was potentially a negative predictor of body 
weight loss, while compliance, triglycerides, VLDL-c, B lymphocytes (CD19+) and GM-CSF were 
potentially positive predictors. These results present a contradiction, BMI, triglycerides and VLDL-c are 
generally associated (Mittendorfer et al., 2016). Mittendorfer and co-workers (2016); found that 
regulation of plasma VLDL-c and triglycerides concentrations is complex and influenced by a multitude 
if metabolic factors. Many individuals with obesity present normal plasma VLDL-c and triglyceride 
concentration (Mittendorfer et al., 2016).  
In addition to this, participants were split into three groups (high responsiveness, with a loss of 
more than 1.5% of initial body weight; low responsiveness, with any increase in body weight; and 
those who could be classed as maintainers, with  relative body weight change between -1.49% and 
0%). The maintainers were excluded from the statistical analysis, and the high respondents and low 
respondents were compared to identify any differences in their baseline values. In contrast to the initial 
hypothesis, I did not find a significant difference in caffeine consumption between groups. Previous 
studies found that caffeine consumption demonstrated increased thermogenesis and therefore energy 
expenditure in the short term, which would contradict the current studies results; however, greater 
weight loss was not found over extended periods in comparison to the placebo (Pasman et al., 1997; 
Lopez-Garcia et al., 2006; Westerterp-Plantenga, 2010). This is believed to be due to the regular 
caffeine consumer becoming habituated to caffeine and losing sensitivity to caffeine (Westerterp-
Plantenga, 2005). This would then explain the lack of significant differences between the current 
studies’s high and low respondents according to their caffeine consumption. In contrast, Lopez-Garcia 
and co-workers (2006) found that long term high caffeine consumption reduced weight gain in 
comparison to subjects who consumed reduced amounts of caffeine, and this was explained through 
caffeine’s influence on energy expenditure and intake. This combination of effects discussed within 
these two studies may be the reason for the lack of significant influence of caffeine consumption 
demonstrated within this present study.  
High and low respondents presented no significant differences in meal distribution patterns, 
except for a lower frequency of midmorning snacking in high respondents. In contrast to the current 
study, other studies have shown inverse relationships between eating frequency and body fat 
  
 
 
90 
 
percentage and BMI in both lean and obese adults (Fabry et al., 1964; Ma et al., 2003). An US study 
found that adults consuming 4 or more meals per day presented a lower risk of obesity in comparison 
to those who ate three or less time per day (Ma et al., 2003; as reviewed by Kulovitz et al., 2014). 
Ohkawara and colleagues (2013) on the other hand found that there were no advantages of 
consuming smaller, more frequent meals on metabolism and appetite, and further suggested that it 
might have adverse effects on hunger and satiety. The disagreement in relation to the influence of 
meal frequency on weight loss leads to the need for future research.  
Baseline BMI and WHeR were significantly lower in high respondents, and body weight, body 
fat percentage, waist circumference, and WHR presented trends in the same direction. Furthermore, a 
borderline positive correlation was observed between BMI and Body weight (%). Therefore, baseline 
BMI appeared as a negative predictor of weight loss in the current study. Initial body weight and BMI 
have been previously identified as useful pre-treatment predictors of weight loss success (Wadden et 
al., 1992; Hansen et al., 2001; Leibbrand & Fichter, 2002; Vogels et al., 2005; Hainer et al., 2008) in 
calorie-controlled treatments. These studies reported that subjects with higher body weight lost more 
weight, as would be expected under reduced calorie conditions. However, as the current study was 
not calorie controlled, rather based on a supplement, it is interesting to see that those with reduced 
indices of obesity showed increased responsiveness. However, there appears to be very little 
literature regarding the relationship between responsiveness in a supplement weight loss treatment 
and indices of obesity. This clearly demonstrates the need for future investigation.  
No significant differences were in either baseline red blood cell series or white blood cell 
counts between high and low respondents. However, it is worth noting that a trend appeared of 
decreased haemoglobin concentration in red blood cells and elevated platelet counts in participants 
who showed low responsiveness to the treatment. This may be explained by heightened indices of 
obesity and iron deficiency as previously discussed.  
The lymphocyte subset CD8+RA+ was the only immune cell type studied to present a 
significantly different value between high and low respondents, with the latter showing increased 
counts. The literature does not give a clear answer to why this had happened. Why would low 
respondents have high values of naïve cytotoxic T cells, could it be suggested that an activated 
immune system helps with losing weight? It is not known, and further research in to the topic would be 
need. In addition, B lymphocytes count was a positive predictor of body weight loss. This is in contrast 
to other studies that have demonstrated impaired B cell capacity in obesity (Frasca et al., 2017), as 
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obese individuals fewer antibodies after vaccination (Karlsson et al., 2016). It is not clear as to the 
reason for this relationship and clearly indicates the need for future studies.  
 
Triglycerides and VLDL were also positive predictors of body weight loss, according to 
correlation analysis. Stroeve and co-workers (2016) concluded that 57% of the variation of weight loss 
observed between people undertaking the same treatment can be predicted by baseline plasma 
metabolic signature. In their study, the total level of triglycerides was negatively correlated with relative 
BMI change (Stroeve et al., 2016), in concordant with the current study’s findings.  
 
Low respondent participants presented significantly elevated baseline IL-6 values, while GM-
CSF on the contrary appeared as a positive predictor of weight loss in females. IL-6 secretion has 
been associated with BMI (Mohamed-Ali et al., 1997). It has been estimated that 30% of all circulating 
IL-6 is derived from white adipose tissue (Fain et al., 2004), and it has been observed that 
subcutaneous adipose tissue is responsible for the expression of a large amount of IL-6 (Fain et al., 
2004). IL-6 is a pro-inflammatory cytokine that promotes neutrophil and T helper 17 cell differentiation 
while blocking regulatory T cell (Treg) differentiation (Covarrubias et al., 2014). Therefore, elevated 
values of IL-6 can indicate low grade inflammation, which is a precursor to metabolic syndrome. It has 
been shown that individuals with metabolic syndrome show reduced response to weight-management 
treatments compared to individuals without (Pi-Sunyer, 2005). However, it should be noted that this 
contradicts the findings that triglycerides acted as positive predictor. Triglycerides are a key feature of 
metabolic syndrome (Eckel et al., 2005) and therefore, if metabolic syndrome reduced an individual’s 
ability to lose weight triglycerides would not be a positive predictor. The current literature does not give 
a clear explanation, and this indicates that further study is required.  
According to these observations, we obtained a multiple regression model on our study 
sample including gender, type of drink consumed, compliance, BMI, triglycerides, B lymphocytes 
(CD19+), T cytotoxic naive cells (CD8+RA+) and IL-6 as predictors. The model was a significant 
predictor of relative body weight change, explaining 20.8% of the variability, but it also showed that 
gender, type of drink, immune cells and IL-6 were not significant contributors. Therefore, a second 
model was developed including compliance, triglycerides, and BMI, which explained 18.1% of the 
variability and was a significantly good predictor of relative body weight change.  
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Robertson and co-workers (2016) found that females and males respond differently to a 
variety of weight loss interventions. Therefore, although gender wasn't identified as a significant 
predictor in the current studies regression analysis, we decided to also build models separately 
according to gender, and by doing this we found that there were different significant predictors for 
males and females.  
In females, a regression model based on compliance alone was a significant predictor of body 
weight change, explaining 17.8% of the variability. Adding naïve T cytotoxic cells (CD8+RA+) explained 
25.2% of the variability, but this model was not significantly better than compliance alone. In a 
subgroup of participants with valid values for GM-CSF, compliance and the chemokine could explain 
30% variability, although again the model was not significantly better than compliance alone (which 
explained 19.5% variability in that subset). In male participants, CD19+ alone explained 8.8% 
variability, and when BMI was added to the analysis, it explained 13.6% variability. 
 
The current studies models explain a greater percentage of variability that previous studies, 
such has Leibbrand and Fichter (2002), who explained 7% of variability in treatment success based on 
baseline BMI, and Hansan and co-workers (2001), who explained 8% of variation by baseline body 
weight, treatment group and age. Handjieva-Darlenska and co-workers (2010) reported that the power 
of their regression analysis was significantly increased from 42% to 50.9% when the participants’ first 
week’s weight loss was added to the model. This could therefore be an interesting future model to 
follow, and an interesting early check to analyse whether the chosen weight loss program is suited to 
the patient.  
5.7. Limitations, strengths and future work  
The current studies study contributed to broaden the approach on identification of possible indicators 
of responsiveness to weight loss. The ability to predict weight loss allows a more specific intervention 
for the individual. 
A strength of the current study was that it tested a far greater variety of biomarkers than 
previous studies. We explored the relationship between many metabolic biomarkers, and immune 
makers that have not been previously tested for their predictive potential in weight loss success.    
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The present study also has several limitations that have been discussed throughout and 
should be addressed. Firstly, a larger sample size would have increased the statically power, 
especially for immune status indicators, such as cytokine levels. Higher statistical power could have 
helped discriminate small differences in the values of serum biomarkers, and between pre- and post-
treatment changes. 
A limitation of this study is that the accuracy and reproducibility of the Tanita scale used to 
determine body fat % were not recorded at the time of data collection, and therefore are not available 
to me. The model used is mainly intended for domestic use, and as such, I can assume that its 
accuracy would be lower than that of a professional one. This would result in a potentially higher intra-
individual variability of body weight and fat measurements, and in consequence a reduced statistical 
capacity to discriminate changes due to the intervention.  
Another limitation of this study was the lack of analysis of the dietary and exercise habits of 
the participants. A more in depth analysis of energy intake and expenditure could have contributed to 
explain the differences observed in participants’ responsiveness to the weight loss treatment. In 
addition, detailed information on specific nutrients, such as saturated and total fat or sugar, could help 
explain the variations in the levels of, cholesterol, triglycerides and glucose observed in participants in 
relation to the indices of obesity. This was not conducted due to the food diaries requiring knowledge 
of the Spanish language and food culture to be analysed, which implies considerable time and the 
participation of additional researchers. This being a master’s project did not allow the time or 
resources to overcome this limitation.  
Future works could involve the study of the influence of the identified potential predictors 
under different weight loss treatments, such as calorie-controlled diets, dietary supplements, or 
pharmaceutical. This may indicate whether certain types of treatment are more suited to individuals 
with specific features, thus creating a more personalised treatment plan, which will produce better 
results.   
 
 
 
 
  
 
 
94 
 
6. Conclusions  
The current study supports a significant relationship between early developmental factors and obesity. 
The results agree with a potential protecting effect of breastfeeding for at least the first four months of 
life against adult obesity. We also observed a U-shape relationship between birth weight and obesity 
in females, and positive linear associations between birth weight and obesity in males. 
The current study also identified reduced markers of haemoglobin status with obesity, 
supporting a relationship between obesity and anaemia, and significantly elevated levels of ferritin with 
obesity suggesting obesity related inflammation. 
White blood cells presented significant elevations with higher indices of obesity (except body 
fat %) further indicating obesity-related inflammation. 
Indicators of the onset of metabolic syndrome were also observed, with significant positive 
correlations between indices of obesity and glucose, triglycerides and cholesterol.  
Overall, the intervention was not successful in reducing obesity in the sample, although 
treatment B2 appeared to effective in improving health markers, significantly reducing BMI, total white 
blood cells, neutrophil counts and CD4+RA+, and increasing haemoglobin and NEFA.   
Compliance, triglycerides, VLDL, GM-CSF and B lymphocytes (CD19+) were positive 
predictors and BMI was a negative predictor of weight loss. In addition, high respondents presented 
lower baseline BMI, WHeR, CD8+RA+ and IL-6. The regression analysis revealed compliance, 
triglycerides, and BMI constituted a good predictive model, which explained 18.1% of the variability. 
Research in this field will allow a more personal and streamlined approach to weight loss and 
contribute to manage the current obesity epidemic.  
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INFORMATION FOR THE PARTICIPANTS 
 
PROJECT TITLE: ASSESSMENT OF THE EFFECT OF A HEALTHY BEVERAGE ON BODY 
WEIGHT MANAGEMENT (PRONAOS PROJECT) 
WHO CONDUCTS THE STUDY? 
This work is being carried out by the Immunonutrition Research Group of the Spanish 
National Research Council (CSIC). The group is settled in the Institute of Food Science, 
Technology and Nutrition (ICTAN), at the University Complutense Campus (Ciudad 
Universitaria). 
The study is part of the PRONAOS Project, an inniciative of the Spanish Ministry of Science 
and Innovation with the aim of encouraging academy and industry to collaborate in the 
development of novel functional food products for the prevention and management of 
overweight and obesity. 
INTEREST OF THE STUDY 
The main concern in relation to obesity lies in its association with diminished quality of life and 
with a higher risk of developing chronic diseases such as diabetes, cardiovascular disease, or 
even cancer. 
Lifestyle habits, especially diet and physical activity, are essential factors in the onset of 
overweight and obesity, and consequently, they are also crucial for prevention and treatment. 
WHAT IS THE AIM OF THE STUDY? 
The aim is to assess whether the regular consumption of a functional beverage has an effect 
on body weight control. To help achieve it, we seek young volunteers (20-40 years old) with a 
body mass index in the range of overweight or obesity (≥24.5 kg/m2) but otherwise healthy. 
WHAT SHALL PARTICIPANTS DO? 
Participants shall drink the beverage daily for 8 weeks. Then they will rest for 4-8 weeks 
(washout period) and then the treatment will be repeated for another 8 weeks. On the second 
phase of the treatment, the taste of the beverage will be slightly different, so as to estimate 
which flavor can be more successful later in the market. 
Optimal beverage consumption is 1L/day (two bottles of 0.5 L). Our recommendation is to drink 
it during the day, preferably in the morning. 
Participants will meet the researcher six times during the study: at the beginning, in the middle 
and at the end of each phase of treatment. On each meeting data will be collected from body 
weight and fat percentage, waist and hip circumference, and physical activity and dietary habits 
(see forms below). 
 
Annex 3: PRONAOS project participant information sheet  
  
 
 
125 
 
On four of the six meetings (at the beginning and at the end of each phase) blood samples will 
be collected as well, for further analysis. 
All data will be kept and analyzed anonymously. We guarantee your privacy and only you will 
have access to your personal individualized information upon request. 
HOW TO PARTICIPATE? 
Your participation in the study is completely voluntary and free. 
If you are interested, you can contact us (Dr. Fátima Pérez de Heredia) by phone (915492300), 
from 10 to 14h, or by email (inmuno.nutri.ictan@gmail.com). 
A personal interview will be then arranged to ask you some questions about personal data and 
medical history and to answer to all the questions you may have. If you fulfill all inclusion criteria 
(aged 20-40, body mass index ≥24.5 and being free of diseases that may interfere with the 
objectives of the study), you will be included in the study. 
All appointments will take place at the Institute of Food Science, Technology and Nutrition 
(ICTAN, former Instituto del Frío), at the University Complutense Campus (Ciudad 
Universitaria, Madrid). 
Participants who complete the study will receive 150€ as gratification. 
IS IT SAFE TO PARTICIPATE? 
The beverage does not contain alcohol, sugar, or any substance that can be considered toxic, 
or for which secondary effects have been described at the doses employed. 
The beverage contains sources of caffeine, and therefore it could have a mild stimulatory 
effect. For this reason we recommend it to be consumed preferably during the morning or 
before 6 p.m. 
It also contains sources of substances that can potentially interfere with iron absorption 
(although at the same level that tea and coffee do). Therefore, we recommend it not to be 
consumed during lunch and wait approximately an hour after having had lunch. 
REGULATIONS FOR THE USE AND GUARANTEE OF PRIVACY OF THE INFORMATION 
OBTAINED  
The project will be conducted in accordance with the ethical principles in the Declaration of 
Helsinki (52nd General Assembly, Edinburgh, Scotland, 2000), the Code of Good Clinical 
Practice, and with current legislation. 
Sample processing 
Biological samples (from blood extractions) will be kept in the ICTAN premises (CSIC), under 
the conditions and for the time required for analysis, in accordance with the objectives of the 
study, and will be conveniently destroyed once analyzed. Similarly, questionnaires will be 
stored in the ICTAN premises for the time required for analysis and will be destroyed after 
being analyzed. 
Data processing 
Each participant will be identified by a code, so as to preserve anonymity. All codified 
information will be also protected from non-authorized use by third parties. Data will not be 
shared with third persons and their use will be exclusively for scientific purposes, and no 
economic profit will be obtained through their exploitation. 
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The information resulting from the study will be considered strictly confidential for the parties 
involved; however, supervision by Health Authorities will be allowed when required, in 
accordance with the regulations included in the Ley Orgánica de Protección de Datos (LOPD 
15/1999). According to these regulations: 
 All personal data subjected to processing cannot be used for any purpose incompatible 
with those for which data were initially collected. 
 Further processing for historic, statistical or scientific purposes will not be considered 
incompatible. 
 Data will not be kept in such a way that allows identification of the participants and they 
will be stored only for the time required to achieve the purposes for which they were 
collected. 
Potential participants will be informed in an express, precise and unequivocal way of: 
a) The storing and processing of personal data, of the aim(s) in obtaining these data, and of 
the person(s) who will have access to them. 
b) The voluntary or compulsory nature of their responses to the questions that they will be 
asked. 
c) The consequences of data collection and the refusal to facilitate them. 
d) The possibility of having rights to access, correction, cancelation or opposition of personal 
data. 
e) The identity and address of the researcher responsible for the treatment, or his/her 
representative instead. 
The processing of personal data will require the unequivocal consent of the participants, save 
when the current legislation stipulates otherwise. 
The consent to which the article refers can be revoked for a justified reason and when 
no retroactive effects apply. 
The person responsible for the files and everyone who participates at any time in the 
collecting and processing of samples and data are bound by professional secrecy and shall 
observe it, even after termination of their relationship with the file holder or the person 
responsible instead. 
Participants’ access rights to personal information 
1. Participants will have the right to request and freely obtain the information related to their 
personal data subjected to processing, to the origin of these data, and to any public 
communication that may result from them. 
2. This information will be provided through simple visualization of data, or in written form, 
through copy, photocopy or telecopy, in a legible and understandable manner, free of 
codes that may require the use of specific devices. 
3. The right of access to which this article refers can only be exercised at intervals no shorter 
than twelve months, unless the participant proves a legitimate interest, in which case 
he/she will be able to exercise his/her right earlier. 
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PROJECT TITLE: 
ASSESSMENT OF THE EFFECT OF A HEALTHY BEVERAGE ON BODY WEIGHT 
MANAGEMENT (PRONAOS PROJECT) 
Informed consent 
Participant’s name: 
Address: 
 
Mr./Ms. ........................................................................... agrees to take part in the present 
study, which is included in the national PRONAOS Project, and is aimed at assessing the 
efficacy of a functional beverage in body weight management. 
 
The volunteer has read and understood all verbal and written information provided by the 
researcher(s) in relation to his/her participation in the study. The volunteer has been allowed 
to ask and comment about this information and has been given satisfactory answers by the 
researcher(s). The volunteer knows that her/his participation is totally free and voluntary, and 
that she/he can drop out of the study at any time, without being obliged to justify it. 
 
The volunteer expresses hereby her/his agreement on allowing Health Authorities to have 
access to medical data. The volunteer also agrees for the personal data collected during the 
study to be computerized (included those related to ethnicity, if necessary). 
 
The project will be conducted in accordance with the ethical principles included in the 
Declaration of Helsinki (52nd General Assembly, Edinburgh, Scotland, 2000), the Code of Good 
Clinical Practice, and with current legislation, and under the regulations included in the Ley 
Orgánica de Protección de Datos (LOPD 15/1999). 
The volunteer will received a copy of this form once signed by all parties. 
Signatures (compulsory): 
Participant:      Researcher responsible: 
 
 
 
  
Annex 4: Informed consent PRONAOS project  
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 MINISTERIO  
 DE CIENCIA  
 E INNOVACIÓN 
 
 
 
 
 
 
Mr/Ms _______________________________________________ with ID number ____________, has 
been informed of the conditions of storage and custody of the blood samples that will be obtained as 
part of the study “Evaluation of the Efficacy of a treatment with a healthy drink on body weight and 
fat control and its effects on related health variables”, included in the national Project Pronaos of the 
Spanish Ministry of Science and Innovation, and of the use that will be made of them. The responsibility 
of these samples belongs to the principal investigator, Professor Ascensión Marcos, with ID number 
00265107D, and the Immunonutrition Research Group, and they will be kept at the premises of the 
Department of Metabolism and Nutrition of the Institute of Food Science and Technology and 
Nutrition (ICTAN), CSIC. 
 
 
 
 
 
 
 
 
 
                                                                                     Madrid, ______________, 2011. 
 
 
 
 
 
 
                                      Signature: 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSEJO SUPERIOR  
DE INVESTIGACIONES 
CIENTÍFICAS 
Annex 5: Informed consent for blood extraction 
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PARTICIPANT’S PERSONAL INFORMATION 
CODE          (to be filled by the researcher)  
 
1. Gender:  Male  Female 
2. Age:     3. Date of birth (dd/mm/yyyy): 
4. Where were you born? 
 Spain → Go to question 6 
 Another country:  
5. When did you move to Spain (month and year)? 
6. What is your weight (naked)?     kg. 
7. What is your height (barefoot)?                 cm. 
8. What was your birth weight?               g. 
9. As an infant 
 you were breastfed 
 you were fed with infant formula 
 you received both 
10. How would you describe your health in the last 12 months? 
 Very good 
 Good 
 Not too good/not too bad 
 Bad 
 Very bad 
11. In the last year, have you been diagnosed by a doctor with any of the illnesses 
below? 
 Infections (respiratory, digestive, etc.) 
 Hypertension 
 High cholesterol levels 
 Overweight/Obesity 
 Diabetes (high blood glucose) 
 Heart disease 
 Anemia 
 Digestive disease 
 Depression 
 Other mental diseases 
 None
Annex 6: Personal data questionnaire  
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12. Regarding medicament use in the last 2 weeks, have you taken any of the 
medicines below? If yes, were they prescribed by a doctor? 
 
13. Have you ever been diagnosed with HAY FEVER or other ALLERGIES? 
 No 
 Yes → How old were you?  years old → Do you get vaccinated?  Yes   No 
I am allergic to: ________________________________________________ 
14. Which of these options describes better your cigarette consumption? 
 I have never smoked or I quitted smoking more than three months ago → go to question 
16 
 I have quitted smoking within the last three months → go to question 16 
 I smoke occasionally 
 I smoke regularly 
15. How many cigarettes do you smoke on average? 
            cigarettes/day on a weekday 
cigarettes/day on the weeken 
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16. How often do you drink these beverages? 
 
17. Have you ever forced yourself vomiting after eating too much or feeling too full? 
 Yes 
 No 
18. Have you got any concerns about losing control over the amount of food you eat? 
 Yes 
 No 
19. Have you recently lost more than one stone (≈ 7 kg) in 3 months? 
 Yes 
 No 
20. Do you think you are too fat although other people tell that you are slim? 
 Yes 
 No 
21. Do you believe that food controls your life? 
 Yes 
 No 
22. At present time, are you following any specific diet or taking any other measure to 
lose weight? 
 No, I believe that my weight is right. 
 No, but I believe I should lose some weight. 
 No, as I need to gain weight. 
 Yes 
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23. Which meals do you have during the day? 
Yes No 
Breakfast       
Midmorning snack      
Lunch        
Afternoon snack     
Dinner       
Bed-time snack      
24. How many glasses of water do you normally drink during the day? 
_____________ glasses 
25. How many times a week do you normally eat these foods? (Please choose only one 
option per row) 
 
26. FOR WOMEN ONLY 
How old were you when you had your first period?             years old. 
Date of your last period: 
THANK YOU FOR YOUR COLLABORATION 
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3-DAY DIETARY RECORD 
 
The dietary record is like a log where you will write down everything you eat and drink over 
24 h. You will need to be particularly aware of common foods that usually go unnoticed, such 
as condiments, spices and salad seasoning, or the sugar added to beverages (tea, coffee, 
etc.). 
 
A proper 3-day dietary record includes 2 working days plus a weekend or holiday day. For 
best results, you should write down your intake after each meal (breakfast, midmorning 
snack, lunch, afternoon snack, and dinner). When foods consist on elaborate meals (like 
soups, stews, etc.), try to specify the ingredients as precisely as possible (for instance, if you 
have had a stew, tell if it contained meat and what type of meat, what type of vegetables, 
and so on), and the rough amount you ate of each one. 
 
On the firs column, you should write where you had your meal and how long it took; on the 
second column, write the foods you ate and the beverages you drank; and on the third 
column, the amount of each food. 
 
It will often be necessary for you to specify the type of food – for instance, if you drink milk, 
you should write whether it is whole, skimmed or semi-skimmed; if you eat bread, whether it 
is baguette, tin bread, white bread, rye bread, etc.; and you should also specify the type of 
fats and oils you consume (olive, sunflower, corn…). 
 
To express amounts, you can use standard home measures such as “spoon”, “glass”, 
“small/large plate”, etc. for uncountable foods. You can also use “slice”, “loaf”, and so on. For 
foods like fruits, vegetables or meat steaks, it is important to mention an approximate size 
(big, medium or small). 
You will find an example 1-day record below. 
Remember that the more precise and specific your answers are, the more useful the 
information becomes. That is why we recommend you not to wait long to record your meal 
after you eat. 
 
 
THANK YOU FOR YOUR COLLABORATION! 
Annex 7: 3-D Dietary record  
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DAY OF THE WEEK:                                                                      DATE:  
 FOOD AMOUNT 
BREAKFAST   
Start:    
End:    
Place:    
MIDMORNING   
Start:    
End:    
Place:    
LUNCH   
Start:    
End:    
Place:    
AFTERNOON   
Start:   
End:   
Place:   
DINNER   
Start:   
End:   
Place:  -   
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DAY OF THE WEEK:                                                                   DATE:  
 FOOD AMOUNT 
BREAKFAST   
Start:   
End:    
Place:    
MIDMORNING   
Start:   
End:    
Place:   
LUNCH   
Start:   
End:    
Place:   
   
AFTERNOON   
Start:   
End:   
Place:home   
DINNER   
Start:   
End:   
Place:   
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DAY OF THE WEEK:                                                                       DATE:  
 FOOD AMOUNT 
BREAKFAST   
Start:   
End:    
Place:    
MIDMORNING   
Start:   
End:    
Place:   
LUNCH   
Start:   
End:    
Place:   
   
AFTERNOON   
Start:    
End:   
Place:    
DINNER   
Start:   
End:   
Place:   
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3-DAY DIETARY RECORD 
 
The dietary record is like a log where you will write down everything you eat and 
drink over 24 h. You will need to be particularly aware of common foods that usually 
go unnoticed, such as condiments, spices and salad seasoning, or the sugar added 
to beverages (tea, coffee, etc.). 
 
A proper 3-day dietary record includes 2 working days plus a weekend or holiday 
day. For best results, you should write down your intake after each meal (breakfast, 
midmorning snack, lunch, afternoon snack, and dinner). When foods consist on 
elaborate meals (like soups, stews, etc.), try to specify the ingredients as precisely 
as possible (for instance, if you have had a stew, tell if it contained meat and what 
type of meat, what type of vegetables, and so on), and the rough amount you ate of 
each one. 
 
On the firs column, you should write where you had your meal and how long it took; 
on the second column, write the foods you ate and the beverages you drank; and on 
the third column, the amount of each food. 
 
It will often be necessary for you to specify the type of food – for instance, if you 
drink milk, you should write whether it is whole, skimmed or semi-skimmed; if you eat 
bread, whether it is baguette, tin bread, white bread, rye bread, etc.; and you should 
also specify the type of fats and oils you consume (olive, sunflower, corn…). 
 
To express amounts, you can use standard home measures such as “spoon”, 
“glass”, “small/large plate”, etc. for uncountable foods. You can also use “slice”, 
“loaf”, and so on. For foods like fruits, vegetables or meat steaks, it is important to 
mention an approximate size (big, medium or small). 
 
You will find an example 1-day record below. 
 
Remember that the more precise and specific your answers are, the more useful the 
information becomes. That is why we recommend you not to wait long to record your 
meal after you eat. 
 
 
THANK YOU FOR YOUR COLLABORATION! 
 
  
Annex 8: 1-D Dietary record example from a participant 
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DAY OF THE WEEK: Monday                                          DATE: June 13th 2011 
 FOOD AMOUNT 
BREAKFAST   
Start: 8.00 White coffee: 1 cup 
End: 8.20 - Semiskimmed milk ½ glass 
Place: home - Sugar 1 spoon 
 Toasts (tin white loaf): 2 slices 
 - Butter 2 spoons 
 - Jam 2 spoons 
MIDMORNING   
Start: 10.15 Orange juice 1 glass 
End: 10.45 Cheese roll:  - white bread 1 baguette 
Place: canteen - Gouda cheese 1 slice 
LUNCH   
Start: 14.30 Lettuce and tomato salad 1 small plate 
End: 15.30 - Olive oil and vinager 1 spoon + ½ spoon 
Place: canteen Roast chicken: 1 chicken leg 
 - Potatoes 1 medium 
 - Onions, tomato ½ small plate 
 Beer 1 glass 
 Orange 1 medium 
AFTERNOON   
Start: Nothing  
End:   
Place:   
DINNER   
Start: Courgette soup (courgettes, potatoes, olive 
oil) 
1 plate 
End: Omelette 2 eggs 
Place: canteen - Olive oil 1 spoon 
 Apple 1 big 
 Semiskimmed milk 1 glass 
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Annex 9: Correlation coefficients between estimated caffeine consumption and body composition-related variables in total sample and according to gender.  
Pearson correlation used. Significance set at P< 0.05. BMI: body mass index; WHR: waist-to-hip ratio; WHeR: waist-to-height ratio. 
 
  
 All  Females  Males  
 BMI Body 
fat 
(%) 
Waist  
(cm) 
WHR WHeR BMI Body 
fat 
(%) 
Waist  
(cm) 
WHR WHeR BMI Body 
fat 
(%) 
Waist  
(cm) 
WHR WHeR 
Total caffeine (mg/day) 0.008 0.030 0.110 0.036 0.029 0.073 0.054 0.301 0.360 0.160 -0.031 0.110 0.074 -0.014 -0.052 
Caffeine from tea and 
coffee (mg/day) -0.092 -0.002 0.067 0.71 -0.040 -0.027 -0.018 0.164 0.122 0.049 -0.130 0.075 0.056 0.001 -0.101 
Caffeine from caffeinated 
and energy drinks 
(mg/day) 
-0.009 -0.017 0.033 0.001 0.011 0.102 0.200 0.274 0.063 0.147 -0.063 0.002 -0.061 -0.114 -0.067 
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Annex 10: Effect of the treatments in all participants. 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and final values compared by two-way ANOVA. Significance at *P < 0.05.  VCAM-1: 
vascular cell adhesion protein 1; ICAM-1: Intracellular adhesion molecule; NEFA: Non-esterified fatty acids 
 
 
 
 
 
 
 
 
 
 
 
 All    
Placebo Functional    
Baseline Endpoint Baseline Endpoint Pd Pt Pi 
Basophil (x103/mm3) 0.0 
(0.0-0.1) 
0.0 
(0.0-0.1) 
0.0 
(0.0-0.1) 
0.0 
(0.1-0.1) 
0.009 0.636 0.350 
Leptin (ng/ml) 4.9±3.8 7.4±6.5 6.4±6.2 7.6±6.9 0.006 0.201 0.349 
VCAM1 (ng/ml) 119.8±32.1 106.8±25.9 119.9±27.0 111.5±25.7 0.001 0.525 0.386 
ICAM1 (ng/ml) 93.6 
(80.1-113.0) 
91.4 
(69.9-120.9) 
93.5 
(76.5-111.7) 
91.0 
(73.0-123.2) 
0.039 0.865 0.691 
NEFA (mmol/L) 0.02±0.01 0.03±0.01 0.03±0.01 0.03±0.01 0.004 0.835 0.349 
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Annex 10: Effect of the treatments in female and male participants. 
Data presented mean ± SD, or median (Q1, Q3), depending on normality. Baseline and final values compared by two-way ANOVA. Significance at *P < 0.05. WBC: white blood 
cell; IL-β: interleukin-1 Beta; TNF-α: tumor necrosis factor alpha; VCAM-1: vascular cell adhesion protein 1; ICAM-1: Intracellular adhesion molecule; NEFA: Non-esterified fatty 
acids; Lymphocyte populations are designated by their cell membrane markers, and defined by the anchor marker, which appears in first place of the subset name. 
 
 
 Female 
Pd Pt Pi 
Male 
Pd Pt Pi Placebo Functional Placebo Functional 
Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint 
WBC (x103/mm3) 6.6 
(5.4 –7.6) 
6.4 
(5.5-7.3) 
6.7 
(5.2–7.6) 
6.2 
(5.7– 7.5) 
NS NS NS 6.2 
(5.3-7.4) 
6.3 
(5.4-7.5) 
6.0 
(5.0-6.9) 
5.7 
(4.8-6.3) 
NS 0.047 NS 
Lyphocyte 
(x103/mm3) 
2.2 
(1.9– 2.6) 
2.3 
(1.9– 2.6) 
2.4 
(2.0–2.6) 
2.4 
(2.1-2.7) 
NS NS NS 2.2 
(1.9-2.6) 
2.3 
(1.9-2.8) 
2.2 
(1.8-2.5) 
2.0 
(0.1-0.2) 
NS 0.042 NS 
Eosinphil (x103/mm3) 0.1 
(0.1– 0.2) 
0.2 
(0.1– 0.3) 
0.2 
(0.1–0.3) 
0.2 
(0.1– 0.2) 
NS NS NS 0.2 
(0.1-0.2) 
0.2 
(0.1-0.2) 
0.2 
(0.1-0.2) 
0.2 
(0.1-0.2) 
NS 0.005 NS 
Basophil (x103/mm3) 0.0 
(0.0– 0.1) 
0.0 
(0.0-0.1) 
0.0 
(0.0–0.1) 
0.0 
(0.0 -0.1) 
NS NS NS 0.0 
(0.0-0.1) 
0.0 
(0.0-0.1) 
0.0 
(0.0-0.0) 
0.0 
(0.0-0.0) 
NS 0.000 NS 
Leptin (ng/ml) 8.0±4.0 12.9±6.9 10.5±7.5 12.9±7.3 NS 0.002 NS 3.0±2.0 3.7±2.4 3.6±2.8 4.0±3.5 NS NS NS 
Grehlin (pg/ml) 209.2±147.2 463.7±186.9 198.3±136.4 437.0±200.9 NS 0.000 NS 440.4±925.1 329.2±356.9 395.6±884.3 932.5±3701.3 NS NS NS 
IL-1β (pg/ml) 1.0 
(0.5-1.5) 
0.7 
(0.5-1.1) 
0.2 
(0.2-0.5) 
1.0 
(0.3-2.0) 
NS NS 0.04
6 
4.4 
(1.2-7.7) 
1.1 
(0.9-1.5) 
1.0 
(0.5-6.7) 
0.9 
(0.8-1.2) 
NS 0.013 NS 
TNF-α (pg/ml) 1.4 
(0.7-4.4) 
1.1 
(0.4-20.8) 
1.4 
(0.8-3.6) 
1.1 
(0.8-5.6) 
NS 0.036 NS 2.9 
(1.2-7.2) 
3.9 
(2.4-6.6) 
4.5 
(0.6-18.4) 
3.1 
(1.3-9.7) 
NS NS NS 
VCAM1 (ng/ml) 114.2±27.3 107.2±28.1 116.3±25.2 108.2±21.6 NS NS NS 123.3±34.5 106.5±246.2 121.0±28.3 113.7±28.2 NS 0.005 NS 
ICAM1 (ng/ml) 82.7 
(68.0-98.9 
89.4 
(64.9-97.6) 
87.9 
(73.1-101.1) 
91.1 
(70.4-105.9) 
NS NS NS 102.6 
(82.1-118.7) 
93.6 
(70.7-142.0) 
97.6 
(81.5-116.7) 
90.7 
(77.5-169.1) 
NS 0.039 NS 
NEFA (mmol/L) 0.03±0.01 0.03±0.01 0.03±0.01 0.03±0.01 NS NS NS 0.03±0.01 0.03±0.01 0.03±0.01 0.03±0.01 0.006 NS NS 
Glucose (mmol/L) 4.8 
(4.4-5.2) 
4.4 
(4.0-4.8) 
4.8 
(4.6-5.1) 
4.3 
(3.9-4.8) 
0.001 NS NS 5.1 
(4.8-5.2) 
5.0 
(4.8-5.4) 
5.0 
(4.5-5.3 
5.1 
(4.7-5.4) 
0.011 NS NS 
Cholesterol (mmol/L) 9.7±2.1 9.0±2.1 9.5±1.9 8.8±1.7 0.041 NS NS 9.3±1.9 9.8±1.7 9.3±1.8 9.8±1.6 NS NS NS 
Iron (mg/dl) 68.0 
(43.0-97.0) 
57.5 
(41.0-88.0) 
72.0 
(53.5-99.5) 
61.0 
(38.0-97.0) 
NS NS NS 98.0 
(76.0-117.0) 
96.0 
(74.0-118.5) 
87.0 
(70.0-106.0) 
86.0 
(70.0-108.0) 
NS 0.044 NS 
Transferrin (mg/dl) 260.1±47.8 243.18±48.7 261.1±52.8 244.0±51.2 0.048 NS NS 242.3±43.3 257.5±35.1 242.6±41.1 256.7±32.7 0.008 NS NS 
CD4+RA+ (Cell/mm3) 443.4±196.5 486.1±216.4 534.8±172.9 537.0±174.7 NS 0.038 NS 431.7±192.6 461.6±197.5 462.4±221.8 439.8±237.7 NS NS NS 
CD4+RO+ (Cell/mm3) 540.0 
(336.0-707.1) 
553.9 
(384.3-713.6) 
404.1 
(277.2-519.3) 
389.1 
(325.4-624.7) 
NS 0.003 NS 403.4 
(276.9-520.0) 
429.7 
(294.1-584.8) 
421.5 
(311.8-597.9) 
426.3 
(325.8-521.4) 
NS NS NS 
